Role of cytokines in the pathogenesis of type 1 diabetes by Hussain, Munther Jaffar
TITLE: 
ROLE OF CYTOKINES IN THE PATHOGENESIS OF TYPE 1 DIABETES 
 
BY 
 
MUNTHER JAFFAR HUSSAIN  
 
A THESIS 
SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN  THE 
BRUNEL UNIVERSITY 
 
DEPARTMENT OF IMMUNOLOGY 
KING'S COLLEGE SCHOOL OF MEDICINE AND DENTISTRY, BESSEMER 
ROAD 
LONDON, SE5 9PJ 
II
TO MY FAMILY  
 
III
ACKNOWLEDGEMENTS 
My gratitude goes to: 
 
Dr DEH Tee, head of the department of Immunology for continuous support while I 
am working in the department. 
Professor Diego Vergani and his wife Professor G. Mieli-Vergani for constant 
supervision, careful guidance and constant encouragement; 
Dr RDG Leslie, who continues the work initiated by Dr D Pyke in collecting the 
largest series of diabetic twins in the world and who has given me the 
opportunity to co-operate with him;  
Dr M Peakman for his competent critical comments of the present work and for 
preventing me from producing too great a damage to the English language. 
 
Much gratitude is also due to: Dr A Lobo-Yeo for constructive advice; Professor AP 
Mowat  for the clinical specimens and related information; Dr B Portmann 
for histopathological consultancy; Mr R Senkus and Mr K Davies for the 
photographic work.  
 
I also would like to thank Mr ET Davies, Mrs L Bevis, Mr HW Jones, Mrs J Ochola 
and Dr A Mustafa for their help and friendly attention throughout the period 
I worked with them, and Mrs G McNab, Miss S Arif and Miss C Gearon 
who have been sharing with me an interest in the immunology of diabetes.  
IV
TABLE OF CONTENTS 
TITLE .........................................................................................................................  I 
ACKNOWLEDGEMENTS ..................................................................................  III 
TABLE OF CONTENTS........................................................................................  IV 
INDEX OF TABLES ..............................................................................................  XI 
INDEX OF FIGURES...........................................................................................XIV 
ABBREVIATIONS .............................................................................................XVIII 
PUBLICATION.................................................................................................. XXIV 
ABSTRACT ............................................................................................................... 1 
 
CHAPTER 1    GENERAL INTRODUCTION 
1.1  HISTORY OF TYPE 1 DIABETES..................................................................... 4 
1.2  DIVERSITY OF DIABETES .............................................................................. 5 
1.3  PATHOGENESIS OF TYPE 1 DIABETES ....................................................... 7 
1.3.1  PATHOLOGICAL CHANGES ........................................................................ 7 
1.3.2  GENETIC SUSCEPTIBILITY ........................................................................  8 
1.3.3  HLA .................................................................................................................... 9 
1.3.4  TWIN STUDIES ............................................................................................. 11 
1.3.5  ENVIRONMENTAL FACTORS.................................................................... 12 
1.3.6  ANIMAL MODELS OF TYPE 1 DIABETES .............................................. 14 
1.4  TYPE 1 DIABETES: AN IMMUNE MEDIATED  
 DISEASE............................................................................................................. 15 
1.5  AUTOIMMUNE HEPATITIS, ANOTHER EXAMPLE OF ORGAN-
SPECIFIC AUTOIMMUNE DISEASE .................................................. 21 
1.5.1  INTRODUCTION ........................................................................................... 21 
1.5.2  AUTOANTIBODIES AGAINST LIVER- 
 SPECIFIC MEMBRANE ANTIGENS ............................................................. 21 
1.5.3  AETIOLOGY ................................................................................................... 22 
1.5.4 AUTOIMMUNE HEPATITIS: AN IMMUNE MEDIATED DISEASE........ 23 
1.5.5  GENETIC PREDISPOSITION ....................................................................... 25 
 
CHAPTER 2    INTRODUCTION TO THE PRESENT STUDY 
2.1  INTRODUCTION .............................................................................................. 28 
2.2  CYTOKINES ...................................................................................................... 30 
2.2.1  INTERLEUKIN 1  ........................................................................................... 30 
V2.2.2  INTERLEUKIN 2  ........................................................................................... 32 
2.2.3  INTERLEUKIN 4 ............................................................................................ 34 
2.2.4  INTERLEUKIN 6 ............................................................................................ 35 
2.2.5  INTERLEUKIN 10 .......................................................................................... 36 
2.2.6  INTERFERON-? .............................................................................................. 37 
2.2.7  TUMOUR NECROSIS FACTOR-@ .............................................................. 38 
2.3  CYTOKINES AND AUTOIMMUNITY ........................................................... 40 
2.3.1  'ABERRANT' MHC EXPRESSION INDUCED BY      CYTOKINES ...........  
2.3.2  CYTOTOXICITY OF CYTOKINES ............................................................. 41 
2.3.3  CYTOKINE PROFILE ................................................................................... 42 
2.4  CYTOKINES AND AUTOIMMUNE CHRONIC LIVER    DISEASE ......... 43 
 
CHAPTER 3    AIMS 
3.1  AIMS OF THE PRESENT STUDY .................................................................. 46 
 
CHAPTER 4    MATERIALS AND METHODS 
4.1  SUBJECTS WITH DIABETES.......................................................................... 49 
4.2  NON-OBESE DIABETIC MICE ...................................................................... 50 
4.3  SUBJECTS WITH AUTOIMMUNE CHRONIC LIVER  
 DISEASE  ............................................................................................................. 50 
4.4  HEALTHY CONTROLS SUBJECTS .............................................................. 51 
4.5  MATERIALS ..................................................................................................... 52 
4.5.1  REAGENTS .................................................................................................... 52 
4.5.2  BUFFERS, SOLUTIONS AND MODIFIED  
 MEDIA ............................................................................................................... 52 
4.5.3  CONSUMABLES ............................................................................................ 53 
4.5.4  MONOCLONAL ANTIBODIES TO CYTOKINES    .................................. 53 
4.5.5  POLYCLONAL ANTIBODIES TO CYTOKINES    .................................... 54 
4.5.6  HYBRIDOMA CELL LINES PRODUCING ANTIBODIES ....................... 55 
4.5.7  CYTOKINE STANDARDS ........................................................................... 55 
4.5.8  PEROXIDASE-CONJUGATED ANTISERA ............................................... 55 
4.5.9  COMMERCIAL KITS .................................................................................... 55 
4.5.10 INSTRUMENTS ............................................................................................ 56 
4.6  METHODS  
4.6.1 PREPARATION OF MONOCLONAL ANTI-CYTOKINE ANTIBODIES 57 
4.6.2  CYTOKINE ASSAYS .................................................................................... 65 
VI
4.6.3  MITOGEN-INDUCED SECRETION OF CYTOKINES  ….. 84 
4.6.4 IMMUNOHISTOCHEMICAL AND IMMUNO-FLUORESCENT 
STAINING OF CYTOKINE   PRODUCING CELLS IN NOD MOUSE  
 PANCREAS SECTIONS ......................................................................... 85 
4.6.5 IMMUNOHISTOCHEMICAL STAINING OF CYTOKINE PRODUCING 
CELLS IN LIVER BIOPSIES ............................................................... 87 
4.6.6  METABOLIC STUDIES ................................................................................ 88 
4.6.7  C-PEPTIDE LEVELS  .................................................................................... 89 
4.6.8 DETECTION OF ORGAN-SPECIFIC AND NON ORGAN-SPECIFIC 
AUTOANTIBODIES ............................................................................. 89 
4.6.9  HLA TYPING ................................................................................................. 92 
4.6.10 STATISTICAL ANALYSIS .......................................................................... 92 
 
CHAPTER 5    STUDIES OF CIRCULATING LEVELS OF CYTOKINES      
 IN PATIENTS WITH TYPE 1 DIABETES  
5.1  SUBJECTS ......................................................................................................... 94 
5.2  RESULTS ........................................................................................................... 94 
5.2.1  MACROPHAGE-DERIVED CYTOKINES .................................................. 94 
5.2.2  TH1 PROFILE .................................................................................................. 97 
5.2.3  TH2 PROFILE ...............................................................................................  100 
5.2.4 LEVELS OF sIL-2R IN TYPE 1 DIABETES................................................ 102 
5.2.5  ASSOCIATION BETWEEN CYTOKINE LEVELS, sIL-2R, BLOOD 
GLUCOSE VALUES AND ISLET CELL AND GAD 
ANTIBODIES IN SUBJECTS STUDIED ............................................ 103 
5.2.6 ASSOCIATION BETWEEN LEVELS OF    CYTOKINES, sIL-2R AND C-
PEPTIDE  
 LEVELS  ........................................................................................................... 103 
5.3  COMMENT ...................................................................................................... 104 
 
CHAPTER 6    PROSPECTIVE STUDY OF CYTOKINE LEVELS IN             
IDENTICAL TWINS OF PATIENTS WITH TYPE 1  DIABETES 
6.1  SUBJECTS........................................................................................................ 108 
6.2  RESULTS................... ………………………………………………………108 
6.2.1  MACROPHAGE-DERIVED CYTOKINES ................................................ 109 
6.2.2  TH1 CYTOKINE PROFILE .......................................................................... 112 
6.2.3  TH2 CYTOKINE PROFILE .......................................................................... 114 
VII
6.2.4  PREVALENCE OF TH1 AND TH2 CYTOKINE  PROFILES IN 
IDENTICAL TWINS OF  PATIENTS WITH TYPE 1 
DIABETES ............................................................................................. 116 
6.2.5  COMPARISON OF PREVALENCE OF TH1 AND TH2 CYTOKINE 
PROFILES IN IDENTICAL TWINS AND PATIENTS WITH TYPE 1  
 DIABETES ....................................................................................................... 116 
6.2.6 ASSOCIATION BETWEEN LEVELS  OF  CYTOKINES, BLOOD 
GLUCOSE LEVELS AND AUTOANTIBODIES IN IDENTICAL 
TWINS .................................................................................................... 118 
6.3  COMMENT....................................................................................................... 119 
 
CHAPTER 7 STUDIES ON CYTOKINES LEVELS AND THEIR 
RELATIONSHIP TO AUTOANTIBODIES AND HLA 
ALLELES IN DIABETIC CHILDREN AND THEIR    FIRST 
DEGREE RELATIVES 
7.1  SUBJECTS ....................................................................................................... 122 
7.2  RESULTS ......................................................................................................... 123 
 7.2.1  CYTOKINES AND sIL-2R LEVELS ...................................................... 123 
 7.2.2 ASSOCIATION BETWEEN LEVELS OF   CYTOKINES AND ISLETS 
CELL ANTIBODIES  
 OR OTHER AUTOANTIBODIES ............................................................. 127 
 7.2.3  ASSOCIATION BETWEEN LEVELS OF  
 CYTOKINES AND HLA CLASS II ALLELES ........................................ 130 
 7.2.4  ASSOCIATION BETWEEN LEVELS OF  CYTOKINES, METABOLIC 
CONTROL AND   DURATION OF DIABETES ........................ 130 
7.3  COMMENT ...................................................................................................... 131 
 
CHAPTER 8 STUDIES OF CYTOKINE SECRETION BY                         
PERIPHERAL BLOOD MONONUCLEAR CELLS IN DIABETIC 
CHILDREN AND THEIR FIRST    DEGREE RELATIVES 
8.1  SUBJECTS ....................................................................................................... 134 
8.2  RESULTS  ........................................................................................................ 135 
8.2.1  TNF-@ AND IL-1@ SECRETION ................................................................. 135 
8.2.2  IL-2 AND IFN-? SECRETION ..................................................................... 136 
8.2.3 ASSOCIATION BETWEEN LEVELS OF CYTOKINE SECRETION 
AND ICA OR OTHER AUTOANTIBODIES ................................... 138  
VIII
8.2.4  ASSOCIATION BETWEEN LEVELS OF CYTOKINE SECRETION, 
METABOLIC CONTROL, DURATION OF DIABETES  
 AND HLA CLASS II ALLELES ...................................................................... 138 
8.3  COMMENT ...................................................................................................... 139 
 
CHAPTER 9 CIRCULATING LEVELS OF CYTOKINES IN NON OBESE    
 DIABETIC (NOD) MICE 
9.1  MICE ………………….................................................................................... 142 
9.2  RESULTS  ........................................................................................................ 143 
9.2.1  CIRCULATING LEVELS OF CYTOKINES  
 IN NOD MICE .................................................................................................. 143 
9.3  COMMENT ...................................................................................................... 145 
 
CHAPTER 10   STUDIES OF CELLULAR EXPRESSION OF TNF-* AND     
IFN-+ IN PANCREATIC SECTION FROM NON-OBESE         
DIABETIC (NOD) MICE 
10.1 MICE ....…………………………………………………………………….147 
10.2 RESULTS ........................................................................................................ 148 
10.2.1 EXPRESSION OF IFN-? AND TNF-@ IN  
 ISLETS OF LANGERHANS ........................................................................... 148 
IX
10.3 COMMENT ..................................................................................................... 152 
CHAPTER 11   STUDIES OF CYTOKINES LEVELS IN AUTOIMMUNE     
HEPATITIS, AN ORGAN-SPECIFIC AUTOIMMUNE  DISEASE 
11.1 PATIENTS .....................................................................................................  155 
11.2 RESULTS ........................................................................................................ 161 
11.2.1 MACROPHAGE-DERIVED CYTOKINES................................................ 161 
11.2.2 TH1 CYTOKINE PROFILE ......................................................................... 164 
11.2.3 TH2 CYTOKINE PROFILE ......................................................................... 165 
11.2.4 LEVELS OF sIL-2R IN CHILDREN WITH  AUTOIMMUNE CHRONIC 
LIVER DISEASE............................................................................. 165 
11.2.5 ASSOCIATION BETWEEN LEVELS OF  
 CYTOKINES AND sIL-2R AND DISEASE  
 STAGE .............................................................................................................. 166 
11.2.6 ASSOCIATION BETWEEN LEVELS OF  
 CYTOKINES AND sIL-2R AND DISEASE  ACTIVITY ............................. 168 
11.2.7 ASSOCIATION BETWEEN CYTOKINES AND  
 IgG LEVELS IN SUBJECTS STUDIED ........................................................ 168 
11.6 COMMENT ..................................................................................................... 169 
 
CHAPTER 12   CELLULAR EXPRESSION OF TUMOUR NECROSIS        
FACTOR-* AND INTERFERON-+ IN THE LIVER   BIOPSIES OF 
CHILDREN WITH CHRONIC LIVER   DISEASE   
12.1 SUBJECTS ...................................................................................................... 173 
12.2 RESULTS  ....................................................................................................... 177 
12.3 COMMENT  .................................................................................................... 180 
 
CHAPTER 13   General Discussion 
13.1 ONSET OF TYPE 1 DIABETES IS ASSOCIATED WITH PRODUCTION 
OF TH1 CYTOKINES …………………………..       184 
13.2 CYTOKINE PROFILE IN A COHORT OF NON-DIABETIC IDENTICAL 
TWINS OF PATIENTS WITH TYPE 1 DIABETES………………………186  
13.3.1 THE ROLE OF UNDERLYING GENETIC TRAITS IN INFLUENCING 
CYTOKINE LEVELS IN PATIENTS WITH TYPE 1 DIABETES AND THEIR 
XSIBLINGS AND PARENTS ………………………………………………….187. 
 
13.3.2 MITOGEN-STIMULATED SECRETION OF CYTOKINES BY PBMC IN 
IN CHILDREN WITH TYPE 1 DIABETES  …………………189  
 13.4 PRODUCTION OF CIRCULATING AND PANCREATIC CYTOKINES 
IN AN ANIMAL MODEL OF DIABETES - THE NOD 
MOUSE……………………………………………………………………..191
13.5 ROLE OF CYTOKINES IN THE PATHOGENESIS OF 
AUTOIMMUNE 
HEPATITIS…………………………………………………………………….193 
 13.6 PRACTICAL APPROACHES TOWARD THERAPY ............................... 196 
 
REFERENCES ...................................................................................................... 198 
XI
INDEX OF TABLES 
Table 4.1 Means of Absorbance reading at 490 nm for anti-cytokine MAb 
(1/10) reactions when used in plate coated with 30 ng/ml of different 
cytokines ........................................................................................................ 60 
Table 4.2 The mean absorbance at 490 nm for TNF-( standards at a range 
of dilutions from 7.5-1920 pg/ml after different TNF-(/anti-TNF-(
MAb (Ab1) reaction incubation times ........................................................... 62 
Table 4.3 Monoclonal and polyclonal anti-human cytokine antibodies 
purchased or donated and used in immunoassay ......................................... 66 
Table 4.4 Monoclonal anti-human cytokine antibodies prepared and used in 
cytokine immunoassay ................................................................................... 68 
Table 4.5 Monoclonal and polyclonal anti-cytokine antibodies prepared or 
donated and the optimum dilution used in immunohistochemical 
staining   . ....................................................................................................... 69 
Table 4.6 Intra-assay variation for TNF-( of 7 serum samples which were 
tested in triplicate 
 ................................................................................................................................ 70 
Table 4.7 Inter-assay variation for TNF-( of 7 serum samples which were 
tested for eight runs........................................................................................ 78 
Table 4.8 The percentage recovery of exogenous  
 TNF-( from serum sample .................................................................................... 79 
Table 4.9 The absorbance at 490 nm for TNF-( standards at a range of 
dilutions from 7.5-2000 pg/ml ...................................................................... 80 
Table 4.10 Patterns of positive staining of non-organ specific autoantibodies 
by two step indirect immunofluorescence technique .................................... 81 
Table 6.1 Comparison of prevalence of TH1 (IL-2 and  
XII
IFN-4) and TH2 (IL-4 and IL-10) cytokine  profiles in identical twins on at least  
 one occasion and patients with Type 1 diabetes ................................................. 117 
Table 6.2 Comparison of prevalence of TH1 (IL-2  and IFN-4) and TH2 (IL-4 
and IL-10) cytokine profiles in identical twins on at least two             
 occasions and patients with Type 1 diabetes       …….           
Table 7.1 Composition of families studied .............................................................. 123 
Table 7.2 Prevalence (%) of organ-specific (excluding islet cell antibody) 
and non organ- specific autoantibodies in children with Type 1 
diabetes, their siblings, parents and controls.............................................. 129 
Table 8.1 Levels of spontaneous secretion of TNF-( by PBMC and after LPS 
stimulation in diabetic children, their siblings, parents and  
 controls ................................................................................................................ 135 
Table 8.2 Levels of spontaneous secretion of IL-1(
by PBMC and after LPS stimulation in diabetic  children, their siblings, parents  
 and  controls .......................................................................................................... 136 
Table 8.3 Levels of spontaneous secretion of IL-2 by PBMC and after PHA 
stimulation in diabetic children, their siblings, parents and  
 controls ................................................................................................................ 137 
Table 8.4 Levels of spontaneous secretion of IFN-4
by PBMC and after PHA stimulation in diabetic  children and their siblings and 
parents ...................................................................................................................... 137 
Table 10.1 Age, sex, immunological and histological details of NOD mice .......... 151 
Table 11.1 Clinical, biochemical, immunological and histological details of 
the patients with autoimmune hepatitis at the time of testing ...........................  
Table 11.2 Clinical, biochemical, immunological and histological details of 
patients with autoimmune sclerosing cholangitis at the time of 
testing ........................................................................................................... 158 
XIII
Table 11.3 Clinical, biochemical, immunological and histological details of 
the patients with Wilson's disease at the time of testing.............................. 159 
Table 11.4 Clinical, biochemical, immunological and histological details of 
the patients with (-1 anti-trypsin deficiency at the time of testing ............. 160 
Table 11.5 Levels of cytokines and sIL-2R in patients with chronic liver 
disease (all groups) according to presence or absence of cirrhosis .......... 167 
Table 11.6 Levels of cytokines and sIL-2R in patients with chronic liver 
disease (all groups) according to disease activity ...................................... 168 
Table 12.1 Clinical, biochemical, immunological and histological details of 
patients with autoimmune liver disease ...................................................... 173 
Table 12.2 Clinical, biochemical and histological details of patients with 
Wilson's disease and alpha 1 antitrypsin deficiency  ................................. 173 
XIV
INDEX OF FIGURES 
Figure 2.1 -  ß-cell immune attack ............................................................................. 40 
Figure 4.1 -  Typical protein content (280 nm absorbance) of eluent against 
time for loading of cell supernatant on to Protein-A Sepharose and 
elution of MAb ............................................................................................... 64 
Figure 4.2 -  Isolation of IgG fraction from sheep anti-IL-1( serum on 
DEAE-Sephacel ............................................................................................. 68 
Figure 4.3 -  A two-site ELISA for measurement of cytokines................................... 71 
Figure 4.4 -  TNF-( standard curves using a range of concentrations of anti-
TNF-(MAb in the capture step in the TNF immunoassay ........................... 72 
Figure 4.5 -  TNF-( standard curves using a range of concentrations of anti-
TNF-( polyclonal antibodies in the revealing step of the TNF-(
immunoassay .................................................................................................. 72 
Figure 4.6 -  Standard curve of IL-1( immunoassay ................................................ 73 
Figure 4.7 -  Standard curve of IL-1A immunoassay ................................................ 74 
Figure 4.8 -  Standard curve of the soluble IL-2 receptor assay using a two-
site ELISA ...................................................................................................... 75 
Figure 4.9 -  Standard curve of the IL-6 assay using a two-site ELISA ................... 76 
Figure 4.10 - Standard curves of IL-4 and IL-10 using two-site ELISA .................. 91 
Figure 4.11 - Standard curve of the IL-2 bioassay using IL-2 dependent cell 
line (CTLL-16) in a colorimetric microassay ............................................... 96 
Figure 5.1 -  TNF-( values in the serum of patients with Type 1 diabetes of 
different duration, Type 2 diabetes, Graves' disease and normal 
subjects .......................................................................................................... 96 
Figure 5.2 -  IL-1( values in the serum of patients with Type 1 diabetes of 
different duration, Type 2 diabetes, Graves' disease and normal 
XV
subjects .......................................................................................................... 97 
Figure 5.3 -  IL-2 values in the serum of patients with Type 1 diabetes of 
different duration, Type 2 diabetes, Graves' disease and normal 
subjects .......................................................................................................... 98 
Figure 5.4 -  IFN-4 values in the serum of patients with Type 1 diabetes of 
different duration, Type 2 diabetes, Graves' disease and normal 
subjects ........................................................................................................ 100 
Figure 5.5 -  IL-4 and IL-10 values in the serum of patients with Type 1 
diabetes of different duration, type 2 diabetes, Graves' disease and 
normal subjects ........................................................................................... 102 
Figure 5.6 -  sIL-2R values in the serum of patients with Type 1 diabetes of 
different duration, Type 2 diabetes, Graves' disease and normal 
subjects ........................................................................................................ 110  
Figure 6.1 -  TNF-( levels in 8 prediabetic and 20 non-diabetic twins ................. 111 
Figure 6.2 -  IL-1( levels in 8 prediabetic and 20 non-diabetic twins ................... 112 
Figure 6.3 -  IL-2 levels in 8 prediabetic and  
 20 non-diabetic twins .......................................................................................... 113 
Figure 6.4 -  IFN-4 levels in 8 prediabetic and 20 non-diabetic twins .................. 114 
Figure 6.5 -  Levels of IL-4 in 8 prediabetic and 20 non-diabetic twins  ............... 114 
Figure 6.6 -  Levels of IL-10 in 8 prediabetic and 20 non-diabetic twins  ............. 115 
Figure 7.1 -  TNF-( values in the serum of children with Type 1 diabetes, in 
their parents, siblings and controls ............................................................. 124 
Figure 7.2 -  IL-1( values in the serum of children with Type 1 diabetes, in 
their parents, siblings and controls  .................................................................  
Figure 7.3 -  IFN-4 values in the serum of children with Type 1 diabetes, in 
their parents, siblings and controls ............................................................. 126 
Figure 7.4 -  sIL-2R values in the serum of children with Type 1 diabetes, in 
XVI
their parents, siblings and controls  ........................................................... 127 
Figure 9.1 -  TNF-( values in the serum of diabetic and non-diabetic NOD 
mice, NODxB10 F1 mice and normal SJL mice ...............................................  
Figure 9.2 -  IL-2 values in the serum of diabetic and non-diabetic NOD 
mice, NODxB10 F1 mice and normal SJL mice ...............................................  
Figure 10.1 - Pancreatic section from diabetic NOD mice showing 
mononuclear cells with a diffuse cytoplasmic staining for IFN-4 .............  148 
Figure 10.2 - Pancreatic section from diabetic NOD  
 mice showing islet cells staining for TNF-( . .................................................... 148 
Figure 10.3 - Pancreatic section from diabetic NOD mice showing islet cells 
staining for TNF-( ..................................................................................... 149 
Figure 10.4 - Pancreatic section from NOD mice at pre-diabetic age of 10 
weeks showing mononuclear cells with a diffuse cytoplasmic staining 
for IFN-4 .....................................................................................................  150 
Figure 11.1 - TNF-( levels in the serum of children with different groups of 
chronic liver disease ................................................................................... 162 
Figure 11.2 - IL-1( levels in the serum of children with different groups of 
chronic liver disease ................................................................................... 163 
Figure 11.3 -  IL-6 levels in the serum of children with different groups of 
chronic liver disease ................................................................................... 164 
Figure 11.4 - IFN-4 levels in the serum of children with different groups of 
chronic liver disease  .................................................................................. 165 
Figure 11.5 - sIL-2R levels in the serum of children with different groups of 
chronic liver disease ................................................................................... 166 
Figure 12.1 - Liver section from a patient with autoimmune hepatitis 
showing large cells with a diffuse cytoplasmic staining for TNF-(
within the portal inflammatory cell infiltrate .............................................. 178 
XVII
Figure 12.2 - Liver section from a patient with autoimmune sclerosing 
cholangitis showing large cells with a diffuse cytoplasmic staining of 
IFN-4 within the inflammatory cell infiltrate............................................... 178 
Figure 12.3 - Liver sections from a patient with autoimmune hepatitis 
showing simultaneous presence of cells posively stained for TNF-(
and IFN-4 within the inflammatory cell infiltrate ...................................... 179 
Figure 12.4 - Correlation between levels of aspartate aminotransferase and 
the score of TNF-( expression in children with autoimmune liver 
disease ........................................................................................................  179 
XVIII
ABBREVIATIONS 
ADCC   = Antibody Dependent Cell-mediated Cytotoxicity 
ADH    = Alcohol Dehydrogenase 
AIH    = Autoimmune Hepatitis 
AMA    = Anti-mitochondrial antibody  
ANA    = Anti-nuclear antibody 
A1ATD  = @-1-antitrypsin Deficiency 
APC    = Antigen Presenting Cell 
ARA    = Anti-reticulin Antibody 
ASC    = Autoimmune Sclerosing Cholangitis 
ASGPR  = Asialoglycoprotein Receptor 
ASP    = Aspartic Acid 
AST    = Aspartate Aminotransferase 
ATCC   = American Type Culture Collection 
BAF    = B Cell Activating Factor 
BB     = Bio Breeding 
BHSE   = Biotin Hydroxy Succinimide Ester 
BSA    = Bovine Serum Albumin 
C = Concordant 
CAH    = Chronic Active Hepatitis 
CBU    = Comparative Biology Unit 
CF-ICA = Complement Fixing Islet Cell Antibodies  
CFD    = Complement Fixation Diluent  
CLD    = Chronic Liver Disease 
CLDF   = Children's Liver Disease Foundation 
Con A  = Concanavalin A  
CTLL   = Cytotoxic T Cell Lymphocytes 
XIX
CV     = Coefficients of Variation 
D = Discordant 
DAB    = Diaminobenzidine Tetrahydrochloride 
DMSO   = Dimethyl Sulfoxide 
DNA    = Deoxyribonucleic acid 
DZ     = Dizygotic  
EDTA   = Ethylenediaminetetra-acetic Acid  
ELISA  = Enzyme Linked Immuno-sorbent Assay 
FCS    = Foetal Calf Serum 
FITC   = Fluorescein Isothiocyanate 
GABA   = Glutamic Amino Butyric Acid 
GAD    = Glutamic Acid Decarboxylase 
GD     = Graves' Disease 
GM-CSF = Granulocyte Colony Stimulating Factor 
GPC    = Gastric Parietal Cell  
HBSS   = Hank's Balanced Salt Solution 
HBV    = Hepatitis B Virus 
HCV    = Hepatitis C Virus  
HLA    = Human Leukocyte Antigen 
IAA    = Insulin Autoantibody  
ICA    = Islet Cell Antibody  
ICSA   = Islet Cell Surface Antibody  
IFL    = Immunofluorescence  
IFN-? = Interferon Gamma  
IL     = Interleukin 
IL-1ra = Interleukin-1 Receptor Antagonist 
LAF    = Lymphocyte Activating Factor 
XX
LGL    = Large Granular Lymphocytes 
LKM    = Liver Kidney Microsomal  
LMA    = Liver Membrane Antibody 
LPS    = Lipopolysaccharide 
LS     = Long-standing 
LSP    = Liver Specific Protein 
MAb    = Monoclonal Antibody 
MHC    = Major Histocompatibility Complex  
MNC    = Mononuclear Cell  
MHC    = Major Histocompatibility Complex 
ml     = Millilitre 
µl     = Microliter 
MZ     = Monozygotic  
NDDG   = National Diabetes Data Group 
NC     = Normal Controls   
NIBSC  = National Institute for Biological Standards and Controls 
NK     = Natural Killer 
NOD    = Non-obese Diabetic  
OCT    = OCT Compound 
OD     = Optical Density 
OPD    = O-phenylenediamine dihydrochloride 
PBC    = Primary Biliary Cirrhosis 
PBMC   = Peripheral Blood Mononuclear Cells  
PBS    = Phosphate Buffered Saline  
PEG    = Polyethylene Glycol  
PHA    = Phytohaemoagglutinin  
PMA    = Phorbol Myristic Acetate 
XXI
PP     = Pancreatic Polypeptide 
PSC    = Primary Sclerosing Cholongitis 
PWM    = Pokeweed Mitogen 
RD     = Recently Diagnosed 
RFLP   = Restriction Fragment Length Polymorphism 
SD     = Standard Deviation 
SEM    = Standard Error of the Mean 
SLA    = Soluble Liver Antigen 
SLE    = Systemic Lupus Erythematosus 
SMA    = Smooth Muscle Antibody 
TCGF   = T Cell Growth Factor 
TH = T Helper   
TNF-@ = Tumour Necrosis Factor-alpha 
Tc = T Cytotoxic 
Ts = T Suppressor  
Type 1 diabetes = Insulin Dependent Diabetes Mellitus 
Type 2 diabetes = Non-insulin Dependent Diabetes Mellitus 
WD     = Wilson's Disease 
WHO    = World Health Organisation   
XXII
PUBLICATIONS 
The following papers have been published or submitted for publication 
reporting studies contained in the present thesis: 
 
1- HUSSAIN MJ, MUSTAFA A, GALLATI H, MOWAT AP, MIELI-VERGANI 
G, VERGANI D.   
Cellular expression of TNF and IFN-? in the liver biopsies of children with chronic 
liver disease. J Hepatol (in press). 
 
2- HUSSAIN MJ, PEAKMAN M, LO SSS, VIBERTI GC, WATKINS PJ, LESLIE 
RDG, VERGANI D.  
Elevated serum levels of tumour necrosis factor-@ and interleukin-1@ presage and 
accompany the onset of Type 1 (insulin-dependent) diabetes.  
 
3- HUSSAIN MJ, MOWAT AP, MIELI-VERGANI G, VERGANI D. 
Serum levels of IL-1, sIL-2R, TNF-@ and IFN-? in children with chronic liver 
disease. 
 
4- HUSSAIN MJ, PEAKMAN M, WARNOCK T, VERGANI D. Circulating 
levels of TNF-@ and sIL-2R are high in families of patients with IDD. 
 
The following papers have been published or submitted for publication 
reporting studies unrelated to this thesis, but carried out during the period of Ph.D. 
studentship of the candidate (1/1990-9/1994):  
 
1- PEAKMAN M, HUSSAIN MJ, MILLWARD BA, LESLIE RDG, VERGANI D. 
(1990) 
Effect of initiation of insulin therapy on T-lymphocyte activation in type 1 diabetes. 
Diabetic Medicine 7:327. 
 
2- SMERDON RA, PEAKMAN M, HUSSAIN MJ, ALVIGGI L, WATKINS P, 
LESLIE RDG, VERGANI D. (1993)  
Increase in simultaneous co-expression of naive and memory lymphocyte markers at 
diagnosis of insulin dependent diabetes mellitus. Diabetes 42:127. 
 
3- GREALLY P, HUSSAIN MJ, SAMPSON AP, PIPER PJ, PRICE JF. (1993) 
Sputum TNF-@ and leukotrine concentration in cystic fibrosis. Arch Dis Child 
68:389.  
 
4- GREALLY P, HUSSAIN MJ, VERGANI D, PRICE JF. (1993) 
Serum IL-1@ and soluble IL-2 receptor concentrations in atopic dermatitis. Arch Dis 
Child 68:785. 
 
XXIII
5- SMERDON RA, PEAKMAN M, HUSSAIN MJ, VERGANI D. (1993)  
Lymphocyte vaccination prevents spontaneous diabetes in the non-obese diabetic 
mouse. Immunology 80:498. 
 
6- SENALDI G, PEAKMAN M, NATOLI C, HUSSAIN MJ, GALLATI H, 
McMANUS T, VERGANI D, IACOBELLI S.   
Relationship between the tumour-associated antigen 90K and cytokines in the 
circulation of persons infected with human immunodeficiency virus. J Infection 
28:31. 
 
7- PETTINGALE KW, HUSSAIN M, INAYAT Q, TEE DEH. (1994)  
Changes in Immune Status following Conjugal Bereavement. Stress Medicine 
10:145. 
 
8- HUSSAIN MJ, LAU JYN, WILLIAMS R, VERGANI D.  
Hepatic expression of tumour necrosis factor-@ in chronic hepatitis B virus infection. 
J Clin Pathol (in press) 
 
1ABSTRACT 
T lymphocytes and macrophages appear to play an important role in 
mediating ß-cell damage and causing Type 1 diabetes. Both activated T cells and 
macrophages operate and interact through the release of soluble factors called 
cytokines, which influence the type and magnitude of immune responses. It has been 
suggested that cytokines such as TNF-@ and IL-1@ can damage the N-cell directly. In 
Type 1 diabetes, cytokines are likely to have a critical role in individuals whose 
immune system is unbalanced allowing the emergence of self-destructive processes. 
To investigate this possibility, sensitive assays to detect a range of cytokines of 
potential relevance to the immune pathogenesis of diabetes were establised. Using 
these, serum levels of IL-1@, IL-1N, TNF-@ and IL-6 (macrophage-derived 
cytokines), IFN-? and IL-2 (T helper 1 cytokine profile) and IL-4 and IL-10 (T 
helper 2 profile) have been measured in patients with Type 1 diabetes of different 
disease duration. Increased levels of TNF-@, IL-1@, IL-2 and IFN-? were found in 
recently diagnosed patients with Type 1 diabetes when compared with both disease 
and metabolic control subjects and with normal controls. The presence of this profile 
of cytokines implies activation of the TH1 subset of helper cells near to diagnosis of 
Type 1 diabetes.  
 After having defined on singleton diabetics which pattern of cytokine 
alterations occur in Type 1 diabetes, studies were performed in a cohort of non-
diabetic identical twins of patients with Type 1 diabetes, some of whom went on to 
develop the disease themselves, in an attempt to determine whether cytokines could 
be involved in the pathogenesis of the disease. Increased levels of TNF-@ and IL-1@,
important mediators of cellular immunity, were detected up to 5 years before the 
clinical onset of Type 1 diabetes, while cytokine profiles classified as TH1 (elevated 
levels of IL-2 or IFN-?) or TH2 (elevated levels of IL-4 and IL-10) existed in both 
prediabetic or non-diabetic twins without dominance of either TH1 or TH2.  To 
examine alteration of cytokine levels and their relationship with autoantibodies and 
HLA alleles, cytokines were investigated in diabetic children and their first degree 
relatives. Circulating levels of TNF-@ and sIL-2R were not only increased in diabetic 
children but also in their first degree relatives and that increase was not related to 
autoantibodies or to any specific HLA class II allele (HLA-DR3/4). The study of 
cytokine secretion by peripheral blood mononuclear cells showed that LPS-
stimulated IL-1@ and TNF-@ secretion by PBMC in vitro are also significantly 
increased in diabetic children and their siblings and parents when compared with 
normal controls and that levels of T-cell cytokines, IL-2 and IFN-?, released after 
2PHA stimulation, are similar in diabetic children, their siblings and parents, and in 
normal controls.    
 Serum levels of cytokines and their cellular expression in the islets of 
Langerhans of non-obese diabetic (NOD) mice, an animal model of Type 1 diabetes 
were also studied to define the pattern of cytokine profile involved in this animal 
model. Serum levels of TNF-@ and IL-2 were elevated in diabetic NOD mice when 
compared with non-diabetic NOD mice and control mice. Both IFN-? and TNF-@
producing cells were present in the islets of Langerhans of diabetic NOD mice.  
 The involvement of cytokines in the development autoimmune liver disease, 
an organ-specific autoimmune disease, was investigated in serum as well as in the 
tissue of the target organ. Serum levels of the cytokines IL-1@, IL-6 and TNF-@ were 
significantly elevated in patients with various forms of chronic liver disease, 
including those with autoimmune hepatitis, when compared with normal controls. 
Levels of IFN-? and sIL-2R were significantly increased in patients with 
autoimmune hepatitis when compared with other forms of liver disease and normal 
controls. In contrast, levels of IL-4 were not different between patients with various 
forms of chronic liver disease and normal controls. Levels of IL-1@, IL-6, TNF-@
and sIL-2R were significantly higher in patients with cirrhosis than in patients 
without. A similar picture was found for disease activity and showed that levels of 
IL-1@, IL-6, TNF-@ and sIL-2R are significantly higher in patients with active 
disease than those with inactive disease.  
 Cells producing TNF-@ and IFN-? were present in the liver inflammatory 
infiltrate of children with autoimmune chronic liver diseases but were rarely seen in 
metabolic diseases such as Wilson's disease and alpha 1 antitrypsin deficiency. 
3CHAPTER 1
GENERAL INTRODUCTION 
41.1 HISTORY OF TYPE 1 DIABETES 
Diabetes mellitus is an ancient disease. The earliest description of its 
symptoms was found in the Ebers papyrus of Egypt, dating back to 1500 B.C 
(reviewed by Notkins, 1979 and Schadewaldt, 1989). In the second century A.D. 
Aretaeus of Cappadocia named the disease diabetes, the Greek word meaning "to 
flow through a siphon". "Diabetes", he wrote, "is a strange disease that consists of 
the flesh and bones running together into the urine". In the sixth century, Indian 
physicians recognised that the urine from diabetic patients was sweet. It was not 
known until the 18th century, however, that the sweet-tasting substance was 
identified as the sugar glucose and the word mellitus, or "honeyed" was added. 
 One of the first clues to the pathology underlying diabetes, came in 1889 
when Oscar Minkowski and Baron Joseph von Mering, working in Strasbourg, 
sought to determine whether the pancreas was essential to life. By careful surgical 
procedures they removed the pancreas from dogs; the day after operation the 
caretaker in the laboratory noticed that the dogs' urine attracted an unusual number 
of flies. In any event Minkowski and von Mering analyzed the urine and found in it 
high levels of glucose, indicating that the removal of the pancreas gave rise to a 
syndrome resembling diabetes. This finding strongly implied that the pancreas was 
secreting a substance that regulated the metabolism of glucose. All attempts 
(Minkowski in 1890, Goldscheider in 1894, Cohnheim in 1903 and others) to 
alleviate experimental diabetes by feeding pancreatectomized dogs raw pancreas or 
by injecting them with crude pancreatic extract, however, were unsuccessful 
(reviewed by Schadewaldt, 1989).   
 The existence of insulin was not known until two Canadian investigators, 
Frederick G. Banting and Charles H. Best, extracted insulin from dog pancreas. The 
first patient to receive the active extract prepared by Banting and Best was Leonard 
Thompson aged 14 who appeared at the Toronto General Hospital with blood 
glucose levels of 500 mg (Banting et al., 1922).  Extracts were first administered on 
January 11, 1922. These authors induced a reduction in the concentration and 
excretion of blood glucose. News of the experiment spread rapidly, and in a short 
time insulin was being widely and successfully employed to treat the acute 
symptoms of diabetes mellitus in patients. Until recently, virtually all insulin for 
therapeutic use was produced from porcine and bovine pancreas. The antigenicity of 
animal insulin led several clinicians to believe that human insulin might be of more 
benefit to diabetic patients (Yalow and Berson, 1961). Human insulin was 
introduced later and was originally prepared by extraction from cadaveric pancreas 
5(Nicol and Smith, 1960). Human insulin is now manufactured on a large scale by 
two fundamentally different processes involving enzymatic conversion of porcine 
insulin (Owens et al., 1986; Pickup, 1986). Alternatively human insulin is 
biosynthesized using recombinant DNA technology (Brange et al., 1988 and 1990). 
Although the treatment with insulin allows patients with diabetes to live an almost 
normal life, it is not able to reduce the prevalence of long-term diabetic 
complications. It may be that in the future, after knowing the cause of the disease, 
alternative approaches, such as immunotherapy and islet cell transplantation, will 
replace traditional insulin treatment.  
 
TERMINOLOGY 
Diabetes is not a single disease but rather a heterogeneous group of diseases 
that lead to an elevation of glucose in the blood. Chronic hyperglycaemia and the 
risk of developing complications are the two unifying properties which have held the 
notion of diabetes together. During the past decades, however, there has been 
remarkable progress in understanding diabetes. In 1951, RD Lawrence described 
"two types of diabetes mellitus, with and without plasma insulin" (Bornstein and 
Lawrence, 1951). The two main nosological entities recognised under the name of 
diabetes have been labelled in turn "diabète maigre" and "diabète gras", "juvenile 
onset type" and "maturity onset type" and more recently "insulin dependent" and 
"non-insulin dependent diabetes mellitus" (Type 1 and Type 2 diabetes) (reviewed 
by Keen and Tang Fui, 1982; Keen, 1986). The purely descriptive terms of Type 1 
diabetes and Type 2 diabetes have now been equated by the National Diabetes Data 
Group (NDDG) and the Expert Committee on Diabetes of the World Health 
organisation (WHO) with the terms "type 1" and "type 2"  to denote their distinct 
pathogeneses (National Diabetes Data Group 1979; WHO Technical Report series 
1980 and 1985). 
 
1.2 DIVERSITY OF DIABETES 
In his Claude Bernard lecture delivered to an audience of European 
diabetologists in 1979, DA Pyke noted that there was no longer serious need to 
debate the proposition that insulin dependent and non-insulin dependent diabetes are 
two distinct entities (Pyke, 1979). The evidence then available consisted of the 
following compelling arguments:  
(1) Type 1 diabetes and Type 2 diabetes are different histologically. A striking 
feature of Type 2 diabetes is the relative normality of the islets compared to Type 1 
6diabetes where they are heavily infiltrated by mononuclear white cells, in a process 
known as insulitis (Gept, 1965). 
(2) If Type 2 diabetes were due to a degenerative process in the N-cell it would 
presumably progress, eventually leading to insulin dependence; yet this is a rarity. 
More often these patients can be controlled without insulin. This static situation in 
Type 2 diabetes is in striking contrast to the insulin dependent type where a 
destructive process affecting the islets leads to complete failure of insulin 
production. 
(3) Islet cell antibodies are commonly found in  newly diagnosed cases of Type 1 
diabetes, rarely in Type 2 diabetes. 
(4) Type 1 diabetes is associated with certain HLA alleles, whereas Type 2 diabetes 
is not. 
(5) Identical twin studies show widely different concordance rates in the two types. 
 The different and often conflicting findings about the nature of diabetes and 
its heterogeneity have provoked the establishment of strict criteria for its diagnosis 
and classification. The NDDG classification of diabetes separates insulin dependent 
(type 1) patients from those who are non-insulin dependent (type 2) irrespective of 
age. A third group of patients fall in the "other types" category, which includes 
hyper-glycaemia associated with other forms of disease such as pancreatic diseases, 
hormonal abnormalities, drug or chemical induced diseases and a variety of genetic 
syndromes. 
 Type 1 diabetes (insulin dependent) is characterised by severe and 
pathognomonic changes in the pancreatic islets, by an eventual absolute deficiency 
of endogenous pancreatic insulin secretion, insulinopaenia, proneness to ketosis and 
a dependency on daily insulin administration for the maintenance of life. It can be 
developed at any age and its onset is more abrupt than type 2 (reviewed by Skyler 
and Cahill, 1981). 
 Type 1 diabetes appears to be heterogeneous in terms of genetics and 
environmental factors that precipitate the disease (Rotter and Rimoin, 1978). 
Genetic determinants are thought to be important in most patients, as expressed by 
the associated increased frequency of certain histocompatibility antigens on 
chromosome 6 (Nerup, 1976; Cudworth and Woodrow, 1976). Abnormal immune 
responses and autoimmunity are also thought to play an aetiologic role, and islet cell 
antibodies are frequently present at diagnosis in this type of diabetes (reviewed by 
Irvine, 1979). 
 Type 2 (non-insulin dependent) diabetes, frequently presents with minimal 
7or no symptoms referrable to the metabolic aberrations of diabetes and is the much 
more prevalent type. It is characterised by retention of endogenous pancreatic insulin 
secretion, although with altered secretory dynamics; the absence of ketosis; and 
insulin resistance due to diminished target cell response to insulin. Patients with 
non-insulin dependent diabetes mellitus are usually not dependent on insulin for 
prevention of ketosis or maintenance of life, although they may require insulin for 
correction of symptomatic or persistent fasting hyperglycaemia, if this cannot be 
achieved with the use of diet or oral agents (reviewed Skyler and Cahill, 1981). The 
whole range of insulin responses to glucose, from low to supranormal has been 
reported to be associated with insulin resistance (Reaven, 1984). Type 2 diabetes 
also has a genetic basis, which appears to be stronger than in type 1 diabetes, as 
evidenced by a more frequent familial pattern of occurrence (Fajans et al., 1978). 
Environmental factors superimposed on genetic susceptibility are undoubtedly 
involved in the onset of the disease. Some of the patients with this type of disease 
may develop insulin dependent diabetes later. Characteristic aggregation of HLA 
types and islet cell antibodies have not been found in patients with type 2 diabetes. 
1.3 PATHOGENESIS OF TYPE 1 DIABETES  
 By the time Type 1 diabetes appears, most of the N-cells in the pancreas have 
been destroyed. Gepts (1965) observed in his seminal study different lesions in 
patients with type 1 diabetes. He concluded that these represent different stages of 
the same destructive process. It was suggested later that the destructive process is 
relatively slow and it might take years for diabetes to develop (Tarn et al., 1987).  
 
1.3.1 PATHOLOGICAL CHANGES 
 A lymphocytic infiltration in and about the islets of Langherans was first 
noted in 1910 by Opie and Weichselbaum. They reported that: "These cells are small 
lymphocytes with an occasional polymorphonuclear cell but without eosinophils or 
plasma cells". This lesion was later to be named as "insulitis" by Von Mayenburg in 
1940.  Subsequently, in 1952, Ware and Le Compte reported that: "This type of 
change is particularly apt to be found in a young individual and is associated with 
severe diabetes". Later, Gepts provided a major contribution in the understanding of 
the pathology of Type 1 diabetes, by observing that islet inflammation is never a 
uniform lesion (Gepts, 1965). 
 Gepts (1965), in his study, observed three types of lesions. The first type is 
insulitis, which is presently considered the hallmark of Type 1 diabetes, but it is not 
8the most frequent lesion observed at the clinical onset of the disease. The second 
type is the pseudoatrophic islet, the most common lesion, which is small, 
inconspicuous and completely devoid of insulin producing N-cells; however, it still 
contains cells secreting glucagon, somatostatin and pancreatic polypeptide. No 
inflammatory cells are present in pseudoatrophic islets. The heavy mononuclear cell 
infiltrate is present in fewer and better preserved islets, where the N-cells are mainly 
surrounded by lymphocytes. The third type is an intermediate lesion between 
insulitis and pseudoatrophic islets which is also described where islets contain 
decreasing amount of N-cells and fewer numbers of inflammatory mononuclear cells. 
Disappearance of N-cells is accompanied by disappearance of inflammatory cells. 
Appearance of foci of N-cell regeneration is associated with reappearance of 
lymphocytes in large numbers. 
 
1.3.2 GENETIC SUSCEPTIBILITY  
 It has been known for some time that diabetic patients frequently have a 
family history of the disease i.e. the disease is present among relatives of diabetics. 
The familial aggregation is more common in Type 2 diabetes than in Type 1 diabetes 
(Gamble, 1980; Rotter and Rimoin, 1981).  
 The evidence that Type 1 diabetes is not entirely genetic in its origin came 
from the world's largest twin study by Pyke and collaborators (Pyke, 1979). Initially, 
this study reported a concordance rate for Type 1 diabetes of 50% (Tattersall and 
Pyke 1972; Pyke, 1979), but a subsequent analysis of an extended series of twins 
suggests a figure of 36% (Leslie and Pyke, 1986); smaller studies show concordance 
of 20% (Gottlieb and Root, 1968; Cahill, 1979). These observations suggest that 
disease susceptibility is inherited and that another factor, presumably environmental, 
converts this susceptibility into clinical disease. 
 The association between the HLA region and Type 1 diabetes came from a 
study on families of affected individuals which showed that type 1 diabetes present 
in family members segregates with particular HLA haplotypes (Cudworth and 
Woodrow, 1975). Subsequent studies found a marked excess of affected sib pairs 
who were HLA identical (i.e., both HLA haplotypes had been inherited in common), 
implying that genes influencing the predisposition to diabetes are often inherited 
from both parents (Cudworth, 1978). Other authors confirmed these observations, 
but considerable argument has taken place concerning the mode of inheritance of the 
HLA susceptibility factor and as to whether it is dominant or recessive (Barbosa et 
al., 1977; Bengsch et al., 1978). Thus, Barbosa et al. (1980) selected patients in order 
9to identify two sets of families: those with horizontal and those with vertical 
aggregation. These authors assumed that the recessive inheritance operates for the 
first set while dominant inheritance operates for the second (Barbosa et al., 1978 and 
1980). This hypothesis has been criticised by Suarez and Van Eerdewegh (1981) 
who found these different aggregation patterns did not reflect true differences in 
mode of inheritance but rather differential selection  of families with an aggregation 
of diabetes susceptibility genes (Suarez and Van Eerdewegh, 1981). 
 Recent combined analyses of a large number of Type 1 diabetic families with 
two or more affected siblings concluded that the HLA region on human 
chromosome six encodes one (or more) susceptibility genes(s) (reviewed by Todd, 
1990). These genes contribute 30 to 60% of genetic susceptibility to Type 1 diabetes 
(Rotter and Landaw, 1984; Risch, 1987). 
 
1.3.3 HLA 
The major histocompatibility complex (MHC) was recognized by its major 
influence on transplantation rejection and by international agreement the human 
MHC has been labelled HLA (Human Leukocyte Antigen) (Roitt, 1988).  
 The genes coding for the HLA antigens are on chromosome 6 and form three 
main classes. Class I molecules consist of one heavy and one light polypeptide chain 
and are the products of three reduplicated loci: HLA-A, HLA-B and HLA-C. These 
loci are paired in each individual and each of these chromosome sets is termed a 
haplotype. Class I molecules are found on almost every nucleated cell in the body 
and transcribed from both the maternal and paternal chromosomes.  
 The genetic region coding for MHC class II molecules is called HLA-D 
region, this includes DP, DQ and DR antigens. Their distribution is more limited 
than that of class I molecules: they are expressed constitutively only on B 
lymphocytes, monocytes/ macrophages, dendritic cells, thymic epithelial cells and 
on activated but not resting T cells (Winchester and Kunkel, 1980).  
 MHC class III molecules comprise a group of complement components. 
These are C2 and C4 of the classical pathway and Bf, coding for factor B of the 
alternative complement pathway. They are proteins found in serum rather than on 
cell surfaces. Unlike class I and II molecules, MHC class III molecules do not appear 
to control the immune response nor do they serve as transplantation antigens (Roitt, 
1988). 
 The genetic association of HLA antigens with Type 1 diabetes was initially 
described in 1974 by Cudworth and Woodrow in Britain and Nerup and colleagues 
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in Denmark. They found that the class I HLA antigens, B8 and B15 are two or three 
times more common in Type 1 diabetics than in Type 2 diabetics. The association 
between Type 1 diabetes and class II antigens/complex (HLA-D/DR locus) was 
reported later by Barbosa et al. (1979) and Sachs et al. (1980) but the information 
was limited. In 1982, Cudworth and Wolf reported that Type 1 diabetes was even 
more closely associated with the class II HLA antigens D/DR3 and D/DR4, in which 
the genes for the B8 and B15 are in linkage disequilibrium. 
 The possibility that more than one gene in the HLA complex determines 
susceptibility to Type 1 diabetes has been suggested by a Danish group (Svejgaard et 
al., 1975). Subsequent studies by Bottazzo and Doniach (1976), and Irvine (1977) 
who proposed that Type 1 diabetes could be subdivided into autoimmune and viral-
induced types, with an intermediate group in Irvine's classification. Rotter and 
Rimoin (1978) proposed further heterogeneity based on differential immunological 
correlations with different HLA phenotypes. These authors postulated that Type 1 
diabetes associated with HLA B8-DR3 is a disease distinct from Type 1 diabetes 
associated with HLA B15-DR4, the first being an autoimmune form, the second 
representing an "insulin antibody responder type", characterised by a vigorous 
humoral immune response to exogenous insulin. 
 Studies of restriction fragment length polymorphism (RFLP) in the HLA-D 
(class II) region suggest that variation in the DQ-N region may be more strongly 
associated with risk for Type 1 diabetes than is variation in the DR region, at least as 
regards the HLA-DR4 associated susceptibility (Owerbach et al., 1983; Monos et al., 
1987; Todd et al., 1987; Nepom, 1990). This variant called the DQ-N w3.2 allele, 
occurs in as many as 90-95% of those Type 1 diabetes who carry the HLA-DR4 
allele and about 60-75% of HLA-DR-carrying of non-diabetic controls (Monos et 
al., 1987). Todd et al. (1987) in their molecular studies focused on the DQ-N region, 
found also a difference between haplotypes which are and are not associated with 
increased risk for Type 1 diabetes. Those haplotypes which are not associated with 
increased risk all coded for the amino acid residue aspartic acid (ASP) at position 57 
of the DQ-N chain, while the "high risk" haplotypes, including DR4/DQ-N w3.2, 
DR3/DQ-N w2, DR1/DQ-N w1.1 and DR2/DQ-N w1.AZH, were all associated with 
residues other than ASP at position 57 (Todd et al., 1987). It was then concluded 
that the disease susceptibility is most closely associated and linked to the HLA-class 
II region, containing the HLA-DR and DQ loci (reviewed by Todd, 1990).  
 Protection from Type 1 diabetes may be conferred by genes in the HLA 
region. These include DR2 (Platz et al., 1981) and a 3.7 kb DQ-N fragment 
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(Owerbach et al., 1983), the latter being protective when carrying an ASP at position 
57 (ASP 57-positive) (Todd et al., 1987). The implication of both DQ-@1 and DQ-
N1 in HLA-associated protection from Type 1 diabetes has been investigated 
recently by Cavan et al. (1993). These authors found that the DQ-@1 and DQ-N1
alleles linked with DR2, DRw6 and DR7 haplotypes are associated with protection 
from diabetes in British Caucasoid, and the presence of aspartate at position 57 is 
unlikely, on its own, to be an important determinant of disease protection (Cavan et 
al., 1993).   The role of HLA in the aetiology of Type 1 diabetes has been 
challenged by a number of studies, including that by Pyke noted above 
demonstrating that concordance rates of Type 1 diabetes in monozygotic twins are 
50% or less (Pyke, 1979). This evidence does not support HLA as being the primary 
familial susceptibility determinant in Type 1 diabetes and suggests that the inherited 
component is disease susceptibility. Thus, so far as Type 1 diabetes is concerned, 
HLA genotyping is of limited value in genetic counselling and can be justified only 
in terms of assessment of disease susceptibility. Attempting to predict the incidence 
of type 1 diabetes by HLA-typing individuals without studying other factors which 
are involved in the predisposition of the disease has no practical value.  
 Studies on identical twins (genetically similar) especially those discordant 
for diabetes (one twin is diabetic and his co-twin is not) may provide information 
regarding the relative role of genetic and environmental factors in developing of 
Type 1 diabetes. 
 
1.3.4 TWIN STUDIES 
Twins studies represent one approach to resolving the question whether 
familial aggregation of a disease can be due either to genetic or environmental 
factors (Rimoin and Rotter, 1984). The frequency of concordance (both members of 
the twin pair affected) of monozygotic (identical) twins is compared with that of 
dizygotic (fraternal) twins. Monozygotic twins share all genes, and thus theoretically 
should be concordant for disorders with purely genetic aetiology. Dizygotic twins 
share only half their genes and are thus no more alike genetically than any pair of 
sibs. The research, conducted by David Pyke and his colleagues at King's College 
Hospital in London, on diabetic twins was started in early 1970's (Tattersall and 
Pyke, 1972). More than a hundred pairs of identical twins were examined, the largest 
series of twins ever studied. They found that when one twin of a pair developed 
diabetes after the age of 50 years, the other twin developed the disease within several 
years in almost every case. If one twin developed the disease before the age of 40, 
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however, the other twin developed it in only half of the cases. They found also that 
the majority  of the twins over 40 had Type 2 diabetes, whereas most of those under 
40 had Type 1 diabetes. It was then suggested that there are at least two types of 
diabetes: one mainly inherited (Type 2 diabetes), the other mainly environmental 
(Type 1 diabetes).    
 The evidence accumulated by the King's twin study, was extended and 
reassessed in 1979 when the number of identical twin pairs recruited into that study 
was 185 (Pyke, 1979). In most concordant pairs, twins became diabetic at about the 
same time within 5 years in two thirds (66%) and within 10 years in nine tenths 
(10%). On the other hand in the discordant pairs, a third (33%) had gone for more 
than a 10 year interval since the first twin developed diabetes and the second twin 
was still not diabetic. The conclusion of this study was that in many, and probably 
most, discordant pairs in which the first twin had Type 1 diabetes for more than 5 
years the second twin would always remain unaffected. This highlights non-genetic 
factors, probably environmental, in the initiation of the disease (Olmos et al., 1988). 
 
1.3.5 ENVIRONMENTAL FACTORS 
Viruses and, to a much lesser extent, toxins are the environmental factors 
that have been recurrently implicated in the development of Type 1 diabetes. 
Epidemiological studies have confirmed the relevance of environmental factors to 
the induction of Type 1 diabetes. Observation on the onset of Type 1 diabetes in 
various seasons of the year forms the first body of circumstantial evidence. The 
possible role of viruses in the cause of diabetes was suggested before the turn of the 
century when its association with mumps was first reported. In the early 1920s, 
Gunderson noted an increased prevalence of diabetes in several Scandinavian 
villages after outbreaks of a mumps virus infection, and in a subsequent publication, 
he asked: "Is diabetes of infectious origin?" (Gunderson, 1927). Although this 
question remains unanswered, intriguing information has accumulated supporting 
the view that viruses may be aetiologically responsible for at least some cases of the 
disease (Gamble and Taylor, 1969; MacMillan et al., 1977). Circumstantial evidence 
connecting viruses with Type 1 diabetes came initially from an association of certain 
childhood viral infections with the onset of the disease.   
 The appearance of Type 1 diabetes may coincide with mumps (Kremer, 
1947; Hinden et al., 1962; Messaritakis et al., 1971), rubella (Forrest et al., 1971; 
Smithsells et al., 1978), cytomegalovirus (Hultqist et al., 1973) and Epstein-Barr 
virus infection (Burgess et al., 1974). In 1968, Gamble et al. reported an association 
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between infection with Coxsackie virus group B, type 4, and Type 1 diabetes 
(Gamble et al., 1969). The claim of these investigations was based on the 
demonstration of an increased prevalence, and high titre, of anti-viral antibodies in 
diabetic subjects, compared to normal controls, though a subsequent study failed to 
demonstrate differences in the antiviral antibody titre in identical twins discordant 
for Type 1 diabetes (Nelson et al., 1975). An increased frequency of IgM antibodies 
to Coxsackie B1-6 was also found in a subsequent study in children, 2-16 weeks 
after the onset of Type 1 diabetes (King et al., 1983). The presence of Coxsackie B 
virus IgM (CBV-IgM) was found not only in children with newly-diagnosed Type 1 
diabetes, but also in a recent study, in their siblings (Frisk et al., 1992). When a high 
cut-off value was used, 16/35 (46%) diabetic children and 16/47 (34%) siblings 
showed positive CBV-IgM antibodies. The first direct evidence that viruses are 
capable of causing diabetes in human beings came in 1979 by Yoon and his 
colleagues. These authors isolated a Coxsackie B4 virus from the pancreatic tissue 
of a child with meningo-encephalitis and diabetes of sudden onset (Yoon et al., 
1979). Subsequent studies of the pathological findings in the child's pancreas, 
however, indicated that extensive N-cell damage with features of chronicity might 
have preceded the infection (Gepts and Lecomte, 1984). It was then recognised after 
reviewing studies on the pathogenesis of Type 1 diabetes that the disease develops 
over years, with viruses representing environmental triggering events, preceding the 
onset of Type 1 diabetes (Bottazzo et al., 1985).  
 The mechanism by which a virus might initiate autoimmunity against beta 
cells is now the subject of considerable speculation. One possible mechanism by 
which viruses, and in particular the CBV, produce diabetes may be by molecular 
mimicry (Rewers et al., 1987; Bae et al., 1990). In molecular mimicry, sequence and 
epitope homologies between viral antigens and host determinants result in the 
generation of host-specific immune responses (Reviewed by Szopa et al., 1993b). It 
has been noted that there was an extensive similarity between the GAD65 proteins 
(glutamic acid decarboxylase, the biosynthetic enzyme of ?-amino-butyric acid 
[GABA], high levels of which are expressed in beta cell) and the P2C protein of 
CB4 virus (Kaufman et al., 1992; Bu et al., 1992). 
 Alternatively, viruses may alter N-cell surface antigens, marking the cell as 
foreign tissue and targeting it for immunological destruction (Oldstone et al., 1991). 
Viruses could also induce the expression of HLA class I and II antigens on the 
surface of N-cells, thereby initiating their destruction, or induce cytokines such as 
interferon, interleukins and tumour necrosis factor, thereby altering the immune 
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response by regulating the expression of N-cell antigens and thus contributing to 
tissue inflammation (Campbell et al., 1988; Cavallo et al., 1994).    
 Toxins can also kill N-cells and give rise to diabetes. Streptozotocin is of 
particular interest because it is directly N-cytotoxic and capable of inducing diabetes 
(Like and Rossini, 1976). Further studies indicated that high doses of streptozotocin 
is directly toxic to the N-cells but seems to induce an autoimmune type of diabetes 
when given as multiple small doses to certain strains of mice (Kolb et al., 1987).  
 A food additive, such as N-nitroso-compounds, a component of processed 
mutton was also reported to cause ketosis-prone diabetes in Iceland (Helgason and 
Jonasson, 1981).  
 Although environmental factors are involved in the pathogenesis of Type 1 
diabetes, they seldom act alone. They act with other factors such as genetic elements 
including the genes within and without the HLA region. An insight on how such 
diverse elements interact to produce Type 1 diabetes can be gained by studying 
animal models of the disease.   
 
1.3.6 ANIMAL MODELS OF TYPE 1 DIABETES 
Major advances in the field of autoimmunity have been achieved using 
animal models. These allow the natural history of a disease to be studied, including 
the subclinical prodrome; they allow manipulation of breeding and rearing to study 
genetic and environmental influences; and they allow experimentation with 
therapies.   
 By the end of 1980 more than 10 strains of spontaneously diabetic rodents 
were established as useful experimental animals (Makino et al., 1980). One of the 
most well known animal models bearing a striking resemblance to human Type 1 
diabetes is the non-obese diabetic (NOD) mouse.  
 The NOD mouse, also called the Tochino mouse, was derived from a sub-
line of the CTS strain in Japan, and has been described by Makino et al. (1980). 
About 80% of females and 20% of males become diabetic. The animals are lean, 
ketosis prone, and develop pancreatic insulitis around 4-5 weeks after birth. 
Following insulitis, total absence of pancreatic N-cells is found, which results in 
insulinopaenia (Kano et al., 1986). The finding of lymphocytes infiltrating islet N-
cells suggested that diabetes in NOD mice is an immune-mediated disease. The 
autoimmune origin of the disease has been further documented by the fact that 
purified T cells from diabetic mice can adoptively transfer diabetes into intact 
newborn, or irradiated adult recipients (Bendelac et al., 1987; Miller et al., 1988). 
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Affected mice usually bear a unique class II MHC gene (Hattori et al., 1986), and 
have reduced numbers of T lymphocytes, natural killer cells and cytotoxic 
lymphocytes (Kataoka et al., 1983). Autoantibodies such as islet cell surface 
antibodies (ICSA), intra-cytoplasmic antigens (ICA) (Yokono et al., 1984; Hari et 
al., 1986) and insulin autoantibodies (Michel et al., 1989) are also detected in sera of 
NOD mice. However, autoantibodies against glutamic acid decarboxylase (GAD) in 
the NOD mouse are absent and it has been demonstrated recently that GAD is 
expressed at low level in mouse islets (Velloso et al., 1993).   
 Thus the NOD model may provide a unique opportunity to evaluate the 
respective contribution of cell-mediated and humoral immune responses in a 
spontaneous organ-specific autoimmune disease.  
 
1.4 TYPE 1 DIABETES "AN IMMUNE MEDIATED DISEASE". 
Eisenbarth (1986) concluded in his seminar given at the Beth Israel Hospital, 
Boston, after evaluating the information available, that there is sufficient evidence to 
support the contention that Type 1 diabetes is an immune mediated disease 
(Eisenbarth, 1986).  
 A variety of humoral and cellular immune changes have been detected in 
newly diagnosed patients with Type 1 diabetes, including production of 
autoantibodies to pancreatic islet cells, increased number of activated T lymphocytes 
and alterations in number and function of immunoregulatory T lymphocytes and 
natural killer cells (reviewed by Vergani, 1987a). Thus, evidence exists supporting 
the concept that Type 1 diabetes is an autoimmune disease.  
1.4.1 STUDIES ON CELLULAR IMMUNITY IN TYPE 1 DIABETES 
The involvement of lymphocytes in the pathogenesis of Type 1 diabetes has 
been proposed on the basis of numerous observations. In 1971, Nerup et al. first 
reported inhibition of migration of leukocytes specific for the endocrine pancreas in 
Type 1 diabetes (Nerup et al., 1971). Subsequent studies confirmed this observation, 
using the leucocyte migration inhibition test for in vitro detection of cellular 
(delayed type) hypersensitivity in man (McCuish et al., 1974).  
 T cell involvement in the pathogenesis of Type 1 diabetes has been 
documented in several studies. The presence of T cells was first detected by 
Bottazzo et al (1985) in the pancreatic islets (insulitis) of a child who died soon after 
the onset of diabetes. This author found that the predominant cells were T cells and 
the majority of these were CD8 positive. In addition, the disease can be transferred 
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with purified T cells from diabetic NOD mice to healthy newborn animals (Bendelac 
et al., 1987). Prevention of the disease by T cell depletion or inactivation has also 
been achieved by neonatal thymectomy in the BB rat (Like et al., 1982) and the 
NOD mouse (Tochino, 1986).  
 The availability of monoclonal antibodies detecting lymphocyte surface 
markers has attracted many investigators to study the possibility that Type 1 diabetes 
is associated with an imbalance in the relative proportion of T lymphocyte subsets. 
Mature T lymphocytes are divided into two main populations, expressing other CD4 
and CD8 molecules (Blue et al, 1985). CD4-expressing T lymphocytes are 
immunoregulatory cells frequently termed helper or helper/inducer in view of their 
ability to initiate, promote and enhance the functions of other immune cells such as 
B lymphocytes and macrophages (Reinherz and Schlossman, 1980). CD8 expression 
is detectable on approximately one third of peripheral blood T cells, and in 
functional terms these cells have come to denote cells with a suppressor or cytotoxic 
function (Gatenby et al., 1982). CD4 and CD8 molecules bind to class II and I HLA 
molecules respectively, stabilising the interaction between the T cell receptor and 
antigen held within the cleft of the HLA molecule on the antigen presenting or target 
cell (Doyle and Strominger, 1987; Norment et al., 1988). More recently, T 
lymphocytes have been divided according to their patterns of secretion of cytokines 
(Mosmann et al., 1986; Romagnani, 1991). This approach was established for CD4+ 
lymphocytes initially. Interleukin-2 and IFN-? secretion defines cells involved in 
delayed-type hypersensitivity reactions (TH1) while TH2 cells, involved in activating 
B lymphocytes, secrete IL-4, IL-5 and IL-10. 
 Several studies have detected abnormal numbers of the main CD4 and CD8 
functional T lymphocytes subsets at diagnosis of Type 1 diabetes, but there is no 
consistent picture as to the direction of the change. Both increased, decreased and 
normal levels of CD4+ lymphocytes have been described (Galluzzo et al., 1984; 
Herold et al., 1984; Scheinin et al., 1988).  A slightly clearer picture has been 
obtained in studies of CD8+ lymphocytes, which appear to be reduced at diagnosis 
in most (Galluzzo et al., 1984; Scheinin et al., 1988 ) but not all (Herold et al., 1984) 
studies. The study of CD8+ T lymphocytes in twin populations with Type 1 diabetes 
has indicated that the reduction may be genetically determined since it was detected 
in diabetic twins of pairs concordant for the disease and also in non-diabetic co-
twins from long term discordant pairs in whom diabetes is unlikely to develop 
(Johnston et al., 1988). A reduction in CD8+ lymphocytes would be consistent with 
one of the classic theories of the pathogenesis of autoimmune disease, namely that a 
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reduction in the suppressor mechanism may facilitate the appearance of 
autoimmunity but it is most unlikely to be the direct cause of Type 1 diabetes 
(Cooke, 1988).  
 Increased levels of circulating activated (HLA-DR+) T lymphocytes at the 
diagnosis of Type 1 diabetes have been a consistent finding (Jackson et al., 1982; 
Pozzilli et al., 1983; Alviggi et al., 1984; Scheinin et al., 1988). They are present 
before insulin treatment (Peakman et al., 1990) and have a tendency to decline as 
time from diagnosis increases (Alviggi et al., 1984).  
 In addition to T cells, macrophages have been demonstrated in insulitis 
lesions. In the BB rat, the appearance of macrophages in islets of Langerhans is the 
first event heralding the onset of insulitis (Walker et al., 1988; Hanenberg et al., 
1989). Manoeuvres designed to inhibit macrophages function, such as 
administration of silica, inhibit the development of diabetes in the BB rat 
(Oschilewski et al., 1985). Macrophages have also been detected in the pancreatic 
islets in man when pancreas from patients with Type 1 diabetes was available for 
histological examination at diagnosis (Foulis et al., 1991).  
 The most convincing evidence of the involvement of the immune system in 
the pathogenesis of Type 1 diabetes was provided by surgeons and not by 
immunologists! Sutherland and colleagues (1984) transplanted a portion of pancreas 
from four identical unaffected twins into their diabetic co-twins. Diabetes was 
initially cured but a few weeks after transplant the disease recurred. The histological 
examination of the transplanted pancreas revealed heavy lymphocytic infiltration of 
the islets and 90% of infiltrating lymphocytes were positive for the CD8 marker, 
which is present on cytotoxic and suppressor T lymphocytes (Sutherland et al., 
1984). Since the twins were genetically identical this cannot be the result of tissue 
rejection and indeed the exocrine pancreas was not involved in the inflammatory 
process. These observations indicate that patients with Type 1 diabetes have 
circulating memory T-lymphocytes which are sensitised to N-cells and capable of 
destroying them. 
 This work by Sutherland provides the strongest evidence currently available 
to answer the question of whether the immune system is connected with the 
development of Type 1 diabetes.  
 
1.4.2  STUDIES ON HUMORAL IMMUNITY IN TYPE 1 DIABETES 
The discovery of islet cell antibodies (ICA) by Bottazzo et al. in 1976 first 
implicated autoimmunity in Type 1 diabetes (Bottazzo et al., 1976). Further studies 
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by others such as Lendrum et al. (1976), Del Prete et al. (1977), Lernmark et al. 
(1987) and Riley et al. (1990) confirmed his observation. These authors found that 
ICA can be detected in 60-70% of newly diagnosed Type 1 diabetic patients and in 
5-8% of first-degree relatives. Immunofluorescence studies show that the antibody 
reacts with the cytoplasmic components of all four cell types in  
the islets (@, N, X and pp)* indicating the lack of specificity for the N-cell (Dobersen 
et al., 1980). In 1980, Bottazzo et al. described complement fixing islet cell 
antibodies (CF-ICA) which seem to be more specific markers of islet-cell damage, 
probably because some of them react exclusively with N-cells (Bottazzo et al., 1980). 
At diagnosis of Type 1 diabetes, CF-ICA is present in fewer patients than 
conventional ICA. Since CF-ICA is directed against cytoplasmic and not membrane 
antigens, attempts were made to identify antibodies directed against surface 
membrane of N-cells. Circulating antibodies against the surface of rat islet cells were 
detected in children with Type 1 diabetes by Lernmark et al. (1978). These authors 
found that islet cell surface antibodies (ICSA) were present in 32% of children tested 
after the onset of the disease (1 day-5 years) (Lernmark et al., 1978) and, in a 
subsequent study, approximately 67% had a positive reaction at diagnosis, but this 
percentage declined thereafter (Lernmark et al., 1981). ICSA, however, is present 
only in about half of the patients with Type 1 diabetes and up to 8% of healthy 
individuals, thus putting its pathogenic role in doubt (Gleichmann and Bottazzo, 
1987). 
 
____________________________________________________________________________________________________
____* The islets of Langerhans are composed of at least four different types of islet 
cells: the insulin-secreting N cells, the glucagon-secreting @ cells, the somatostatin-
secreting X cells, and a fourth type of cells which have been shown to secrete 
pancreatic polypeptide (pp) and are therefore designated as pp cells. They have a 
distinct pattern of localization. For example, in the islets of the tail, the body and the 
ventral part of the head, N cells represent the predominant type of cells (71%), 
followed by @ cells (20%), D cells (8%) and PP cells (<2%). 
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Another autoantibody found in Type 1 diabetes is the insulin autoantibody 
(IAA) (Palmer et al., 1983). IAA has been detected in 38% newly diagnosed patients 
before treatment with insulin and in 47% of unaffected identical twins of Type 1 
diabetes (Wilkin et al., 1985). IAAs appear to have little prognostic significance in 
the absence of ICAs, however, these are present in combination in 50% of those who 
develop Type 1 diabetes and are highly predictive (Ziegler et al., 1989; Atkinson et 
al., 1986). It has been suggested that anti-insulin antibodies may originate from 
insulin receptor antibodies in accordance with the idiotype anti-idiotype mechanism 
(Cooke et al., 1984). Although IAA is directed at a N-cell specific product, insulin, it 
is unlikely to be the initiator of N-cell damage, since insulin has a protected location 
within  granules in the N-cell, a site surely inaccessible to the immune system.  
 In the early 1980, Baekkeskov et al. reported that sera from newly diagnosed 
diabetic children consistently immunoprecipitated a human pancreatic islet cell 
protein having a molecular weight of 64 kilodaltons (64 kD) (Baekkeskov et al., 
1982). Antibodies to a 64 kD protein are associated with Type 1 diabetes and have 
been detected years before the onset of symptoms. They are also present in the two 
animal models of Type 1 diabetes, the NOD mouse and the BB rat (Baekkeskov et 
al., 1984; Atkinson and Maclaren, 1988; Atkinson et al., 1990). A 64 kD islet cell 
protein identified as glutamic acid decarboxylase (GAD) (Baekkeskov et al., 1990) 
responsible for the synthesis of ?-amino-butyric acid (GABA) was found in the 
brain, peripheral neurons, the pancreas and other organs (Baekkeskov et al., 1990; 
Erdö and Wolff, 1990). Autoantibodies to a 64 kD protein appear to be more 
predictive for diabetes than insulin or islet cell cytoplasmic antibodies which can be 
detected years before symptoms of Type 1 diabetes (Atkinson et al., 1990).   
 Antibodies to other protein fragments of 50 kD, 40 kD and 37 kD have been 
reported in patients with new-onset type 1 diabetes (Christie et al., 1990). Antibodies 
to the 50 kD fragment are found in most Type 1 diabetic patients (81%) and is 
positively associated with antibodies to the 64 kD fragment, but is also present in 
15% of identical twins who remain discordant for diabetes (Christie et al., 1991). In 
contrast, antibodies to the 40 kD and 37 kD antigens were found in the majority of 
Type 1 diabetic patients (78%), correlated well with ICA. However no association 
was found with the 64 kD fragment and the 40 kD and 37 kD autoantibodies were 
present in only 2% of discordant twins (Genovese et al., 1991).  All autoantibodies 
described so far belong to the immunoglobulin G class and freely cross the placenta. 
In mothers with Type 1 diabetes, therefore, these autoantibodies are transferred to 
the foetus (Gleichmann and Bottazzo, 1987). In spite of this, there is no reported 
evidence of babies born to mothers with Type 1 diabetes having perinatal diabetes. 
This contrasts, for example, with Graves' disease, in which the placental transfer of 
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antibodies to thyroid-stimulating hormone receptor produces neonatal thyrotoxicosis 
(McGregor et al., 1984). This finding cannot exclude a pathogenic role of 
autoantibodies in Type 1 diabetes, because failure to transfer the disease trans-
placentally could be due to low levels of autoantibodies in the circulation of the 
mothers.  
 On the basis of the available evidence, the precise role of autoantibodies in 
the pathogenesis of Type 1 diabetes is uncertain and still disputed. Nevertheless, the 
relatively frequent presence of these autoantibodies in prediabetic individuals may 
be a useful indication of predisposition to the development of Type 1 diabetes, 
particularly when they are present in high titre and in combination with one another 
(Seißler et al., 1992).  
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1.5 AUTOIMMUNE HEPATITIS, ANOTHER EXAMPLE OF ORGAN-
SPECIFIC AUTOIMMUNE DISEASE  
1.5.1 INTRODUCTION 
 Autoimmune hepatitis (AIH) is characterised by the histological picture of 
chronic aggressive hepatitis and elevated levels of serum immunoglobulins and non-
organ- and liver-specific autoantibodies. The involvement of the immune system in 
the pathogenesis of chronic active hepatitis was suspected shortly after its first 
description in 1947 (Kelsall et al., 1947). Several authors (Waldenström and 
Blutrotein, 1950; Saint et al., 1953) drew attention to the fact that the affected 
patients, mainly females, have high serum gammaglobulin levels and that the 
inflammatory cells characteristically present in portal and peri-portal areas are 
mostly lymphocytes and plasma cells. These patients were subsequently shown to 
have high titre of circulating autoantibodies against nuclear components (Bouchier et 
al., 1964), the actin of smooth muscle (Johnson et al., 1965), liver/kidney 
microsomes (Rizzetto et al., 1973) or a liver cell cytoplasmic protein called soluble 
liver antigen (Manns et al., 1987).  
 Autoimmune hepatitis has been divided according to the serum profiles of 
autoantibodies detected (Johnson and McFarlane, 1993): Type I AIH is associated 
with smooth muscle antibody (SMA) with or without antinuclear antibody (ANA), 
type II AIH is associated with anti-liver/kidney microsomal type 1 (LKM-1) 
antibody and type 3 AIH is associated with antibodies to soluble liver antigen (SLA) 
in patients who are seronegative for ANA, SMA and LKM-1. Type 2 AIH has been 
further divided into type 2a (younger, predominantly female patients without 
evidence of hepatitis C virus [HCV] infection) and type 2b (older, predominantly 
male patients with HCV infection) (Johnson and McFarlane, 1993).  
 Although most of these autoantibodies are non organ-specific and may be 
found in other diseases (Rizzetto et al., 1973), when present at high titres they are 
important diagnostic markers of AIH.  
 
1.5.2  AUTOANTIBODIES AGAINST LIVER-SPECIFIC MEMBRANE 
ANTIGENS  
Autoantibodies directed against liver-specific antigens in patients with AIH 
were first described by Meyer zun Büschenfelde et al. in 1968. These antibodies 
react with a macromolecular antigenic complex called "liver-specific protein" or 
LSP on the hepatocyte cell membrane (Meyer zum Büschenfelde and Miescher, 
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1972). More autoantibodies against liver-specific antigens were later detected such 
as liver membrane antibodies (LMA) (Meyer zum Büschenfelde and Hütteroth, 
1979), anti-SLA antibodies (Manns et al., 1987) and anti-asialoglycoprotein receptor 
(ASGPR) (McFarlane et al., 1986). Anti-ASGPR titres are positively correlated with 
disease activity (McFarlane et al., 1986). More recently it has been demonstrated in 
our laboratory that children with AIH have antibodies to liver alcohol dehydrogenase 
(ADH), which is also a component of the LSP complex (Ma et al., 1993).  
 The role of these autoantibodies in the pathogenesis and course of the 
disease is not known, but they are of great diagnostic importance (Manns, 1989).  
 
1.5.3  AETIOLOGY 
The aetiology of autoimmune hepatitis is unknown. However, similarity in 
clinical, biochemical, histological and even serological features can be found in AIH 
and other conditions, some of which have a recognised aetiology (reviewed by 
Mieli-Vergani and Vergani, 1993). Chronic aggressive hepatitis is a typical 
histological picture of AIH and may be seen at various stages of primary biliary 
cirrhosis (PBC), primary sclerosing cholangitis (PSC) (El-Shabrawi et al., 1987) and 
in chronic hepatitis B virus infection (Odievre et al., 1983). The presence of various 
non organ specific autoantibodies in AIH (i.e. antinuclear antibody, smooth muscle 
antibody and anti-liver/kidney microsoml antibody) can be found in other 
conditions, such as primary biliary cirrhosis and malignant disease (Rizzetto et al., 
1973; Whitehouse and Holborow, 1971).   
 Environmental factors such as viruses have been proposed to trigger the 
autoimmune process in AIH (McFarlane, 1984). Indeed, high titres of antibodies 
against the measles and rubella viruses have been detected in patients with AIH 
(Christie et al., 1983; Robertson et al., 1987) suggesting that these viruses might be 
the trigger of autoimmunity in autoimmune hepatitis. The observation that LKM-1 
antibody is associated with infection by the recently described hepatitis C virus 
(HCV) (Lunel et al., 1992) has provoked great interest amongst hepatologists on the 
possible viral aetiology of AIH. Early reports of a strong association between anti-
HCV and LKM-1 appears to divide LKM-positive AIH into two subgroups: one 
composed of young patients, usually females with high levels of LKM and negative 
for anti-HCV, in whom liver damage may be due to a direct autoimmune attack; the 
other subgroup consisting of older patients, frequently males, with low titre of LKM 
and positive for anti-HCV, in whom the autoimmune process may be a consequence 
of the viral disease (Lenzi et al., 1990; Margrin et al., 1991; Todros et al., 1991).       
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Using immunofluorescence technique, anti LKM-1 antibody stains the 
cytoplasm of human hepatocytes and proximal renal tubules and has been reported 
to recognise a 50 kD microsomal protein which has been identified as the 
cytochrome P4502D6 (CYP2D6) (Alvarez et al., 1985; Zanger et al., 1988; Manns 
et al., 1989). The demonstration of a partial identity between cytochrome CYP2D6 
and HCV has led to the suggestion that HCV may initiate autoimmunity, possibly by 
molecular mimicry (Manns et al., 1991). It has been recently demonstrated in our 
laboratory that whilst antibodies producing the characteristic LKM-1 fluorescent 
pattern can react with CYP2D6, not all LKM-1-positive sera do so, particularly if 
obtained from patients with chronic HCV infection suggesting that LKM-1 in HCV 
infection recognises epitopes or antigens different from those targeted in AIH which 
implies that they represent two distinct groups (Ma et al., 1993; Ma et al., in press).  
 
1.5.4  AUTOIMMUNE HEPATITIS "AN IMMUNE MEDIATED DISEASE" 
The clinical onset of AIH is characterised by a variety of cellular and 
humoral immune changes including production of autoantibodies to hepatocytes, 
increased number of activated T lymphocytes and alterations in number and function 
of immunoregulatory T lymphocytes. Some of these immune responses are specific 
for the liver and this has been taken as evidence that AIH is an autoimmune disease 
(reviewed by Mieli-Vergani and Vergani, 1993).  
 
1.5.4.1 CELLULAR IMMUNE RESPONSE 
Early investigation of cellular immune mechanisms involved in the 
pathogenesis of AIH, largely used in vitro tests of delayed hypersensitivity to crude 
liver antigen preparations (Smith et al., 1972; Miller et al., 1972; Lee et al., 1975); or 
cytotoxicity tests with mixed populations of peripheral blood lymphocytes as 
effector cells and various allogenic monodispersed hepatocyte preparations 
(Thompson et al., 1974). The consensus of opinion derived from these studies was 
that patients with AIH had circulating lymphocytes that were "sensitised" to liver 
antigens and were able to "kill" the various target cells in vitro and that this was true 
also of patients with HBV-CLD and some with PBC (reviewed by McFarlane, 1984; 
and Vento and Eddleston 1987).  
 Patients with autoimmune hepatitis often have evidence of impaired cell-
mediated immunity. This is characterised by total T-cell reduction and an increased 
ratio of helper to cytotoxic/suppressor T cells (Lobo-Yeo et al., 1987). Using various 
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in vitro assays, impaired T cell suppressor function has been demonstrated in both 
adults (Nouri-Aria et al., 1985) and children (Lobo-Yeo et al., 1987) with AIH. 
Impaired immunoregulation, due to decreased T cell suppressor function, could play 
an important pathogenetic role in AIH by leading to the persistence of autoimmune 
reactions. Imbalance of helper T cells which may explain the enhanced immune 
reactivity typical of the disease has been demonstrated in AIH. Lobo-Yeo et al. 
(1990B) have shown that levels of activated T lymphocytes expressing surface 
HLA-DR (mainly of the CD8 phenotype) or IL-2R (mainly of the CD4 phenotype) 
are elevated in the circulation of children with AIH with active disease compared to 
those with inactive or other forms of chronic liver disease. 
 Experiments using subpopulations of T and non-T lymphocytes indicated 
that cytotoxicity was mediated by non-T lymphocytes (Mieli-Vergani et al., 1979). 
This observation and the blocking effect of aggregated IgG suggested that 
cytotoxicity, in AIH, is an antibody-dependent cell-mediated cytotoxicity (ADCC). 
Studies of the hepatic lymphocyte infiltrate have shown a predominance of B 
lymphocytes and T helper cells with relatively few cytotoxic/suppressor T cells, 
whereas cytotoxic/suppressor lymphocytes predominate in areas of necrosis (Eggink 
et al., 1982; Senaldi et al., 1992). 
 
1.5.4.2 HUMORAL IMMUNE RESPONSE 
Autoantibodies have been implicated in the pathogenesis of patients with 
AIH. They comprise non-organ specific (ANA, SMA and LKM antibodies) and 
organ specific autoantibodies (LMA, LSP and ASGPR antibodies). Humoral 
evidence for the involvement of autoreactions in liver disease rely on the finding of 
circulating autoantibodies that fall into one of the three groups (reviewed by 
McFarlane, 1991): (1) those that are neither organ nor disease specific, such as ANA 
and SMA antibodies; (2) those such as AMA and LKM antibodies, that are not 
directed at liver-specific antigens but subtypes of which are mainly confined to 
certain liver disorders; and (3) those such as LMA, LSP and ASGPR antibodies, that 
are more particularly related to the liver but are not necessarily confined to a specific 
hepatic disorder. Antibodies to the liver cell membrane could be involved in liver-
damaging immune reactions either through complement-mediated cytolysis or by the 
recruitment of cytotoxic, Fc receptor bearing, cells (Vergani et al., 1987b).  
 Low levels of complement factors have been found in chronic active 
hepatitis and reported by several authors (Munoz et al., 1982, Vergani, 1985). These 
studies show that both patients with AIH and hepatitis B virus (HBV) related CAH 
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have low concentrations of C3 and C4, but C3d (a split product of C3) levels were 
increased only in the HBV group, indicating that activation of complement was 
restricted to HBV-related CAH. Vergani et al. (1985) reported low serum C4 levels 
in children with AIH and demonstrated that this is not due to complement activation 
since none of the patients with low C4 had increased levels of C4d, a fragment 
which is invariably generated when C4 is broken down during activation of classical 
pathway (Milgrom et al., 1980). Moreover, parents and siblings of the patients also 
had low C4 levels, suggesting that low C4 levels in AIH are genetically determined 
(Vergani et al., 1985). In fact, the C4 phenotypes of children with AIH showed a 
significantly increased prevalence of null allotypes, particularly at the A locus 
(C4AQ0). Genetically determined low C4 levels also occur in other autoimmune 
disorders such as systemic lupus erythematosus (SLE) (Fielder et al., 1983) and 
Type 1 diabetes (Vergani et al., 1983).  
 
1.5.4  GENETIC PREDISPOSITION 
White patients with AIH have an increased frequency of the 
histocompatibility antigens HLA A1/B8/DR3, a haplotype characteristically 
associated with other autoimmune conditions, including autoimmune thyroiditis, 
systemic lupus erythematosus, insulin-dependent diabetes, in which there is 
excessive production of antibody to extrinsic and auto-antigens (Galbraith et al., 
1976). In a reported family with multiple occurrence of AIH, female sex and 
possession of DR3 was more important than B8 in conferring susceptibility to the 
disease (Hodges et al., 1991), suggesting that a defective antigen recognition by T 
cells in the context of class II HLA molecules plays a central role in generating 
autoimmunity, in association with gender determined factors (genes and hormones). 
Recently, it has been shown that susceptibility to AIH is conferred independently by 
two genes within the major histocompatibility complex linked to the DR3 and DR4 
genes (Donaldson et al., 1990). When compared to the DR4-positive patients, those 
with A1/B8/DR3 were shown to present at an earlier age, to relapse more frequently 
and to be more frequently referred for liver transplantation. Haplotypes conferring 
susceptibility to the juvenile or mature form of AIH have been further characterised 
and the possession of the haplotype A1-B8-DRB3*0101-DRB1*0301-DQA1*0501-
DQB1*0201-DPB1*0401 has been shown to predispose to the development of the 
disease in paediatric age (Doherty et al., 1991). This study shows the importance of 
the DQ alleles in predisposing to AIH.  
 Children with AIH have an isolated partial deficiency of the complement 
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component C4, which is not due to impaired hepatic synthesis or immune 
consumption, but is genetically determined and is associated with the possession of a 
silent gene at the C4A locus, C4AQ0 (Vergani et al., 1985). C4AQ0 either in 
linkage with A1/B8/DR3 or on its own has been reported in association with other 
autoimmune disorders (Lachmann and Peters, 1982) and could represent the true 
disease susceptibility gene. The genetically determined partial C4 deficiency 
resulting from the possession of null C4 genes may be a predisposing factor to 
autoimmunity. C4 has a key role in virus neutralisation (Daniels et al., 1969) and 
failure to eliminate viruses might lead to the development of immune and 
autoimmune reactions directed against antigens on the persistently infected cells. 
The specificity of the autoimmune reaction would possibly derive from the tropism 
of the virus. 
 All the above data suggest that AIH conforms to a multi-factorial model 
(Whittingham et al., 1981). This proposes that a disease develops when a threshold 
is exceeded by a number of different combinations or interactions of multiple 
genetic and environmental factors. 
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CHAPTER 2
INTRODUCTION TO THE PRESENT STUDY 
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2.1 INTRODUCTION 
 Development of insulin dependent diabetes, as discussed previously, 
involves both a genetic and an environmental component. The role of the immune 
system is to respond to stimuli coming from the environment under the control of 
genetic factors. It has been suggested that the immune attack on the N-cell has both 
cellular and humoral autoaggressive elements (reviewed by Vergani, 1987a). T 
lymphocytes are capable of killing the insulin-producing ß-cells both directly and 
indirectly, through the recruitment of other effector mechanisms.  
 Figure 2.1 summarizes the possible mechanisms leading to an immune 
attack on the ß-cell. A ß-cell surface antigen is presented to helper T (TH1 or TH2) 
lymphocytes either directly on the cells's surface or by an antigen presenting cell 
(APC), in the context of class II MHC antigens. Then if T suppressor (Ts) cells do 
not oppose, the T helper cells alert one or more effector cell mechanisms.  Direct 
killing of the ß-cell can derive from activation of cytotoxic T lymphocytes (Tc) 
which, through their receptors, recognise target antigens in association with class I 
MHC antigens on the cell surface.  The ß-cell can also succumb to the joint attack of 
TH1 and activated macrophages. This pathway operates mainly through the release 
of cytokines produced by macrophage and TH1. Macrophage-derived cytokines such 
as tumour necrosis factor (TNF) and interleukins (IL) 1 have the potential to kill the 
ß-cell in their own right (Mandrup-Poulsen et al., 1987a; Sandler et al., 1991; Ling et 
al., 1993). TH1-derived cytokines can attract macrophages to the site of reaction with 
the target cell, and make them metabolically 'angry'. Angry macrophages can dispose 
of ß-cells by the release of monokines, proteolysis and phagocytosis. B-lymphocytes 
can also be engaged in an immune attack on the ß-cells under effect of TH2-derived 
cytokines by producing autoantibodies. A target coated with an antibody can be 
destroyed by activation of the complement system or by killer cells (Roitt, 1988). In 
the context of the present study, it is important to note the potential key role played 
by soluble factors - cytokines - in both the orchestration and execution of the 
immune attack on the ß-cell. 
 This chapter will give a brief biological definition for some of cytokines 
which are likely to play an important role in the pathogenesis of Type 1 diabetes.  
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Figure 2.1. ß-cell immune attack.  A ß-cell ("target cell") antigen is presented to 
helper (TH1 or TH2) lymphocytes either directly on the cell's surface or by an antigen 
presenting cell (APC), in the context of class II MHC antigens. If there is no 
opposition from T regulatory (Tr) lymphocytes, then a variety of effector 
mechanisms are triggered. ß-cell destruction could derive from the action of: (a) T 
cytotoxic (CTL) lymphocytes which react with the self antigen(s) in the context of 
class I MHC antigens or (b) cytokines produced by TH1 lymphocytes and recruited 
macrophages. K, killer lymphocytes; B, B lymphocyte; M, macrophage; P, plasma 
cell. 
IL-12
Class I
B
P
CTL
Th2
cell
Liver
Th1Tr
IL-4
NK IL-17
IL-6
TsTh17
IL-17
TGF-
Th0
IL-4
IL-2
IL-1
M
Co stimuli-
IFN- 
IFN- 
TNF- 
APC
Class II
Peptide
IL-10
IL-13
Class II
30 
 
2.2 CYTOKINES 
"Cytokine" is one term for a group of protein cell regulators, variously called 
lymphokines, monokines, interleukins and interferons, which are produced by a 
variety of cells in the body. Since most cytokines possess more than one biologic 
property, descriptive names can be misleading. Therefore, a nomenclature has been 
developed that employs the term "interleukin" followed by a number (Aarden et al., 
1979).  
 Cytokines generally are glycoproteins with molecular weights of less than 
80 kD. They are involved in immunity and inflammation where they regulate the 
amplitude and duration of the immune response. Cytokines are extremely potent, 
generally acting at picomolar concentrations. They interact with high affinity cell 
surface receptors specific for each cytokine group (Reviewed by Balkwill and Burke, 
1989).  
 Cytokines have been reported to be involved in the immunopathology of 
several autoimmune diseases including Type 1 diabetes (Dinarello and Mier, 1987). 
There is evidence that cytokines could have a direct role in N-cell death (Mandrup-
Poulsen et al., 1989). The macrophage released cytokines, TNF-@ and IL-1, are 
cytotoxic to islet N-cells in vitro (Mandrup-Poulsen et al., 1986; Campbell et al., 
1988).  Interleukin-6, also produced by macrophages, is a key mediator of multiple 
inflammatory and immune responses (Hirano et al., 1990), and regulates insulin 
secretion in vitro in concert with IL-1 (Campbell et al., 1989). IFN-?, produced by 
activated T lymphocytes, activates macrophages (Murray, 1988), enhances class I 
Major Histocompatibility Complex (MHC) antigen expression and induces class II 
expression in combination with TNF on normal cultured human islet cells (Pujol-
Borrell  et al., 1987); IFN-? also enhances TNF induced human islet cells 
cytotoxicity (Soldevila  et al., 1991). These studies indicate that cytokines may have 
a role in the pathogenesis of Type 1 diabetes.  
 The biological properties of these cytokines and their potential role in the 
pathogenesis of Type 1 diabetes will be discussed next.  
 
2.2.1 INTERLEUKIN-1 
 The first described activity of IL-1 was in 1972 by Gery et al. They 
discovered a lymphocyte-activating factor (LAF) in the supernatant of cultures of 
adherent human peripheral blood cells and murine splenocytes, which was 
mitogenic for murine thymocytes. In 1974, it was reported that cultured human 
monocytes also secreted a B cell-activating factor (BAF) that stimulated antibody 
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production by T cell-depleted murine splenocytes (Wood and Gaul, 1974). 
Subsequent analyses revealed that the biochemical properties of LAF and BAF were 
similar, resembling the structure of a pyrogenic macrophage-derived factor which 
was later called IL-1. 
 IL-1 is a 12-16 kD glycoprotein. It is produced by all the macrophage-
containing tissues including pulmonary alveolar cells, hepatic Kupffer cells and 
bone marrow (Moore et al., 1980). Resting monocytes or macrophages produce little 
or no IL-1. Mitogens such as lipopolysaccharide (LPS) and phorbol myristic acetate 
(PMA) were reported to stimulate macrophages to induce IL-1 production 
(Oppenheim et al., 1979). Activated lymphocytes can also stimulate macrophages to 
produce IL-1 by releasing lymphokines such as colony-stimulating factor, which 
stimulate macrophages (Moore et al., 1980). IL-1 exists in 2 molecular forms called 
IL-1@ and IL-1N (reviewed by Dower and Urdal, 1986). Both peptides although 
distinct gene products, share many biological activities and are recognised by the 
same receptors (Wood et al., 1985; Kilian et al., 1986). Biologically active IL-1@,
but not IL-1N, has been detected on the surface of cells and can thus participate in 
interactions during cell-to-cell contact. Therefore after its production, IL-1@ remains 
mainly cell-associated, whereas IL-1N is primarily the released form.    
 IL-1 has wide-ranging biological effects and plays a central role in the 
activation of cells involved in inflammatory and immune responses (reviewed by 
Pober and Cotran, 1990; Rees, 1992). IL-1 can stimulate proliferation of mouse and 
human T lymphocytes (Mizel et al., 1981), possibly due to the ability of IL-1 to 
induce the release of IL-2 (Smith et al., 1980). Production of immunoglobulins by 
human B lymphocytes also appears to be augmented by IL-1. Human IL-1 can 
partially restore pokeweed mitogen (PWM)-induced immunoglobulin production in 
cultures of macrophage-depleted human lymphocytes (Rosenberg and Lipsky, 
1981). Some of its effects on B cells may be mediated through its induction of IL-6, 
which is a B cell differentiation factor (Dinarello et al., 1987).  
 IL-1 also regulates several non-immunological responses involving 
macrophages. It stimulates the release of acute phase reactants by hepatocytes, the 
release of prostaglandins and collagenase from synovial cells, and the cell division 
of fibroblasts. Therefore, IL-1 may be involved in fibrosis-associated with cell-
mediated immunological reactions such as rheumatoid arthritis as well as in non-
immunological inflammatory reactions (reviewed by Mantovani and Dejana, 1989) 
 Naturally-occurring inhibitors of IL-1 have been reported in a variety of 
biological fluids such as serum, synovial exudates and urine (Larrick, 1989; 
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Seckinger and Dayer, 1987). Cultured mononuclear cells from synovial fluid have 
been formed to secrete an IL-1 inhibitor, which was identified as an IL-1 receptor 
antagonist (IL-1ra) (Roux-Lombard et al., 1992). IL-1ra blocks binding of IL-1 to its 
receptors and has been cloned and produced in recombinant form and found to 
reduce the severity of various diseases such as sepsis, colitis, arthritis and diabetes in 
animal models (reviewed by Dinarello and Thompson, 1991). There are two IL-1 
receptors, now indicated as IL-1R type I and type II, corresponding to the 80 kD 
(Sims et al., 1988) and 68 kD (Horuk and McCubrey, 1989) IL-1 binding proteins on 
T and B cells respectively. Although the type I receptor appears to account for nearly 
all of the biological activity of IL-1, the two receptors may cooperate in binding and 
signal transduction on some cells (reviewed by Dinarello and Thompson, 1991). The 
type II receptor is probably proteolytically cleaved to yield the soluble IL-1 binding 
protein described by Symons et al. (1991). This molecule is released as a 47 kD 
protein from Raji cells, and has high affinity for IL-1N (but does not bind IL-1@), 
which suggests that it is a naturally-occurring inhibitor for IL-1N (Scapigliati et al, 
1989; Scott et al., 1991).    
2.2.2 INTERLEUKIN 2 (IL-2) 
 Interleukin 2 was originally called T cell growth factor (TCGF) and 
described as a lymphokine present in lymphocyte-conditioned medium that 
enhanced thymocyte mitogenesis and maintained in vitro growth of T-cell lines 
(Morgan et al., 1976). IL-2 is 15 kD glycoprotein. Studies of isolated subpopulations 
of lymphocytes and thymocytes show that antigens induce IL-2 production from 
CD4 helper T cells. Potent polyclonal mitogens and class I MHC alloantigens can 
also stimulate the CD8 T lymphocytes to produce IL-2 (Smith, 1987). In addition, a 
subset of large granular lymphocytes which are closely related to NK cells can 
release IL-2 when stimulated with mitogens such as PHA (Itoh et al., 1985).   
 In order to exert its biological effects, IL-2 must interact with specific 
membrane receptors (Robb et al., 1981). This interaction is critical to the 
development of a normal immune response. Interleukin 2 receptors are not 
expressed on resting T lymphocytes, but are expressed rapidly following activation 
with antigen or mitogen. The IL-2 receptor complex comprises an @ chain of 55 kD 
(also known as CD25, Tac, p55), first identified in an adult T cell leukaemia (Smith, 
1987), and a ß chain of 75 kD (p75) (Greene and Leonard, 1986). Depending on the 
relative expression of the @ and N subunits at the cell surface, they constitute low (Kd
10-8M), intermediate ((Kd 10-9M), or high affinity (Kd 10-11M) receptor for IL-2 
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(Hatakeyma et al., 1989). Controversy has surrounded the presence of a ? chain in 
the receptor complex: the question has recently been settled following the cloning of 
a ? chain from a human T cell line into which the ß chain had been transfected 
(Takeshita et al., 1992). The minimal receptor configuration for signal transduction 
now appears to be the IL-2Rß? heterodimer, which binds its ligand with an 
intermediate affinity, whilst the combination of @, ß and ? chains results in a high 
affinity binding. The ? chain also appears to be critical for internalisation of the 
receptor-ligand complex (Takeshita et al., 1992). The @ chain alone binds IL-2 with 
a relatively low affinity  and lacks the ability to transduce an activation signal. 
However, IL-2@ chains have a slow turnover rate on the cell surface (>6 hours 
compared with 2-3 hours for the IL-2R@ß heterodimer, or 15 minutes when bound to 
IL-2) and act as a trap for IL-2 which can then be passed to intermediate or high 
affinity receptors, by lateral diffusion, for internalisation (Saragovi and Malek, 
1990). Such a process enhances the overall affinity of a cell for IL-2, shifting the 
dose-response curve to the left and increasing the sensitivity of IL-2 mediated 
activation.   
 The biological effects of IL-2, although originally defined on the basis of the 
growth of T cells in culture, have expanded to include interaction with macrophages, 
activated B cells (Mond et al., 1985, Kishi et al., 1985), natural killer (NK) (Ortaldo 
et al., 1984) and other cytotoxic cells (Gillis et al., 1979). This response to IL-2 
requires the expression of @ or N IL-2-binding protein on the unstimulated 
mononuclear cells. Monocytes and macrophages normally express a low density of 
IL-2R @ chain. Activation of macrophages by IFN-? or LPS, however, results in the 
development of high affinity IL-2 receptors consisting of p75 and the p55 Tac 
antigen. Addition of IL-2 to these activated macrophages results in the activation of 
the Tac, granulocyte macrophage colony-stimulating factor (GM-CSF), and G-CSF 
genes and also augments the tumoricidal activities of these macrophages. 
 Large granular lymphocytes (LGL), which exhibit antigen-nonspecific NK 
cell activity express the p75 antigen; after in vitro incubation with IL-2, LGL begin 
to express both p55 Tac antigen and the high-affinity IL-2 receptor complex. When 
activated, these cells have been shown to mediate potent antitumour cytotoxicity in 
vitro against target tumour cells freshly derived from "solid" tumour tissue 
(Rosenberg et al., 1985). 
 High-affinity receptors for IL-2 have been found on B lymphoblasts. 
Activated normal as well some transformed B lymphoblasts, but not resting B cells, 
express about 30% as many Tac antigen receptors for IL-2 as do activated T cells. 
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IL-2 can induce both increased antibody production and proliferation (Falkoff et al., 
1984). 
 Lymphocytes exposed to IL-2 also release a number of cytokines. These 
include IFN-? (Kasahar et al., 1983), TNF-@ and N (Nedwin et al., 1985) and 
differentiation factors such as IL-4 and IL-6 (Ohara and Paul, 1987; Rees, 1992).  
 One of the important aspects of T cell-derived cytokines is that many act in 
synergy with others, and thus the net effect may be considerably greater than that of 
the individual components. Well known synergies are those of IL-2 and IL-4 in T 
cell growth (Spits et al., 1987). IL-10 was also found to synergise with IL-2 for the 
proliferation of mature and immature T cells (MacNeil et al., 1990), their 
differentiation into cytotoxic effectors (Chen and Zlotnik, 1991) and more recently 
was shown to enhance the proliferation and differentiation of normal and leukaemic 
B cells upon CD40 triggering (Anne-Catherine et al., 1993).   
2.2.3 INTERLEUKIN 4 
Interleukin 4 (IL-4) is another T-cell-derived cytokine. It is similar in size to 
IL-2 but binds to a distinct cell surface receptor (Ohara and Paul, 1987). IL-4 is an 
alternative (to IL-2) growth factor for certain T cells but exerts its principal action on 
B-cells where it serves both as an activation factor for resting cells and as an isotype 
switching factor to IgG1 and immunoglobulin E for stimulated cells (Snapper et al., 
1988). IL-4 acts also on macrophages as an activating factor by inducing MHC Class 
II molecules and induces proliferation of mouse mast cells especially in synergy with 
IL-3 (Paul and Ohara, 1987). According to Mosmann et al. (1986), two distinct 
cytokine secretion patterns have been defined among a panel of mouse T cell clones, 
TH1 and TH2. TH1 cells secrete predominantly IL-2 and IFN-?, and are associated 
with delayed-type hypersensitivity reactions while TH2 cells secrete IL-4, IL-5, IL-6 
and IL-10 and are associated with high antibody levels (Mosmann et al., 1986).  
 The effect of IL-4 on the kinetics of other cytokines has been studied in 
further experiments and it has been shown that IL-4 suppresses LPS-induced 
stimulation of IL-1, TNF-@ and IL-6 synthesis by human monocytes, the effect being 
manifested at the level of mRNA (Cheung et al., 1990). The addition of IL-4 to 
activated CD4+ cell cultures induces secretion of high levels of TH2 cytokines (Seder 
et al., 1992) and preferentially stimulates the growth of TH2-like cells (Fernandez-
Botran et al., 1988) while IFN-?, which is produced by TH1 cells, was found to 
inhibit IL-4-induced switching. Recently, it was demonstrated that the combination 
of IL-4 and IL-10 increased T cell replication but results in lower immunoglobulin 
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production (Rousset et al., 1992).  Many cell types bear receptors for IL-4 such as 
endothelial cells and certain tumour cell lines (Lowenthal et al., 1988), which 
renders these cells susceptible to the effects of IL-4.       
 
2.2.4 INTERLEUKIN 6 
Interleukin 6 (IL-6) was originally identified as a T cell-derived factor acting 
on B cells, in order to induce the final maturation to antibody-forming plasma cells 
and called B cell stimulating factor-2 (BSF-2) (Yoshizaki et al., 1982). IL-6 is a 26 
kD glycoprotein. It can be produced by several cells, including T and B 
lymphocytes, monocytes, endothelial cells and fibroblasts (Aarden and Van Kooten, 
1992). IL-6 appears to function as a growth factor for certain transformed B cells. 
The identification of IL-6 as plasmacytoma and hybridoma growth factor supports 
this idea (Kawano et al., 1988). IL-6 also promotes the proliferation of Epstein-Barr 
virus-infected B cells and permits their growth at low densities (Tosato et al., 1988). 
It has been demonstrated that freshly isolated human myeloma cells both produce 
IL-6 and express IL-6 receptors (Kawano et al., 1988). Moreover, anti-IL-6 
antibodies inhibit the growth of the myeloma cells in vitro, suggesting that IL-6 may 
function as an autocrine signal in the process of uncontrolled proliferation during 
myeloma (Kawano et al., 1988). A relationship between deregulated IL-6 production 
and polyclonal plasmacytosis has been observed in patients with uterine cervical 
carcinoma, rheumatoid arthritis, and acquired immune deficiency syndrome (AIDS) 
(Kishimoto and Hiravot, 1988). 
 IL-6 can act as a stimulatory factor for T cells at different stages of 
differentiation. For example, IL-6 can stimulate the proliferation of CD4+ and CD8+
subsets of thymocytes that have been co-stimulated with IL-2 and IL-4 (Hodgkin et 
al., 1988). In mature T cells, IL-6 can activate the production of IL-2, although it 
does not stimulate cellular proliferation (Garman et al., 1987). 
 IL-6 acts as a hepatocyte-stimulating factor (HSF), inducing the synthesis of 
acute phase proteins in the liver, including C-reactive protein (CRP), @1-acid 
glycoprotein, fibrinogen, and @-2-macroglobulin (Revel, 1988; Richards et al., 
1991). The expression of some of these acute-phase proteins is also modulated by 
IL-1 or TNF-@, which combine synergistically with the HSF activity of IL-6 (Wong 
and Clark, 1988). High doses of IL-6 also produce fever by stimulating the 
hypothalamic fever centre; IL-6 therefore acts as an endogenous pyrogen (Frei et al., 
1989).  
 IL-6 can be induced in response to other cytokines such as recombinant 
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tumour necrosis factor (Zhang et al., 1988) and IL-1 (Hirano and Kishimoto, 1989). 
High levels of circulating IL-6 have been found in several diseases, including 
fulminant liver failure and chronic hepatitis B (Sheron et al., 1990). In each case 
high levels of IL-6 have been found to correlate with similar elevated high levels of 
TNF-@, implying either that both are released as a result of a common stimulus or 
that circulating IL-6 is produced in response to circulating TNF or other cytokines 
(Sheron et al., 1990).  
 
2.2.5 INTERLEUKIN-10 
Interleukin-10 (IL-10) (originally known as cytokine synthesis inhibitory 
factor (CSIF)) is an acid-labile 35-40 kD homodimer that is produced by TH2 but not 
TH1 cell (Mossmann et al., 1986). It was discovered and isolated on the basis of its 
ability to suppress cytokine synthesis by TH1 helper T cell (e.g. IL-2/IFN-?)
(Fiorentino et al., 1989; Moore et al., 1990; Vieira et al., 1991). IL-10 suppresses 
both cytokine production and antigen-specific proliferation of cultured clones of TH1
cells when they are activated in an accessory cell-dependent manner (Vieira et al., 
1991). The addition of anti-IL-10 antibodies to primary cultures of helper T cells, in 
some in vitro systems, enhances the emergence of cells bearing a TH1 cell phenotype 
suggesting that IL-10 may play a role in diminishing delayed-type hypersensitivity 
reactions and other TH1 cell-mediated responses (Howard and O'Garra, 1992).  
 IL-10 also suppresses the ability of murine macrophages, but not B cells, to 
stimulate TH1-cell clones to synthesize cytokines (Fiorentino et al., 1991). While IL-
10 is a potent immunosuppressant of macrophage function, it exerts a wide array of 
immunostimulatory effects on B cells. These include enhancement of in vitro 
viability and upregulation of MHC class II molecule expression by highly purified, 
small, dense B cells obtained from spleens of unstimulated mice (Go et al., 1990). 
The effects of IL-10 on activated B cells have been studied in vitro. Rousset et al. 
(1993) and Defrance et al. (1992) reported that IL-10 augments both proliferation 
and differentiation of activated B cells into antibody-secreting cells and this effect 
was enhanced in the presence of IL-2 (Anne-Catherine et al., 1993). In addition, IL-
10 was found to be a stimulant to other cell types. It augments the proliferative 
response of murine thymocytes and T cells that have been activated with IL-2 and 
IL-4 (Suda et al., 1990; MacNeil et al., 1990), and may, therefore, play a role in T-
cell development. The ability of IL-10 to suppress synthesis of a subset of T-cell-
derived cytokines (e.g. IFN-?, IL-2 and TNF-N), in addition to suppression of 
monokine synthesis, makes IL-10 an attractive candidate for prolonging allograft 
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survival, and for treatment of a variety of T-cell-mediated autoimmune diseases, 
such as Type 1 diabetes and multiple sclerosis (Howard and O'Garra, 1992).  
 
2.2.6 INTERFERON-+
Interferon-? was originally identified by its antiviral activity and was 
discriminated from IFN-@ and IFN-N by its lability at pH 2.0, a property often used 
as a simple method of identification (Faltynek and Kung, 1988).  
 IFN-? is a 17 kD glycoprotein. It is produced mainly by activated T 
lymphocytes following exposure to antigen or mitogen (Street and Mosmann, 1991). 
Using mouse T cell clones, it has been found that TH1 but not TH2 cells secrete IFN-
? (Mosmann et al., 1986).  Natural killer (NK) cells also produce IFN-? when 
triggered by mitogens such as phytoheamoagglutinine (PHA) (Matsumura and 
Nakano, 1988). Production of IFN-? by T lymphocytes can be dependent upon 
secretion of other cytokines. Farrar et al. (1981) found that IFN-? production by 
lymphocytes is dependent upon secretion of IL-1 by accessory adherent cells and 
secretion of IL-2 by T helper cells. IL-2 can also stimulate the production of high 
titres of IFN-? in culture in the absence of any other known inducers (Lee et al., 
1986). 
 IFN-? not only acts as an antiviral agent but also exerts several effects on 
vital cellular and body functions, including cell proliferation, hormone stimulation, 
immune responses, and tumour development (reviewed by Ijzermans and Marquet, 
1989; Billian and Dijkmans, 1990). The immunomodulatory activities of interferon 
are mediated by its effects on the cells responsible for host defense, i.e., 
macrophages, T and B lymphocytes and LGL with NK activity. IFN-? exerts effects 
on macrophages, and acts as a potent macrophage activating factor, resulting in 
increased production of IL-1@ (Arenzana-Seisdedos et al., 1985) and TNF-@ (Collart 
et al., 1986). Activation of macrophages is accompanied by increased expression of 
receptors for the Fc portion of immunoglobulins (FcR) (Vil_ek and Demaeyer, 
1984). This results in the increase in both the phagocytosis of immune complexes 
and in the capacity of the macrophages to lyse antibody-coated bacteria, parasites, 
and tumour cells by antibody dependent cell-mediated cytotoxicity (ADCC). IFN-?
boosts and maintains the level of class II histocompatibility molecules on the surface 
of macrophages, (Kelley et al., 1984) as well as on other cell types such as T and B 
cells (Pober et al., 1983; Berrih et al., 1985). IFN-? induces expression of class II 
MHC antigens on epithelial, endothelial and connective tissue cells, lymphoid cells 
and monocyte cell lines (Steeg et al., 1982, Wong et al., 1983) and of class I MHC 
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on cytotoxic T lymphocyte targets (Pestka et al., 1987). The expression of class II 
will allow these cells to become active in antigen presentation. 
 IFN-? can either augment or suppress cellular and humoral immunity, 
depending on the dose and time of administration (Trinchieri and Perussia, 1985). In 
general, in vivo administration of IFN-? before or concomitant with antigenic 
sensitization has considerable inhibitory effects, whereas administration of 
interferon after antigenic sensitization augments both cellular and humoral immune 
responses (Baron et al., 1991). Anti-proliferative effects of IFN-? in immune 
regulation have been studied in vitro using murine helper T lymphocyte clones and 
found that IFN-? inhibits the proliferation of TH2 and favours development of TH1, 
suggesting the ability of IFN-? to direct TH1-like and TH2 immune responses 
(Gajewski et al., 1989; Noble et al., 1993). IFN-? also acts as a B-cell maturation 
factor, inducing the maturation of resting B lymphocytes and resulting in surface 
phenotype changes and immunoglobulin secretion (Leisbon et al., 1984). In the 
mixed lymphocytes reaction (MLR), IFN-? has been reported to be the predominant 
cytokine in culture and was responsible for generation of cytotoxic T lymphocytes 
(CTLs) (Simon et al., 1979). Effects of IFN-? on natural killer (NK) cell activity has 
been reported extensively (Trinchieri and Perussia, 1985).  NK cell activity is 
mediated by the cytotoxic effects of large granule lymphocytes, in the absence of 
prior sensitization, against virus-infected cells or certain tumour cell lines. Both in 
vivo and in vitro adminstration of IFN-? enhances the NK cell activities of LGL 
(Trinchieri and Perussia, 1985). 
 IFN-? also affects the complement system, by enhancing production of 
complement factors (B, C2 and C1-inhibitor) (Littman et al., 1989) and promotes 
adherence of macrophages to membrane glycoproteins (Show and Mercurio, 1989). 
 IFN-? can act synergistically with other cytokines. The effects of this 
synergism depend mainly on the target cells (reviewed by Balkwill and Burke, 
1989). For instance, IL-4 and IFN-? have similar or synergistic activities, such as 
activation of T cells, but their actions on immunoglobulin isotype selection or MHC 
class II expression are differential or antagonistic (Siegel, 1988). IFN-? acts 
synergistically with TNF-@ to increase class I and II MHC antigen expression on a 
variety of cells (Baron et al., 1991) and this expression is thought to play an 
important role in the initiation of the autoimmune process.  
 
2.2.7  TUMOUR NECROSIS FACTOR-* (TNF-*/CACHECTIN) 
 TNF-@ was first found in serum of animals that were primed with 
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mycobacterial antigens, Bacillus-Calmette-Guérin, and then challenged with 
lipopolysaccaride (LPS). TNF-@ activity caused the necrosis of certain tumours 
when injected into tumour-bearing animals. This selective killing in vivo occurs 
without any apparent species-specificity (reviewed by Cerami and Beutler, 1988). A 
molecule identical to TNF-@ and named cachectin (it cause cachexia) was isolated 
from serum of endotoxin-sensitive mice treated with LPS (Beutler et al., 1985). 
 
TNF-@ is a 17 kD polypeptide (Beutler et al., 1985; Spies et al., 1986). Many 
cell types can produce TNF-@. Monocyte-macrophages produce TNF-@ in response 
to stimulation by phorbol myristate acetate, lipopolysaccharides and bacillus 
calmette Guérin (Männel et al., 1980; Matthews, 1981). Other cells, including T and 
NK cells can produce TNF-@ (Feldmann et al., 1989). A number of endogenous 
mediators such as IL-1, IL-3, granulocyte macrophage colony stimulating factor 
(GM-CSF), IFN-? were reported to induce production of TNF in conjunction with 
LPS and TNF-@ itself (Oppenheim et al., 1989). A related molecule, lymphotoxin, 
produced by activated lymphocytes, shares many of IL-1 properties (Tartaglia and 
Goeddel, 1992). It binds to the same receptor as cachectin/TNF-@ and evokes similar 
biological responses (Paul and Ruddle, 1989). 
 TNF-@ has a variety of immunological properties. Like IL-1, TNF-@ is co-
mitogenic for thymocytes and enhances IL-2 receptor and MHC class II expression 
on T cells (Feldmann et al., 1989). In addition, TNF-@ has been shown to augment B 
cell proliferation, surface immunoglobulin receptor expression, and antibody 
production (Beutler and Cerami, 1989). TNF-@ may play a critical role in preventing 
the spread of invading pathogens by stimulating release of other cytokines from 
lymphocytes. The spread of invading pathogens has been shown to be reduced 
significantly following administration of small amounts of TNF-@ in mice infected 
with murine malaria (Djeu et al., 1986).  TNF-@ is a mediator of general 
inflammation, it induces (together with IL-1) a fever by the stimulation of 
hypothalamic prostaglandin-E2. It also stimulates the synthesis of IL-1, IL-6, IL-8 
and several other pro-inflammatory mediators (Bachwich et al., 1986). TNF-@
promotes the expression of adhesion molecules on leucocytes and endothelial cells. 
This mechanism initiates the recruitment of leucocytes to the site of infection.    
 TNF-@ acts synergistically with IFN-?, and causes enhanced anti-
proliferative activity which is known to decrease the growth of cancer cells in 
culture (Brouckaert et al., 1986); expression of class I and II MHC antigens is also 
induced on various cell types (Lapiérre et al., 1988, Leeuwenberg et al., 1988). The 
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cytokine-induced expression of MHC antigens on various cells during an immune 
response have important immunological implications and suggest an 
immunoregulatory role for cytokines.  
 
2.3 CYTOKINES AND AUTOIMMUNITY 
 A role for cytokines in the initiation of the autoimmune process has been 
proposed for several autoimmune disorders (reviewed by Brennan and Feldmann, 
1992). Increased levels of IL-1, IL-2 and IL-6 have been found in the synovial fluid 
of rheumatoid arthritis (RA) and some of these cytokines are correlated with disease 
activity (Hopkins et al., 1988; Buchan et al., 1988; Feldmann, 1988). Lymphoid cells 
from the thyroid glands of patients with autoimmune disease were found to produce 
spontaneously cytokines such as IFN-?, TNF-@, lymphotoxin, IL-6, IL-1@ and IL-1N
(Grubeck-Lobenstein et al., 1989). High levels of cytokines were also observed in 
the plasma of patients with systemic lupus erythematosus and chronic progressive 
multiple sclerosis (Huang et al., 1988; Cavallo et al., 1994). Most experimental data 
indicate that cytokines have direct effects not only on the state of immune activation 
in autoimmune diseases but also on the target organ which is important in the 
autoimmune disease. Cytokines such as IL-1 (both @ and N) and TNF-@ were found 
to be cytotoxic to several cell lines including N-cells. They also activate osteoclasts 
involved in bone resorption, and bone synthesis is inhibited by both IL-1@ and TNF-
@ (reviewed by Akira et al., 1990). In addition, IFN-? is capable of inducing aberrant 
class II MHC antigens on a variety of cell lines such as thyroid cells, N-cells and 
hepatocytes (reviewed by Cavallo et al., 1994). Such expression is thought to be 
important and rendering target cells more susceptible to immune attack and to the 
cytotoxic effect of other cytokines.  
 
2.3.1  'ABERRANT' MHC EXPRESSION INDUCED BY CYTOKINES 
 The role of 'aberrant' expression of MHC class II molecules and antigen 
presentation in the induction of endocrine autoimmunity was initially proposed by 
Bottazzo et al. (1983). If cells are induced to express MHC class II antigens, they 
may then 'present' their particular cell surface antigen to potentially autoreactive T 
helper lymphocytes, which would initiate an autoimmune response. The hypothesis 
is important since there is a marked genetic component to the risk of acquiring the 
disease which is linked to class II MHC genes (HLA-DR type). 
 In some autoimmune states, inappropriate expression of class II antigens has 
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been noted on the target organ. This was observed in the synovia of joints affected 
with rheumatoid arthritis (Klareskog et al., 1982), thyrocytes in Hashimoto's and 
Graves' diseases (Hanafusa et al., 1983) and also on the islet N-cells of both patients 
and animals with Type 1 diabetes (Bottazzo et al., 1985, Dean et al., 1985). This has 
led to the proposition that such 'aberrant' class II expression enables these cells to 
present tissue bound self antigen and initiates the disease process.  
 The expression of class II MHC products, on N-cells, was initially observed 
by Bottazzo (1985) in a single case of recent onset of Type 1 diabetes. More cases 
have been studied by Foulis et al. (1989). They reported that 21 out of 23 patients 
with recent disease had aberrant expression of class II MHC molecules on N-cells. 
No such expression was seen on glucagon-secreting @ cells or somatostatin secreting 
X cells. In addition, Foulis found a marked hyper-expression of class I MHC 
molecules on islet endocrine cells. No such class I or II MHC expression was found 
in the pancreas of patients with Type 2 diabetes, chronic pancreatitis or cystic 
fibrosis.  Cytokines are probably the principal modulating influence on MHC 
product expression in vitro and in vivo. The ability of interferons to induce MHC-
product expression was first shown by Lindal and co-workers (1973; 1976). They 
showed that interferons induce histocompatibility antigen expression on mouse 
L1210 lymphoma cells in vitro and on lymphoid cells in vivo. The effect has been 
demonstrated with both natural and recombinant interferons, and of type I (@ and N)
and type II (?). The most striking effects, however, were demonstrated with IFN-?
which enhances the expression of class II antigens or induces them de novo in a 
large number of cell types such as human and animal N-cells.   
 Induction of MHC expression on human and murine N-cells by IFN-? has 
been reported by several authors (Wright et al., 1986; Campbell et al., 1986; Pujol-
Borrell et al., 1987). They found initially that IFN-? enhances the expression of 
HLA-A,B,C (class I MHC) but not HLA-DR (class II MHC) on human pancreatic N-
cells in vitro. Induction of class II MHC antigens was observed on human islet cells 
only when exposed to the combination of IFN-? plus TNF-@ (Pujol-Borrell et al., 
1987).  Recently, Soldevila et al. (1991) reported that the combination of IFN-? plus 
TNF-@ not only induced expression of class II antigens but was also associated with 
their cytotoxic effects on human islet cells in vitro. This observation together with 
the initial report of aberrant expression of class II and the recent finding of IFN-?
producing cells in the pancreas of newly-diagnosed diabetic patients (Foulis et al., 
1991) is of potential interest because a role for these cytokines in the destruction of 
N-cells is suggested.  
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2.3.2 CYTOTOXICITY OF CYTOKINES 
All cytokines apparently have a growth factor activity, but the ability to 
inhibit cell growth or kill cells is limited to a number of them such as TNF-@, IL-1 (@
and N) and IFN-? (Mestan et al., 1986). These are cytotoxic to a range of cell types 
including N-cells (Mandrup-Poulsen et al., 1989). IL-1N, TNF-@ and IFN-?, alone or 
in combination have been reported to be cytotoxic to murine and human islet N-cells. 
IL-1N causes selective morphological and functional changes to pancreatic N-cells in 
vitro suggestive of cytotoxicity (Bendtzen et al., 1986; Mandrup-Poulsen et al., 
1987a; Sandler et al., 1987). In addition, IL-1N has been shown to have complex 
dual effects on N-cell function: at a low concentration and short exposure (60-90 
min), IL-1N stimulates proinsulin biosynthesis and insulin secretion while at a high 
concentration and long (>24 hour) exposure, it causes inhibition of proinsulin 
biosynthesis and insulin secretion (Spinas et al., 1987). TNF-@ alone, or in 
combination with IFN-? was also found to exert cytotoxic effects on rat and mouse 
islet cells in vitro, resulting in a reduction of insulin release and with obvious N-cell 
damage (Campbell et al., 1988). The effect of cytokines on human islets has been 
reported recently by Soldevila and his colleagues (1991). These authors found that 
combination of IFN-? and TNF-@ exerts a cytotoxic effect on human islet cells in 
vitro with a reduction in insulin release, and associated cell damage. TNF-@ alone 
produced inhibition of insulin release while IFN-? had little effect. In addition, they 
observed that there is a time course relationship between MHC class II induction and 
the cytotoxic effect of IFN-? plus TNF-@ on the same islet cells. The synergistic 
effects of combination of IFN-? and TNF-@ have been reported in a variety of 
situations, including induction of MHC molecule expression (Pujol-Borrell et al., 
1987), protection of cells from viral infection (Wong and Goeddel, 1986) and 
cytotoxicity to tumoral cell lines (Sugarman et al., 1985). It has been postulated that 
this synergism is due to the up-regulation of TNF-@ receptors on the cell surface by 
IFN-? (Aggarwal et al., 1985).  
 
2.3.3 CYTOKINE PROFILE 
Two types of helper T cell clones (TH1 and TH2) have been recognized in the 
mouse on the basis of a pattern of cytokine secretion (Mosmann et al., 1986). T-cell 
clones of the TH1 subset synthesize and secrete IL-2 and IFN-?, whereas T-cell 
clones of the TH2 subset produce IL-4, IL-5, IL-6 and IL-10 but not IL-2 and IFN-?.
Human CD4+ T cell clones with an intermediate cytokine profile have also been 
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described and termed TH0 (Romagnani, 1992). It was thought that this classification 
is not valid for human T cells until recently. It has been found that CD4+ T-cell 
clones that exhibit TH1- or TH2-like profiles can accumulate in tissue or peripheral 
blood of patients in different disease states (Romagnani, 1992). These clones were 
found also to differ in their cytolytic potential and mode of help for B-cell Ig 
synthesis. For instance, the majority of TH1 (77%), but only a minority of TH2 (18%) 
clones exhibit cytolytic activity in a 4h PHA-dependent assay, while TH2
(noncytolytic) clones induced synthesis of IgM, IgG, IgA and IgE by autologous B 
cells in the presence of the specific antigen and the degree of response was 
proportional to the number of TH2 cells added to B cells (Romagnani, 1992). Based 
on these findings, it has been suggested that the TH1 subset represents the most 
important effector cells in inflammatory reactions associated with vigorous delayed-
type hypersensitivity, but low antibody production; while the functional phenotype 
of most TH2 cells may account for the persistent production of antibodies 
(Romagnani, 1991).  
 It has been proposed that the balance of TH1 and TH2 cells is critical in the 
development of Type 1 diabetes. This suggestion is made on the basis that at-risk 
first degree relatives who have poor delayed-type hypersensitivity responses to 
specific islet antigens (eg glutamic acid decarboxylase, GAD) may be less likely to 
develop diabetes (Harrison et al., 1993). In addition, there is evidence from the non-
obese diabetic (NOD) mouse model of spontaneous diabetes that GAD-responsive, 
IFN-? producing TH1 lymphocytes are an early feature of the disease process 
(Kaufman et al., 1993).  
 
2.4 CYTOKINES AND AUTOIMMUNE CHRONIC LIVER DISEASE  
Autoimmune chronic liver disease (aCLD) is characterised by progressive 
liver damage associated with autoimmune reactions to specific liver antigens (Vento 
et al., 1984). The hallmark of aCLD is a mononuclear cell infiltrate present on the 
portal tract and spilling over into the parenchyma. Activated T lymphocytes and 
macrophages are conspicuous in this infiltrate (Eggink et al., 1984). It has been 
suggested that liver damage in aCLD is likely to be orchestrate by CD4+ T
lymphocytes which recognise a self antigenic peptide as foreign (reviewed by Mieli-
Vergani and Vergani, 1993). During the autoimmune response the peptide is 
presented to the CD4+ T cells by either a professional antigenic presenting cell such 
as a macrophage, or by the hepatocyte itself. The T helper cell then becomes 
activated and can initiate a cascade of immune reactions by producing cytokines, 
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activating cytotoxic T cells and inducing autoantibody production by B 
lymphocytes. This model is supported by a number of observations: (a) hepatocytes 
from patients with active autoimmune hepatitis express class II MHC antigens not 
normally expressed on liver cells (Lobo-Yeo et al., 1990A) and can therefore present 
autoantigenic peptides; (b) CD4+ and activated lymphocytes are present in areas of 
piecemeal necrosis (Colucci et al., 1983; Senaldi et al., 1992); (c) a high proportion 
of circulating helper T lymphocytes express the activation marker IL-2 receptor 
(Lobo-Yeo et al., 1990B) and (d) high titre liver-specific autoantibodies are present 
in the circulation of these patients.  
 In liver disease, cytokines may contribute to liver cell destruction either 
directly through their cytotoxic potential or by recruiting inflammatory cells capable 
of bringing about cell death. Previous studies on hepatitis B virus infected animal 
model give support to this concept and demonstrated that hepatitis B serface antigen 
positive transgenic mouse hepatocyte is selectively sensitive to destruction by TNF-
@ and IFN-? and this process can be reduced by the prior administration of 
neutralizing anti-TNF-@ and anti-IFN-? specific monoclonal antibodies (Gilles et al., 
1992). A further study also showed that both TNF-@ and IFN-? exerted a 
cytotoxicity to cultured rat hepatocytes by increasing apoptosis (Shinagawa et al., 
1991). These findings indicate that cytokines may play a role in both the 
orchestration and execution of the immune attack on hepatocytes.  
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3.1 AIM OF THE PRESENT STUDY  
The aim of the present study is to investigate the role of cytokines in the 
development of organ-specific autoimmune disease. Cytokines will be measured in 
serum and in supernatants of cultured peripheral blood mononuclear cells (PBMC), 
as well as being detected in situ in the tissues of the target organ. The diseases which 
will be studied are type 1 diabetes and autoimmune hepatitis. The power of these 
investigations will be enhanced by access to unique study groups. First, non-diabetic 
identical twins of patients with type 1 diabetes will be studied prospectively from 
diagnosis of diabetes in their co-twin. Such non-diabetic twins have a 200-fold 
higher chance of developing diabetes than the general population, but not all do so. 
Thus two populations of twins at risk of diabetes will be studied, one of whom 
becomes diabetic, whilst the other does not, allowing the examination of patterns of 
cytokine release which presage diabetes. The second population for study is a colony 
of non-obese diabetic (NOD) mice with a high incidence of spontaneous diabetes. 
 Specific aims of the project in the investigation of the pathogenesis of type 1 
diabetes will be: i) to establish assays to measure the cytokines IL-1@, IL-1N, IL-2, 
IL-4, IL-6, IL-10, IFN-? and TNF-@ and sIL-2R at picogram (pg) per millilitre 
concentration or less; ii) to measure serum levels of IL-1@, IL-1N and TNF-@
(macrophage derived cytokines), IL-2 and IFN-? (TH1 derived cytokine), IL-4, IL-6 
and IL-10 (TH2 derived cytokine) and sIL-2R in patients with type 1 diabetes of 
varying disease duration to define if there is a pattern of cytokine alterations 
characteristic of the disease; iii) to determine whether circulating cytokine levels 
show a pattern characterising the pre-diabetic period by studying a cohort of non-
diabetic identical twins of patients with type 1 diabetes; iv) to examine cytokine 
levels in first degree relatives of patients with type 1 diabetes, their relationship to 
HLA type and autoantibodies; v) to investigate cytokine secretion by PBMC from 
patients with type 1 diabetes stimulated with mitogens in tissue culture; vi) to 
measure serum levels of TNF-@, IL-2 and IL-4 in NOD mice to define the cytokine 
profile involved in the development of Type 1 diabetes in this model; vii) to 
examine cellular expression of cytokines (TNF-@ and IFN-?) in islets of Langerhans 
of NOD mice of various ages with and without diabetes.  
 A study of cytokine levels in another organ-specific autoimmune disease, 
autoimmune hepatitis, will also be performed. i) Circulating levels of cytokines will 
be measured in children with autoimmune chronic liver disease and chronic liver 
disease due to metabolic causes, namely Wilson's disease and alpha 1 antitrypsin 
deficiency as controls; ii) cytokine-producing cells will be examined in the 
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inflammatory cell infiltrate in liver biopsies from the same children. Cytokine 
producing cells will be detected in cryostat sections using indirect 
immunohistochemical or immunofluorescence techniques.  The study of cytokines 
in patients with autoimmune diseases will not only increase our understanding of the 
role of these factors in disease, but also provide the basis for the utilisation of anti-
cytokine therapy (blocking antibodies, soluble receptors) as part of immunotherapy 
in order to prevent or abrogate autoimmune disease. 
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CHAPTER 4
MATERIALS AND METHODS 
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4.1 SUBJECTS WITH DIABETES 
In these studies, patients with Type 1 diabetes are defined in accordance with 
the guidelines of the National Diabetes Data Group (National Diabetes Data Group, 
1979), requiring insulin to prevent diabetic ketoacidosis and sustain life. At 
diagnosis, all had elevated blood glucose and glycosuria. Since collection of blood 
was usually performed for immunological studies, and bearing in mind that immune 
function is affected by both metabolic control and intercurrent illness, samples were 
only obtained from patients who were not in ketoacidosis and had no symptoms or 
clinical evidence of infection.  
 
4.1.1 PATIENTS WITH TYPE 1 DIABETES 
 Patients studied were divided into three categories according to the timing of 
blood sampling in relation to diagnosis of Type 1 diabetes. Patients bled 
immediately before or within one week of commencement of insulin treatment were 
considered newly-diagnosed. Those sampled within the first year were considered 
to be within the group of recent-onset. Patients with treated Type 1 diabetes for 
more than 5 years were considered to have long-standing disease. Patients were 
mainly recruited from the Diabetic Department at King's College Hospital, although 
some were also studied whilst attending clinics at Guy's, Westminster and 
Farnborough Hospitals. Ethical permission for all studies was obtained from the 
respective District Health Authority Ethical Committees. 
 
4.1.2 PATIENTS WITH TYPE 2 DIABETES 
 Unlike type 1 diabetes, patients with type 2 diabetes do not require insulin to 
prevent ketoacidosis and sustain life. Type 2 diabetics will be studied mainly as 
"metabolic controls" since, whilst they experience a metabolic imbalance similar to 
that of Type 1 diabetes, their condition has, almost certainly, an aetiology and 
pathogenesis distinct from that of type 1 diabetes. All patients studied were 
attending the Diabetic outpatient clinic at King's College Hospital. 
 
4.1.3 FAMILIES WITH AN INDEX CASE OF TYPE 1 DIABETES 
 Twenty-nine families, all with an index case of Type 1 diabetes attending the 
District Diabetes Centre, Farnborough Hospital, volunteered to be bled en masse 
once in 1989 and once in 1990. As far as possible, samples were obtained from all 
siblings and both parents: due to the pressures of family life, this was not always 
possible.  
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4.1.4 IDENTICAL TWINS OF PATIENTS WITH TYPE 1 DIABETES  
 Blood samples from monozygotic twins have been collected and stored in 
the Department of Immunology at King's College School of Medicine and Dentistry 
for almost 10 years. These samples derive from a unique collection of twin pairs in 
which at least one of the twins has Type 1 diabetes. The twin collection was begun 
by Dr David Pyke and has been continued by Dr David Leslie. Zygosity is assessed 
by typing for the blood groups ABO, CDE, MN, S, P, Lua, K, Lea and Fya, which 
establish monozygosity with a less than 3% chance of error (Cederlöff et al., 1961; 
Tattersall and Pyke, 1972, Barnett et al., 1981). 
 The twins studied in this thesis can be allocated into two groups on the basis 
of the outcome of their risk of developing Type 1 diabetes. In the first group are non-
diabetic identical twins of patients with Type 1 diabetes, ascertained within one year 
of the diagnosis of the index and followed until they themselves became diabetic. 
This is the pre-diabetic group. The second set of subjects are also twins ascertained 
within one year of the onset of Type 1 diabetes in the index twin, but who had not 
developed Type 1 diabetes 6 years after this diagnosis. Actuarial analysis has shown 
that by this time, they have a less than 2% chance of ever developing Type 1 
diabetes (Olmos et al., 1988). These form the diabetes-resistant group. 
 
4.2 NON-OBESE DIABETIC MICE  
 Cytokines were also studied in an animal model of diabetes (non obese 
diabetic [NOD]) mouse. We have established a colony of NOD mice in the 
Comparative Biology Unit (CBU) at King's. These animals were obtained from Dr. 
Hattori, Joslin Diabetes Centre, Boston, U.S.A. The incidence of diabetes in both 
female (80%) and male (50%) mice is high compared with other centres. During 
their growth the mice are monitored for weight changes and by weekly urinalysis for 
glycosuria. 
 
4.3 SUBJECTS WITH AUTOIMMUNE CHRONIC LIVER DISEASE   
 Children with autoimmune chronic liver disease are considered as another 
group of patients with organ-specific autoimmune disease. Children were recruited 
from Child Health outpatient clinic at King's College Hospital. This group includes 
patients with autoimmune hepatitis (AIH) and a form of sclerosing cholangitis, the 
pathogenesis of which is considered to be autoimmune, autoimmune sclerosing 
cholangitis (ASC) (El-Shabrawi M et al., 1987). They were diagnosed according to 
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internationally agreed criteria (Scheuer, 1991) and differentiated by the fact that 
ASC had characteristic cholangiographic bile duct changes. Children with other 
chronic liver diseases such as Wilson's disease (WD) and alpha-1-antitrypsin 
deficiency (A1ATD) were studied as pathological controls. Clinical, biochemical, 
immunological and histological details of the patients with autoimmune chronic 
liver disease are summarised in table 11.1.
4.4 HEALTH CONTROLS SUBJECTS 
 Healthy adults were recruited as control subjects from laboratory, secretarial, 
medical and portering staff within King's College Hospital and also from blood 
donors of the South East Thames Regional Blood Transfusion Service. When fresh 
blood was required for lymphocyte studies, it was drawn from controls at the same 
time as for the patient group to avoid biases resulting from seasonal, diurnal, or 
technical variations. 
 Healthy children were recruited by the Medway and Gillingham Branch 
(Kent) of the Children's Liver Disease Foundation (CLDF), and gave blood after 
informed consent from themselves or their parents, as appropriate.  
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4.5 MATERIALS  
4.5.1 REAGENTS  
Benzylpenicillin (sodium) BP (Glaxo, Greenford, UK). 
Bovine serum albumin (Sigma Chemical Company, Poole, 
Dorset). 
Collagenase type V (Sigma). 
3,3-Diaminobenzidine hydrochloride (DAB) (Sigma). 
Ficoll-hypaque (Pharmacia, Uppsala, Sweden). 
Foetal calf serum, heat inactivated, virus and 
mycoplasma free (Gibco, Paisley, UK).  
Hank's balanced salt solution (Gibco).  
Human AB serum, heat inactivated (Donated by Blood Donor 
whose blood group is AB). 
Lauryl sulphate (Sigma). 
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5   
diphenyltetrazolium  bromide) (Sigma). 
O.C.T medium (BDH, Poole, Dorset).  
o-phenylenediamine dihydrochloride (OPD)(Sigma). 
Preservative-free heparin (Leo Laboratories, Princes  
Risborough, UK).   
Phytoheamoagglutinine (PHA) and Lipopolysaccharride (LPS) (Sigma) 
Rabbit, Mouse and Swine serum (Flow Laboratories,  
Rickmansworth, UK). 
RPMI 1640 with glutamine (Gibco). 
Streptomycin sulphate (Evans, Greenford, UK) 
Tween 20 (Sigma). 
All other chemicals were "analar" or at the highest   
available purity and were obtained from BDH, Sigma, 
Hopkins and Williams, Chadwell Heath, UK or Fisons, 
Loughborough, UK 
 
4.5.2 Buffers, solutions and modified media 
Blocking buffer (Phosphate Buffered Saline, 1% BSA). 
Coating buffer (0.05M Sodium Carbonate pH 9.6). 
Chromatography buffers (Chemicals from BDH, Poole, UK): 
ion-exchange starting buffer:10 mM Phosphate buffer; pH 
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8.0; protein-A loading buffer: 1.5 M glycine, 3 M NaCl, 
pH 8.9; protein-A eluting buffer: 100 mM citric acid, pH  
5.0. 
Phosphate buffered saline (PBS): 15mM NaCl, 15mM KCl, 
8mM Na2HPO4,15mM KH2PO4, pH 7.2. 
RPMI culture medium: RPMI 1640 containing 2mM glutamine, 
200 U/ml penicillin, 100 µg/ml streptomycin and 10% 
foetal calf serum. 
Substrate Solution for ELISA: o-phenylenediamine 
dihydrochloride (OPD). For 20 mls: OPD 8mg, 10mls 
pyrogen free water, 4.9 mls of 0.01M citric acid, 5.1 
mls of 0.2M Na2HPO4 (dihydrate) and 300 µl H2O2 (6%). 
Substrate Solution for Immunohistochemical Staining:     
3,3-Diaminobenzidine (DAB). For 5 mls: DAB 3mg and 5mls 
of PBS. After filtration, 10 µl of H2O2 (6%)(w/v) was 
added (just before using).  
Washing buffer (PBS, 0.1% Tween 20, 0.1% BSA). 
 
4.5.3 Consumables 
Gelbond plastic film (Marine Colloids, MA, USA). 
LP3 tubes (Luckham, Burgess Hill, UK). 
Minicon B15 concentrator (Amicon Ltd, Buckinghamshire, 
UK) 
Polystyrene microtitre plates class II and MaxiSorp F96 
(Dynatech Immulon, Dynatech Laboratories, Sussex, UK and 
Nunc Plastic, Poskilde, Denmark). 
Tissue culture microtitre plate (Becton Dickinson, 
Labware, New Jersey, USA). 
Tissue culture tubes (Gibco). 
"Vacutainers" (plain glass tubes and 'EDTA-tubes') and  
syringes (Becton Dickinson, Rutheford, NJ, USA). 
Visking tubes (Pharmacia). 
Universal containers (Sterilin, Teddington, UK). 
 
4.5.4 MONOCLONAL  ANTIBODIES (MAb) TO CYTOKINES 
Anti-human IL-2 (clone DMS-1) (Genzyme, Genzyme  
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Diagnostics, Kent, UK). 
Anti-human IL-4 (clone 82) (ams Biotechnology Europe 
Ltd, Oxon, UK). 
Anti-human IL-4 labelled with biotin (clone 12) (ams  
Biotechnology Europe Ltd) 
Anti-human IL-6 (clone CLB.IL-6/8) (Lab Impex 
Diagnostics, Middlesex, UK). 
Anti-human IL-6 (clone 1G61) (Dr. Nobuo Ida, Medical  
Devices and Diagnostics Research Labs, Toray  
Industries, Kanagawa, Japan). 
Anti-human IL-10 (clone JES3-9D7) (ams Biotechnology  
Europe Ltd). 
Anti-human IL-10 labelled with biotin (clone JES3-12G8)  
(ams Biotechnology Europe Ltd). 
Anti-human IFN-? (clone 69) (Dr. Gallati, Hoffmann-La  
Roche, Switzerland). 
Anti-human IFN-? peroxidase labelled (clone 123) (Dr. H. 
Gallati, Hoffmann-La Roche).  
Anti-human soluble IL-2 receptor (clone ACT-1, anti-Tac)  
(Dako, High Wycombe, UK). 
Anti-mouse TNF-@ (clone TN3 19-12) (Dr. M. Bodmer,  
Celltech Ltd, UK). 
Anti-mouse IL-2 (clone JES6-1A12) (ams Biotechnology  
Europe Ltd). 
Anti-mouse IL-2 labelled with biotin (clone JES6-5H4)  
ams Biotechnology Europe Ltd). 
Anti-mouse IL-4 (clone BVD4-1D11) (ams Biotechnology  
Europe Ltd). 
Anti-mouse IL-4 labelled with biotin (clone BVD6-2492)  
(ams Biotechnology Europe Ltd). 
 
4.5.5 Polyclonal antibodies to cytokine 
Mouse, rabbit and sheep IgG serum (Serotech, UK). 
Sheep anti-human IL-1N (Dr. H. Gallati). 
Sheep anti-human IL-1N peroxidase labelled (Dr. H. 
Gallati).  
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Sheep anti-human IL-1@ (S76@BM) (Dr. R. Thorp, National 
Institute for Biological Standards and Control  
(NIBSC), Mill Hill, UK). 
Rabbit anti-IL-2 (Genzyme). 
Rabbit anti-human TNF-@ (Dr. M. Bodmer, Celltech Ltd). 
Sheep anti-mouse TNF-@ (Dr. A. Meager, NIBSC). 
 
4.5.6 Hybridoma cell lines producing antibodies 
Mouse hybridoma cell line producing anti-human IL-1@
(clone 364/3B3-14) (Dr. R. Thorp, NIBSC). 
Mouse hybridoma cell line producing anti-human TNF-@
antibody (clone 357-27-8) (Dr. A. Meager, NIBSC). 
Mouse hybridoma cell line producing anti-human sIL-2R 
antibody (7G7/B6) (American Type Culture Collection 
(ATCC), Rockville, MD, USA).   
Rat hybridoma cell line producing anti-mouse IFN-?
antibody (46A4) (Dr. A. Meager). 
 
4.5.7 Cytokines standards 
Recombinant human TNF-@ (BASF/Knoll, Germany). 
Recombinant human IL-1@, IL-1N , IL-2, IL-4, IL-6 and 
IL-10 (NIBSC). 
Recombinant human IFN-? (Hoffmann-La Roche). 
Recombinant mouse TNF-@, IL-2 and IL-4 (NIBSC). 
Recombinant mouse IFN-? (NIBSC). 
4.5.8 PEROXIDASE-CONJUGATED ANTISERA  
Affinity purified swine anti-rabbit (Dako).    
Goat anti-sheep immunoglobulin (Dako).  
Rabbit anti-mouse (Dako).  
Strept-avidin (Dako). 
 
4.5.9 COMMERCIAL KITS  
C-peptide radioimmunoassay (Behringwerke AG, Marburg, 
Germany). 
Particle agglutination kits (Serodia-ATG, Serodia-ACM;  
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Fujirebio, Tokyo, Japan). 
 
4.5.10 INSTRUMENTS   
Cell freezer (Planer products Ltd, Middlesex, UK). 
CO2 Incubator (Leec, Colwick, UK). 
-70oC Freezer (Science Temp, Adrian, Mich, USA). 
Gamma counter (LKB, 1260 MultiGamma, Bromma, Sweden). 
Microelisa reader (MR 700 Microplate Reader, Dynatech). 
Mistral 6 L centrifuge (MSE instruments, Crawley, UK). 
Mesh (Endecott's, London, UK). 
Plate Washer (Dynatech AutoWash 2000, Dynatech). 
Polyvar Reichert-Jung fluorescence microscope equipped 
for epifluorescence (Polyvar, Vienna, Austria). 
Peristaltic HiLoad P-50 pump (Pharmacia Biotechnology 
Ltd, Herts., UK) 
Plotter UV-Recorder 2-Channel (Pharmacia Biotechnology 
Ltd, Herts., UK)  
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4.6 METHODOLOGY   
4.6.1 PREPARATION OF MONOCLONAL ANTI-CYTOKINE 
ANTIBODIES  Four of the 15 monoclonal antibodies (MAbs) used in the 
studies of this thesis were prepared "in-house" (monoclonal antibodies to human 
TNF-@, IL-1@ and soluble IL-2 receptor, and to mouse IFN-? antibodies). They were 
prepared by culturing antibody producing (anti-cytokine) hybridoma cell lines in 
vitro, according to the general guidelines reported by Goding (1986). The remaining 
11 MAbs were either a gift or purchased. All these were pure and of the IgG class, 
except for anti-human IL-6 antibodies, which were unpurified MAb, and obtained in 
ascites fluid.  
 Purified antibodies were then extracted from both culture supernatants and 
ascites fluid (i.e. in case of anti-IL-6 MAb) by affinity chromatography (protein-A) 
and were assessed for the amount and purity of yield, prepared for long-term storage 
and tested and titrated for subsequent cytokine assays. 
Culture of Hybridoma Cell Lines. Hybridomas were thawed on arrival in less than 
60 sec in a 37oC water bath and put into culture medium. Immediate culture upon 
receipt proved to be important in maintaining high cell viability, whilst further 
storage after arrival reduced viability. 
 Before initiating culture, the number of viable hybridomas was assessed in a 
Neubauer's chamber using Trypan blue as an indicator of viability (Hudson and Hay, 
1989). Viability ranged in the different lines between 50 and 70% with a median of 
60%. Cell numbers were then adjusted in suspension to a concentration of 
0.5x106/ml in RPMI 1640 containing 2mM L-glutamine, 200 U/ml penicillin, 100 
µg/ml streptomycin, 2 µg/ml amphotericin B and 10% heat-inactivated foetal calf 
serum (FCS) (from now on referred to as the culture medium) and initially cultured 
in 25 cm2 tissue culture flasks in an incubator at 37oC in 5% CO2. Aliquots of 5 ml 
of cell suspension were distributed in each flask containing 15 ml culture medium, 
for further growth and antibody production. Hybridoma cell number and viability as 
checked daily and 5 ml of fresh culture medium was added to each flask when the 
number of viable cells exceeded 1x106/ml. When the number of viable hybridoma 
cells increased to 4x106/ml, they were transferred from 25 into 50 cm2 tissue culture 
flasks containing 30 ml of culture medium. Again hybridoma cell number and 
viability was checked daily so that, by addition of fresh culture medium, now 
containing 2% FCS, viable cells were maintained in culture at a concentration of 
5x106/ml. The decrease of FCS concentration in the culture medium was adopted in 
order to reduce the final concentration of bovine immunoglobulin, which is only 
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present in FCS in small amounts, but is sufficient to compromise optimal purity and 
yield of MAb after chromatography (Manil et al., 1986). The rate of growth varied 
from cell line to cell line. However, hybridomas reached an adequate number to 
allow transfer from small (25 cm2) to bigger flasks (50 cm2) between approximately 
3 and 7 days. This time was found to be the most suitable, since longer periods did 
not improve antibody yield, decreased hybridoma viability and increased the risk of 
microbiological contamination, while shorter culture periods reduced the yield of 
antibodies. The contents of flasks after this culture period were centrifuged at 2000 g 
for 30 min, the pellet discarded and the supernatant pooled and either purified 
immediately or stored at -20oC.  
 An aliquot of the hybridoma cells obtained after initial growth was removed 
from culture and suspended in culture medium containing 40% FCS and 10% 
dimethysulphoxide at a concentration of 5x106/ml. One ml of this cell suspension 
was immediately frozen in a controlled rate cell freezer (-1 oC/ minute) and stored in 
liquid nitrogen (-70oC) for future needs. 
 
Purification of Monoclonal and Polyclonal anti-cytokine Antibodies. MAb 
obtained in ascitic fluid or supernatant after hybridoma culture in vitro was purified 
by affinity (protein-A) chromatography. Ion-exchange chromatography was used to 
purify polyclonal antibodies. Chromatography was always performed in columns at 
room temperature. 
Protein-A chromatography. Protein-A is a protein from Staphylococcus aureus 
which binds to the Fc portion of IgG from a wide range of species (Goudswaard et 
al., 1978). Protein-A is covalently coupled to a cross-linked matrix, Sepharose CL-
4B. This matrix exhibits high chemical and mechanical stability (Ey et al., 1978).  
 The IgG binding properties of protein A make chromatography with protein 
A-Sepharose CL-4B immunoadsorbents a very simple method for preparing IgG 
since it has excellent purification properties in terms of both the amount and purity 
of yield, whilst at the same time being rapid to perform (Manil et al., 1986). 
 Protein A-Sepharose CL-4B beads were hydrated with saline solution, 
poured, packed and equilibrated with loading buffer in a chromatography column 
according to manufacturer's instructions. A 5 cm length x 1 cm diameter column 
was prepared, which is able to bind 25 mg of murine immunoglobulin.  
 After recovery from culture or following storage at -20oC, 200 ml of 
supernatant was filtered using 0.22 µm micropore filters and mixed with an equal 
volume of loading buffer for affinity chromatography with protein-A. The 
59 
 
composition and pH of the loading (alkaline) and eluting (acid) buffers were those 
recommended by Pharmacia (Mariani et al., 1989). Adjusted to the optimal pH of 
8.9, the mixture of supernatant and buffer was loaded on the column at a flow rate of 
30 ml/hour controlled by a peristaltic pump. The eluent was monitored for protein 
content with an UV (280 nm absorbance) spectrophotometer connected to a plotter 
(Figure 4.1, phase 1). Once the mixture of supernatant and buffer had passed 
through the column, it was rinsed with approximately 200 ml of loading buffer alone 
flowing at the same speed. During this procedure no protein eluted from the column 
(Figure 4.1, phase 2). At this stage the column was treated with the eluting buffer at 
pH 3.0, flowing at the same rate as above, to yield the MAb retained by protein-A 
(Figure 4.1, phase 3). 20 ml of eluting buffer was sufficient to remove the MAb 
from the protein-A column completely; the eluent was collected in fractions of 5 ml. 
Each fraction neutralised with 5 ml of 1 M carbonate buffer at pH 8.0, to prevent 
degradation occurring in the acid conditions. The fractions were then pooled and 
concentrated by ultrafiltration to a final volume of 5 ml which were dialysed 
overnight at 4oC against 1 litre of PBS containing 0.01% sodium azide and changed 
twice. MAb present in this final solution was assessed for yield, tested and titrated 
for cytokine assays and stored as described below.  
 Purification of MAb obtained in ascitic fluid, as in case of MAb anti-human 
IL-6 antibodies, was achieved in similar manner to purification of MAb obtained in 
supernatants of tissue culture using protein A chromatography.   
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Figure 4.1. Curve describing the protein content in the fluid leaving the protein A 
chromatography column as determined with an UV spectrophotometer (280 nm 
absorbance). On the vertical axis is the absorbance and on the horizontal axis the 
time. When initially the mixture of supernatant and buffer was loaded on the column 
a high content of proteins, deriving from foetal calf serum in the supernatant, was 
found (phase 1). When subsequently loading buffer alone was loaded the protein 
content gradually declined (phase 2). When the eluting buffer was loaded on the 
column the monoclonal antibody retained by protein-A was released and found in 
the eluate (phase 3). 
 
Ion-exchange chromatography. This method was preferred to protein-A 
chromatography for the purification of the IgG class polyclonal antibodies (raised in 
sheep: anti-IL-1 and anti-IL-6 or in rabbit: anti-TNF). In this method, proteins are 
bound electrostatically on to an ion-exchange matrix bearing an opposite charge. 
The degree to which a protein binds depends upon its charge density. Proteins are 
then eluted differentially by: 
(a) Increasing the ionic strength of the buffer running through the column. As the 
concentration of buffer ions is increased proteins are displaced from the charged 
groups on the ion-exchanger. 
(b) Alteration of the pH. As the pH of the buffer approaches the isoelectric point of 
each protein, the net charge on the protein becomes zero and so the protein no longer 
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binds to the ion-exchanger. 
 This technique offers the potential for separation of one immunoglobulin 
class from others, as is the case of a polyclonal antibodies in hyperimmunised 
animals (Hudson and Hay, 1989). 
 A matrix for anionic ion-exchange chromatography (DEAE-Sephacel) was 
obtained pre-swollen. A column of 40 cm length and 1.5 cm diameter was packed 
according to the manufacturer's instructions and equilibrated with starting buffer. 
The size of the column was selected on the basis of the volume and viscosity of the 
sample to be purified. The composition and pH of the starting buffers were used 
according to the technique by Hudson and Hay (1989). 
 Polyclonal serum was prepared for chromatography by overnight dialysis at 
4oC of 5 ml serum against 1 l of starting buffer. The sample was then loaded and the 
column flushed through with three column volumes of starting buffer. IgG was 
eluted in a single asymmetric peak (Figure 4.2) and impurities were bound and 
retarded by the exchanger. The eluate was collected and the fractions comprising the 
first protein peak were pooled and dialysed as for the fractions obtained with 
protein-A chromatography and finally diluted in PBS with 0.01% sodium azide to a 
final volume of 5 ml. The MAb and polyclonal antibodies obtained after purification 
were further processed as described below. 
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UV   Absorbance   (280 nm) 
 
Figure 4.2. Isolation of IgG fraction from sheep anti-IL-1( serum on DEAE-
Sephacel chromatogram. On the vertical axis is the absorbance (280 nm) and on the 
horizontal axis is the time. The peak shown was obtained by elution of IgG fraction 
with 10 mM phosphate buffer, pH 8.0.  
 
Assessment of amount and purity of monoclonal and poly-clonal antibodies.
This procedure was necessary to ascertain the performance, in both quantitative and 
qualitative terms, of the MAb and polyclonal production and purification, and to 
allow appropriate dilution for storage and titration. 
 Protein content of the final MAb and polyclonal solutions recovered after 
protein-A or ion-exchange chromatography was measured by a Coomassie blue 
method (Bradford, 1976) using a commercially available kit and following 
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manufacturers's instructions. It was calculated that each ml of culture supernatant 
contained between 100-300 µg of MAb (median 230 µg), while each ml of 
polyclonal serum contained 7-10 mg (median 8 mg). 
 To evaluate the efficiency of extraction of MAb, mouse immunoglobulin 
content was measured in both the original solution (supernatant, ascites) and the 
purified final product by radial immunodiffusion. A gel containing 1% agarose, 2% 
polyethylene glycol and 1% rabbit anti-mouse immunoglobulin was cast on to a 
plastic support medium (Gelbond) in a template to give a final thickness of 1.5 mm. 
Thirty wells of 2 mm diameter were punched and loaded with 10 µl from (A) neat 
supernatants, (B) ascites diluted 1/400 in PBS, (C) purified protein solutions (A and 
B) diluted 1/40 in PBS and (D) six doubling dilutions of standard mouse serum in 
PBS from 1/100 to 1/3200 to obtain a reference curve. After a 48 hour incubation at 
4oC, diameters of the precipitation rings formed around each well were measured, 
the reference curve plotted and the unknown concentrations derived. The results 
were expressed as percentages of the maximum standard (100%). A similar 
approach was adopted to evaluate the efficiency of extraction of polyclonal 
antibodies of sheep and rabbit immunoglobulins. Pre:post-purification ratios were 
calculated, to yield the percentages of extracted MAb and polyclonal antibody. 
These ranged between 43% and 93% and had a median of 81%.  
Storage of monoclonal and polyclonal antibodies. All antibodies were adjusted to 
final concentration of approximately 1 mg/ml using PBS containing 0.01% sodium 
azide. They were then divided into 1 ml aliquots and stored at -70oC. 
Biotin-conjugation. This technique was required to conjugate MAb anti-IL-6 to 
biotin which was used in the revealing step of IL-6 immunoassay as described later 
(vide 4.6.2). The conjugation was performed according to the technique of Bayer 
and Wilchek (1980) and at relatively low protein concentration (1 mg/ml).   
 Biotin hydroxy succinimide ester (BHSE) was dissolved immediately before 
use in dimethyl sulfoxide (DMSO) at a final concentration of 50 mg/ml. Purified 
anti-IL-6 MAb was adjusted to 1 mg/ml and dialyzed in "Visking" tubes against 1 
litre of 0.1M NaHCO3 buffered, pH 9.5. BHSE solution was added dropwise to the 
anti-IL-6 preparation at a protein/BHSE ratio of 1mg/ 1mg. The mixture was kept 
agitated for 15 minutes, and then allowed to stand for 180 minutes at room 
temperature. The unbound biotin was removed by dialysis against 20 ml of PBS 
using a Minicon B15 concentrator. Biotinylated anti-IL-6 MAb was then aliquoted 
and stored at -70oC. Optimum conjugate concentrations of anti-IL-6 MAb used in 
the immunoassay were determined as described for standardisation methodology for 
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the indirect ELISA of TNF-@ (vide 4.6.1.6).  
 
Specificity of Anti-cytokine Antibodies. A direct enzyme linked immuno-sorbent 
assay (ELISA) was used to check whether a given antibody reacts specifically with a 
corresponding cytokine. This technique was performed according to Lamche and 
Adolf (1990). Microtitre plates were coated (16 hour, 4oC) with corresponding 
recombinant cytokine (30 ng/100 µl carbonate buffered solution, pH 9.5, per well). 
After washing the plates (0.05% Tween 20 in PBS) and treating them with 1% 
bovine serum albumin (BSA) (60 min, at room temperature to block non-specific 
binding sites), 100 µl of 1/10 dilution of each antibody (monoclonal and polyclonal 
anti-cytokine antibodies) was added to the wells of corresponding and irrelevant 
cytokines. After 60 min at 37oC, the plates were washed and incubated (60 min at 
37oC) with horseradish peroxidase-conjugated anti-species sera (e.g. goat anti-
mouse, goat anti-rabbit or rabbit anti-sheep), followed by addition of the enzyme 
substrate, o-phenylenediamine dihydrochloride (OPD) (vide 4.5). Optical density 
(OD) at 490 was determined after a 15-30 min incubation at room temperature using 
Microelisa Auto Reader. All anti-cytokines antibodies reacted specifically with 
corresponding cytokine antigens and did not cross react with irrelevant cytokine 
(Table 4.1).
Table 4.1 Means of Absorbance reading at 490 nm for anti-cytokine MAb (1/10) 
reactions when used in plate coated with 30 ng/ml of different cytokines (e.g. human 
TNF-(, human IL-1(, human sIL-2R or mouse IFN-4) in the direct ELISA technique.  
 
1/10 dilution of anti-
cytokine antibody 
Human 
TNF-*
Human IL-
1*
Mouse IFN-
+
Human sIL-
2R      
Anti-human TNF-*MAb 0.781 0.009 0.002 0.000 
Anti-human IL-1*MAb 0.001 0.562 0.001 0.001 
Anti-mouse IFN-+MAb 0.000 0.005 0.925 0.000 
Anti-human sIL-2R MAb 0.001 0.001 0.000 0.458 
Test and Titration of Monoclonal and Polyclonal Antibodies used in cytokine 
assays. These procedures have aim to establish that the functional capability of the 
antibody has been preserved during culture and purification and to find the optimal 
concentrations for use in cytokine assays comprising immunoassay and 
65 
 
immunohistochemical staining. These techniques were as described for 
standardisation methodology of TNF-@ immunoassay (vide 4.6.2) and 
immunohistochemical staining of TNF-@ in the liver (vide 4.6.5).  
 
4.6.2 CYTOKINE ASSAYS 
Levels of cytokines were measured in the serum or in the supernatant of 
stimulated peripheral blood mononuclear cells (PBMC) using either ELISA or 
bioassay, while cytokine producing cells were detected in cryostat tissue sections 
using indirect immunohistochemical or immunofluorescence technique.  
 
4.6.2.1 CYTOKINE IMMUNOASSAY 
An ELISA technique for measurement of cytokine levels in biological fluid 
including serum has been introduced by Meager et al. (1987). This technique offers 
a number of advantages compared with bioassay and radioimmunoassay (Meager et 
al., 1987): it can be performed in short time and without using radiolabelled 
materials, multiwell microtitre plates used as the solid phase are easy to handle and 
wash, and when used with automated readers and multiple well washers allow a 
large number of samples to be assayed (reviewed by Kemeny and Chantler, 1988).  
 For the measurement of cytokines, a two-site ELISA was used where the 
antibody (i.e. anti-cytokine antibody) was employed on the solid phase to capture the 
corresponding antigen (cytokine) in the test sample. The concentration of cytokine in 
a sample was determined by the amount of enzyme-labelled anti-cytokine IgG bound 
to the cytokine captured by the first, immobilized, anti-cytokine antibody (Figure 
4.3A). If the revealing antibody was unlabelled, a subsequent addition of enzyme-
labelled anti-species antibody was used (Figure  4.3B).  
Monoclonal anti-cytokine antibodies to different group-common epitopes on 
the analyte (cytokine) can be used or, alternatively, combinations of monoclonal and 
polyclonal reagents may be used for capture and detector phases of the cytokine 
immunoassay (Clayton et al., 1986; Kemeny and Richards, 1987). All labelled 
antibodies employed in the revealing steps of the cytokine immunoassays were 
HRP-labelled antibodies, and O-orthophenylene diamine (OPD) was used as a 
substrate for the of HRP enzyme. 
4A 
A = "capture anti-cytokine antibody" adsorbed onto a         microtitre well. 
B = cytokine (standards or test samples). 
C = enzyme labelled anti-cytokine antibody. 
 
4B 
A = "capture anti-cytokine antibody" adsorbed onto           microtitre well. 
B = cytokine (standards or test samples)  
C = unlabelled revealing anti-cytokine antibody . 
D = enzyme labelled anti-species antibody. 
 
Figures 4.3 (A and B). A two-site ELISA for measurement of cytokines. 
Assay optimization for TNF-* and IL-1* immunoassays.
The optimum concentration of the various components is determined by 
chequerboard titration, initially using a wide range of dilutions to identify the working range 
of the assay and subsequently small dilution increments around the optimum to determine 
the precise concentration (Kemeny and Chantler, 1988).  
 
 Determination of Optimum anti-TNF-* and IL-1* monoclonal antibodies 
concentrations for coating of microtitre plates. 
 100 µl of monoclonal anti-TNF-@ or anti-IL-1@ antibodies diluted in coating buffer 
(0.1M bicarbonate buffer (pH 9.5)) at various concentrations (0.5, 1, 2.5 and 5 µg/well) 
were coated onto ELISA plates overnight at 4°C. Plates were washed 3 times in phosphate 
buffered saline (PBS) supplemented with 0.1% bovine serum albumin and 0.01% Tween 20 
(washing buffer) and non-specific binding sites were blocked by incubation with blocking 
buffer (PBS with 1% BSA) for 1 hour at room temperature. After washing, 100 µl of 
standard (recombinant TNF-@ and IL-1@) was added for 2 hour at room temperature with 
constant shaking. Plates were then washed and 100 µl polyclonal rabbit anti-TNF-@ or sheep 
anti-IL-1@ antibodies at concentrations of 1 µg/ml and 0.5 µg/ml respectively diluted in the 
dilution buffer and supplemented with 2% mouse serum (Meager et al., 1987) (to block 
possible non-specific reaction) were added and incubated for 2 hour at room temperature 
with constant shaking. After washing, 100 µl of horseradish peroxidase-conjugated goat 
anti-rabbit or anti-sheep immunoglobulins were added in a dilution of 1/2000, supplemented 
with 2% mouse serum and incubated for 1 hour at room temperature with constant shaking. 
The reaction was developed using 100 µl of substrate (0.4 mg/ml o-phenylenediamine in 
citrate phosphate buffer (pH 5.0)) containing 4 µl/ml of 3% hydrogen peroxide for 30 
minutes in the dark at room temperature. The reaction was stopped with 50 µl of 4N H2SO4
and the absorbance at 490 nm was read in a Dynatech plate-reader. Tests were performed in 
triplicate and unknown values read from standard curves constructed using recombinant 
TNF-@ and IL-1@ at a range of dilutions from 7.5-1920 pg/ml.  
The results obtained indicated that the maximum response (OD) was given by 2.5 
µg/ml for both TNF-@ and IL-1@. No increase was found at highest concentration, hence 2.5 
µg/ml was determined to be the optimum concentration (Figure 4.4). 
Figure 4.4. TNF-( standard curves using a range of concentrations (0.5, 1, 2.5 and 5 
µg/well) of anti-TNF-( MAb in the capture step in the TNF immunoassay.  Polyclonal 
rabbit anti-TNF-( and horseradish peroxidase-conjugated anti-rabbit antibodies were used 
in the revealing step at a concentration of 1 µg/ml. Standard curves were constructed using 
recombinant TNF-( at a range of serial doubling dilutions from 7.5-1920 pg/ml (horizontal 
axis) and optical density at 490 nm was read in an ELISA reader (vertical axis). Optimal 
concentration of coating antibody was found to be 2.5 µg/ml. 
 
 Determination of optimum incubation times for cytokine/anti-cytokine MAb (Ab1) 
reaction of TNF-* and IL-1* immunoassays. 
A range of incubation times (1, 2 and 18 hours) for the cytokine/anti-cytokine MAb 
reaction were investigated for both TNF-@ and IL-1@ immunoassays. From the results 
shown in Table 4.2, optimum binding was found after 2 hour incubation for both TNF-@
and IL-1@.
Table 4.2 The mean absorbance at 490 nm for TNF-( standards at a range of dilutions from 
7.5-1920 pg/ml after different TNF-(/anti-TNF-(MAb (Ab1) reaction incubation times. 
 
Incubation time  Concentration of TNF-* (pg/ml)    
 
7.5       30       120       480      1920 
1 hour 0.000     0.065    0.215     0.758    1.542 
2 hour 0.015     0.092    0.329     1.070    2.456 
overnight (18 
hour) 
0.009     0.086    0.289     1.056    1.952 
 Determination of optimum anti-TNF-* and IL-1* polyclonal antibodies 
concentrations used in the revealing step of the TNF-* and IL-1* immunoassays. 
 Having optimised anti-TNF-@ and IL-1@ MAb concentrations employed in the 
coating step, a range of concentrations of anti-TNF-@ and IL-1@ polyclonal antibodies (0.2, 
0.5, 1 and 2 µg/ml) were then tested in the revealing step of the immunoassay as described 
above. The results obtained indicated that the appropriate polyclonal antibodies 
concentrations used in the revealing steps were found to be 1 µg/ml for TNF-@ (Figure 4.5)
and 0.5 µg/ml for IL-1@ which provided high absorbance values for TNF-@ and IL-1@
standards and constant low values for nonspecific background.         
Figure 4.5. TNF-( standard curves using a range of concentrations (0.2, 0.5, 1 and 2 µg/ml) 
of anti-TNF-( polyclonal antibodies in the revealing step of the TNF-( immunoassay.  The 
plate was coated with capture MAb anti-TNF( at a concentration of 2.5 µg/well. Standard 
curves were constructed using recombinant TNF-( at a range of serial doubling dilutions 
from 7.5-1920 pg/ml (horizontal axis) and optical density at 490 nm was read in an ELISA 
reader (vertical axis). The optimal concentration of revealing antibody was found to be 1 
µg/ml. 
 
 Determination of optimum conjugate concentration. 
 Horseradish peroxidase-conjugated goat anti-rabbit or anti-sheep immunoglobulins 
used in the immunoassay were diluted 1/2000 in the dilution buffer as recommended by the 
manufacturers. The results shown in Figure 4.4-4.6, were found most satisfactory with 
maximal binding of cytokines and with negligible background for the blank wells.  
 
Figure 4.6. A standard curve of IL-1( immunoassay. The plate was coated with anti-IL-1(
monoclonal antibody at a concentration of 2.5 µg/well. A polyclonal sheep anti-IL-1( and 
polyclonal horseradish peroxidase-conjugated anti-sheep antibodies were used in the 
revealing step at a concentration of 0.5 µg/ml and 1 µg/ml respectively. The plot represents 
the absorbances at 490 nm (vertical axis) versus the standard of IL-1( at a range of 
dilutions from 7.5-1920 pg/ml (horizontal axis).   
 
Table 4.3 and 4.4 show  optimum concentrations of the monoclonal and polyclonal 
antibodies used in the coating and revealing steps for cytokines studied such as IL-1N, IL-6, 
IFN-? and sIL-2R as determined in similar manner to those of the TNF-@ and IL-1@
immunoassays, the optimal concentration were adopted for use in cytokine immunoassays. 
 Optimum dilutions of anti-cytokine and conjugated anti-species antibodies used for 
detection of cytokine producing cells were determined using a chequerboard titration test 
(Kemeny and Chantler, 1988) in similar manner to that for immunoassays using the two-
step indirect immunohistochemical or immunofluorescence staining techniques (vide 4.6.4) 
(Table 4.5). The specificity of the staining was determined by prior incubation of anti-
cytokine antibody with 100 µg/ml of corresponding cytokine, which resulted in abolition of 
peroxidase staining.   
 
Table 4.3 Monoclonal and polyclonal anti-human cytokine antibodies purchased or donated 
and used in immunoassay. 
 
Antibody Form  Concentrat-ion* Source purpose of 
use
Monoclonal anti-IFN-+ Ascitic fluid 5 µg/well Hoffmann-La 
Roche 
Coating step 
Monoclonal anti-IFN-+
HRP labelled 
Ascitic fluid 1 µg/ml Hoffmann-La 
Roche 
Revealing step
Polyclonal anti-IL-1K Sheep 
serum 
5 µg/well Hoffmann-La 
Roche 
Coating step 
Polyclonal anti-IL-1K
HRP labelled 
Sheep 
serum 
1 µg/ml Hoffmann-La 
Roche 
Revealing step
Monoclonal anti-sIL-
2R biotin labelled 
Ascitic fluid 2 µg/ml  Dako Revealing step
Polyclonal anti-IL-1* Sheep 
serum 
0.5 µg/ml NIBSC Revealing step
Polyclonal anti-TNF-* Rabbit 
serum 
1 µg/ml Celltech Revealing step
Monoclonal anti-IL-6 Ascitic fluid 1.5 µg/well Lab Impex 
Diagnostics 
Coating  step 
Monoclonal anti-IL-6 
biotin labelled 
Ascitic fluid 2 µg/ml  Toray Industries Revealing step
Monoclonal anti-IL-4 Ascitic fluid 1 µg/well ams  
Biotechno-logy 
Coating  step 
Monoclonal anti-IL-4 
biotin labelled 
Ascitic fluid 1 µg/ml ams  
Biotechno-logy 
Revealing step
Monoclonal anti-IL-10 Ascitic fluid 1 µg/well ams Biotechno-
logy 
Coating  step 
Monoclonal anti-IL-10 
biotin labelled 
Ascitic fluid 1 µg/ml ams Biotechno-
logy 
Revealing step
* Concentrations of coating antibodies given as µg/well while concentration of revealing 
antibodies given as µg/ml.  
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Table 4.4 Monoclonal anti-human cytokine antibodies prepared and used in cytokine 
immunoassay. 
 
Monoclonal 
Antibody 
Form   Clone Concentration* Purpose of use
Anti-TNF-* Culture 
supernatant 
357-27-8 2.5 µg/well  Coating layer 
Anti-sIL-2R Culture 
supernatant 
7G7B6 5 µg/well Coating layer 
Anti-IL-1* Culture 
supernatant 
3B3-14 2.5 µg/well Coating layer 
* Concentrations of coating antibodies given as µg/well while concentration of revealing 
antibodies given as µg/ml. 
 
Table 4.5 Monoclonal and polyclonal anti-cytokine antibodies prepared or donated 
and the optimum dilution used in immunohistochemical staining. 
 
Antibody Form  Titre* Source 
Monoclonal anti-
human TNF-* (clone 
27) 
Culture 
supernatant 
(prepared) 
1/10 NIBSC 
Monoclonal anti-
human IFN-+
Ascitic fluid 
(donated) 
1/20 Hoffmann- La 
Roche 
Polyclonal anti-mouse 
TNF-*
Sheep serum 
(donated) 
1/200 NIBSC 
Monoclonal anti-
mouse IFN-+
Culture 
supernatant 
(prepared) 
1/10 NIBSC 
* Antibody titre of the original protein concentration of 1 mg/ml 
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Intra-assay and inter-assay variations. The cytokine immunoassay was tested for 
the intra-assay and inter-assay coefficients of variation (CV) using seven serum 
samples. These were tested in triplicate for intra-assay variation and eight runs for 
inter-assay variation. An example for the intra-assay and inter-assay variation of 
TNF-@ is shown in Table 4.6 and 4.7 Mean CV values were ranged between 3.7%-
9.1% for intra-assay and 8%-15% for inter-assay. 
 
Table 4.6 Intra-assay variation for TNF-( of 7 serum samples which were tested in 
triplicate. 
 
Sample no. Mean (pg/ml) Standard 
Deviation (pg/ml) 
Coefficient of 
Variation (%) 
1 28 3 9 
2 35 3 9.1 
3 40 2 5 
4 142 7 5 
5 237 10 4.2 
6 515 18 4 
7 620 23 3.7 
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Table 4.7 Inter-assay variation for TNF-( of 7 serum samples which were tested for 
eight runs. 
 
Sample no. Mean (pg/ml) Standard 
Deviation (pg/ml) 
Coefficient of 
Variation (%) 
 
1 12 1.8 15 
2 35 4 11.4 
3 49 5 10.2 
4 75 7 9.3 
5 120 14 9.1 
6 162 13 8 
7 354 29 8.2 
Recovery of exogenous TNF-* and IL-1* from serum samples. In order to 
examine whether this ELISA is suitable for use with biological fluids, the following 
experiments were performed. Human recombinant TNF-@ or IL-1@ was added to 
serum samples obtained from 7 apparently healthy subjects, at a final concentration 
of 500 pg/ml and assayed in ELISA. Table 4.8 shows the results of a recovery test 
for IL-1@ from serum samples. The mean percentage recovery of TNF-@ and IL-1@
from 7 different serum samples was >90%, indicating that the inhibition by serum 
components was negligible.  
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An example for the percentage recovery of TNF-@ is shown in Table 4.8. 
%Recovery was calculated as: 
[{Observed TNF-baseline TNF}- Amount of TNF added]X 100%  
 
Table 4.8 The percentage recovery of exogenous TNF-( from serum sample.
Sample 
no. 
Without 
TNF-*
addition 
500 
pg/ml 
TNF-*
added 
TNF-*
recovered 
(pg/ml) 
%
recovered 
1 0 500 485 97.0 
2 0 500 432 86.4 
3 0 500 493 98.6 
4 0 500 429 85.8 
5 0 500 468 93.6 
6 0 500 480 96.0 
7 0 500 434 86.8 
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Sensitivity of TNF-* and IL-1* immunoassays. The sensitivity of the 
immunoassay for TNF-@ and IL-1@ was calculated and found to be 7.5 pg/ml (Table 
4.9). The plot of the absorbance versus IL-1@ concentration in picograms/ml (pg/ml) 
for the standards is shown in Figure 4.6. When OD values were below the lowest 
value of the reference curve, a value of 0 pg/ml was assigned. 
Table 4.9 The absorbance at 490 nm for TNF-( standards at a range of dilutions from 
7.5-2000 pg/ml. 
 
TNF-* standard Concentration 
(pg/ml) 
OD 490 nm 
(triplicate) 
Average  OD 
490 nm 
Standard 1A,1B 0 (Blank) 0.001, 0.001, 0.003 0.002 
Standard 2A,2B 7.5 0.012, 0.014, 0.018 0.015 
Standard 3A,3B 15 0.042, 0.036, 0.042 0.040 
Standard 4A,4B 30 0.090, 0.092, 0.094 0.092 
Standard 5A,5B 60 0.217, 0.220, 0.236 0.224 
Standard 6A,6B 120 0.335, 0.323, 0.319 0.325 
Standard 7A,7B 240 0.652, 0.652, 0.650 0.651 
Standard 8A,8B 480 1.060, 1.080, 1.075 1.070 
Standard 9A,9B 960 1.762, 1.754, 1.724 1.746 
Standard 
10A,10B 
2000 2.450, 2.412, 2.462 2.441 
Measurements of IFN-+ and IL-1K. Interferon-? and IL-1N were measured 
according to the technique of two-site ELISA by Gallati et al. (1988) using 
combinations of anti-IL-1N coating antibody and peroxidase labelled anti-IL-1N
polyclonal revealing antibodies for IL-1N immunoassay and anti-IFN-? coating 
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antibody and peroxidase labelled anti-IFN-? monoclonal revealing antibodies for 
IFN-?. A one-step incubation was adopted in this assay since the detecting antibody 
used in the revealing step was conjugated with a peroxidase (i.e. detecting antibody 
was added immediately after the cytokine containing sample). The optimum 
concentrations of these antibodies and incubation time used in the immunoassay 
were determined in similar way to TNF-@ immunoassay.   
 Microtitre plates were coated with 100 µl murine anti-IFN-? monoclonal 
antibody and goat anti-IL-1N antibody diluted in 0.1M bicarbonate buffer (pH 9.5) to 
a concentration of 5 µg/well for both. Plates were then incubated at 4oC for 24 h, 
followed by incubation at 37oC for 1 hour with 100 µl blocking buffer to eliminate 
non-specific binding to the plastic wells. Serial dilutions of standards or test samples 
in dilution buffer were added (final volume 100 µl/well). 50 µl of horseradish 
peroxidase-conjugated monoclonal anti-IFN-? and polyclonal anti-IL-1N
immunoglobulins diluted in PBS buffered containing 0.1% BSA to a concentration 
of 1 µg/ml were added immediately after the cytokine containing sample and 
incubated overnight at 4oC. After washing, the reaction was developed as described 
for TNF-@ and IL-1@ immunoassays. Tests were performed in duplicate and 
unknown values read from standard curves constructed using recombinant IFN-?
and IL-1N. The standard curve ranged between 15-1920 pg/ml (Figure 4.7). The 
sensitivity of the assay was 30 pg/ml for both IFN-? and IL-1N. No cross-reaction for 
either IFN-? and IL-1N assays with other cytokines such as IL-1@, TNF-@, IL-4 and 
IL-10 was found as determined methodology similar to that for the TNF-@
immunoassay. The intra-assay and inter-assay variations (%) for both IL-1N and 
IFN-? ranged between 8%-15%    
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Figure 4.7. A standard curve of IL-1A immunoassay. The plate was coated with anti-
IL-1A monoclonal antibody at a concentration of 1 µg/well and horseradish 
peroxidase- conjugated anti-IL-1A polyclonal antibody was added immediately after 
the cytokine containing sample and incubated overnight at 4oC. The plot represents 
the absorbances at 490 nm (vertical axis) versus the standard of IL-1A at a range of 
dilutions from 15-1920 pg/ml (horizontal axis).     
 
Measurement of IL-6 and soluble IL-2 receptor (sIL-2R). The determination of 
IL-6 and soluble IL-2R levels was performed by the technique of two-site ELISA by 
Aarden et al. (1992) and Rubin et al. (1985a) in which combinations of two 
monoclonal antibodies (i.e. clones 8 and 1G61 for IL-6 and clones 7G7B6 and anti-
TAC for sIL-2R) were used in the coating and revealing steps respectively each 
clone recognises different epitope of either IL-2R or IL-6 respectively. The second 
antibodies used in the revealing step (i.e. anti-sIL-2R (anti-TAC) and anti-IL-6 
(1G61)) were labelled with biotin and the reaction was developed by addition of 
peroxidase-conjugated streptavidin. The optimum concentrations of coating and 
revealing antibodies were determined as described for TNF-@ immunoassays.  
 Wells of flat-bottomed 96-well microtitre plates were coated with 100 µl 
purified anti-sIL-2R (7G7B6) and anti-IL-6 (clone CLB. IL-6/8) antibodies 
overnight in coating buffer at optimal concentration of 5 µg/well and 1.5 µg/well 
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respectively. After washing, 100 µl of test samples or standard were added to 
duplicated antibody-coated wells. After a 2 hour incubation at 37oC, the plates were 
washed with washing buffer and 100 µl of second biotinylated monoclonal anti-sIL-
2R (anti-TAC) and anti-IL-6 (1G61) antibodies diluted in the dilution buffer and 
supplemented with 2% mouse serum to a final concentration of 2 µg/ml (to block 
possible non-specific reaction), were added into each well. After an additional 2 
hour incubation at room temperature, plates were washed and 100 µl of horseradish 
peroxidase-conjugated streptavidin was added at a dilution of 1/2000 and 
supplemented with 2% mouse serum. The wells were then incubated for 1 hour at 
room temperature with constant shaking. The reaction was developed after washing 
as described for TNF-@ and IL-1@ immunoassays (vide 4.6.2). Tests were performed 
in duplicate and unknown values read from standard curves constructed using 
recombinant IL-2R and IL-6 (Figures 4.8 and 4.9). The sensitivity of the assay was 
30 U/ml for sIL-2R and 7.5 pg/ml for IL-6. No cross reaction was observed with 
other cytokines such as IL-1@, TNF-@ and IFN-?. Intra-assay and inter-assay 
coefficient of variation (%) of test samples ranged between 7%-13% for both sIL-2R 
and IL-6.   
Figure 4.8. A standard curve of the soluble IL-2 receptor assay using a two-site 
ELISA. The plate was coated with MAb anti-sIL-2R (7G7B6) at a concentration of 5 
µg/well. A biotinylated second monoclonal anti-sIL-2R (anti-TAC) antibody and 
streptavidin horseradish peroxidase-conjugated were used in the revealing step at 
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concentrations of 2 µg/ml and 1 µg/ml respectively. The plot represents the 
absorbances at 490 nm (vertical axis) versus the standard of sIL-2R at a range of 
dilutions from 30-1920 U/ml (horizontal axis).    
 
Figure 4.9. A standard curve of the IL-6 assay using a two-site ELISA. The plate 
was coated with anti-IL-6 MAb (clone CLB. IL-6/8) at a concentration of 1.5 
µg/well. A biotinylated second anti-IL-6 (1G61) MAb and streptavidin horseradish 
peroxidase-conjugated were used in the revealing step at concentrations of 2 µg/ml 
and 1 µg/ml respectively. The plot represents the absorbances at 490 nm (vertical 
axis) versus the standard of IL-6 at a range of dilutions from 7.5-1920 pg/ml 
(horizontal axis).   
 
Measurement of IL-4 and IL-10. The determination of IL-4 and IL-10 was 
performed according to the technique of two-site ELISA by Abrams et al. (1992) in 
which combinations of two monoclonal antibodies (clones 82 and 12 for IL-4 and 
JES3-9D7 and JES3-12G8 for IL-10) that recognise distinct epitopes of IL-4 and IL-
10  were used in coating and revealing steps respectively. The antibodies used in the 
revealing step were biotinylated and the reaction was developed by addition of       
peroxidase-conjugated streptavidin.  
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IL-4 and IL-10 immunoassays were performed in similar conditions used for 
the IL-6 immunoassay except that: samples and standards were incubated overnight 
at 4oC instead of the 2 hour incubation time at room temperature. The optimum 
concentrations of coating and revealing antibodies and incubation times were 
determined as described previously for TNF-@ immunoassay. The sensitivity of the 
assay was 10 pg/ml for IL-4 and 6 pg/ml for IL-10 (Figures 4.10). No cross reaction 
was observed with other cytokines such as IL-1@, IL-1N, TNF-@ and IFN-?. Inter-
assay and intra-assay coefficient of variation (%) of test samples for both IL-4 and 
IL-10 were determined in a similar manner described in TNF-@ immunoassay and 
ranged between 6%-8%.   
Figure 4.10. Standard curves of IL-4 (A) and IL-10 (B) using two-site ELISA. The 
plate was coated with MAb anti-IL-4 (clone 82) and anti-IL-10 (JES3-9D7) at a 
concentration of 1 µg/well for both. A biotinylated second MAb anti-IL-4 (clone 12) 
and anti-IL-10 (JES3-12G8) and streptavidin horseradish peroxidase-conjugated 
were used in the revealing step and all at concentrations of 1 µg/ml. The plot 
represents the absorbances at 490 nm (vertical axis) versus the standard of IL-4 at a 
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range of dilutions from 10-2430 pg/ml and IL-10 at a range of dilutions from 6-
1620 pg/ml (horizontal axis).    
 
4.6.2.2 IMMUNOASSAYS OF MOUSE CYTOKINES  
Serum levels of mouse TNF-@, IL-2 and IL-4 were measured using two-site 
ELISA as described in section 4.6.2. Immunoassay of mouse TNF-@ was established 
similarity to that for human TNF-@ immunoassay using hamster anti-mouse TNF-@
monoclonal antibody (clone TN3 19-12) in the coating step and sheep anti-mouse 
TNF-@ polyclonal antibody in the revealing step. Immunoassays for the 
measurement of murine IL-2 and IL-4 were set up using combinations of two 
monoclonal antibodies (JES6-IA12 and JES6-5H4 clones for IL-2 and BVD4-1D11 
and BVD6-2492 clones for IL-4) recognising distinct epitopes on the cytokines and 
were used in coating and revealing steps of IL-2 and IL-4 respectively. The 
antibodies used in the revealing step were biotinylated. The assay was assessed in 
similar manner to the human IL-4 immunoassay. The optimum concentrations of 
antibodies used in the immunoassay were determined as described above (vide 
4.6.2.1).  
 The sensitivity of TNF-@, IL-2 and IL-4 was 10 pg/ml. No cross reaction was 
observed with mouse IL-1@ and IFN-? or human cytokines. Inter-assay and intra-
assay coefficient of variation (%) of test samples ranged between 7%-12% for both 
IL-2 and IL-4, and 5%-11% for TNF-@.
4.6.2.3 CYTOKINE BIOASSAY  
IL-2 bioassay. Levels of IL-2 activity in the serum and tissue culture supernatant 
were measured in a bioassay using an IL-2 dependent cell line (CTLL-16, murine 
cytotoxic T-cell line) (Gillis et al., 1978). This cell line was maintained in RPMI 
1640 culture medium containing 10% foetal calf serum and supplemented with 100 
U/ml recombinant human IL-2. Cell proliferation was assessed using a rapid and 
sensitive modified colorimetric method (Heeg et al., 1988), which is based on the 
ability of viable cells to cleave 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide MTT and can be measured on a scanning multiwell spectrophotometer 
(ELISA reader).  The CTLL-16 cells were washed four times in Hank's balanced salt 
solution (HBSS) to remove any IL-2 contamination. The cells were then 
resuspended in RPMI 1640 medium at a concentration of 1x105 cells/ml and 100µl 
of this suspension were pipetted into each well of flat-bottomed 96 well microtitre 
plates. This was followed by the addition of 100µl of the test sample (serial dilution 
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of test sera or supernatant) to each well in triplicate. After incubation for 20 hour at 
37oC/5% CO2, 20µl of 2.5 mg/ml MTT was added to each well. After additional 
incubation at 37oC for 4 hour, 100µl of acid isopropanol were added (to dissolve 
blue formazan crystals). The optical density was read in an ELISA reader using dual 
wavelength to remove the absorbance caused by interfering factors such as dirt, 
tissue culture debris, scratches and moisture in the plastic of microtitre plate. The 
test wavelength was set at 570 nm and the reference wave length set at 690. A 
typical sigmoid standard curve of the IL-2 bioassay is shown in Figure 4.11. The 
levels of IL-2 in test samples were derived using a known standard and calculating 
the percentage of maximal CTLL stimulation as described by Kay et al. (1986).  
 The percentage of maximal CTLL stimulation= 100x ([OD of maximal 
CTLL stimulation in test sample - background activity] divided [maximal CTLL 
stimulation in standard - background]). 
TNF-* bioassay. To measure the biological activity of TNF-@ levels in serum 
detected in the TNF-@ immunoassay, a TNF-@ bioassay was set-up using the L929 
cell line cytotoxicity assay based on detachment of damaged cells from the wells 
(Meager et al., 1987). 100 µl RPMI culture medium containing 2x105 trypsinized 
L929 cells were distributed in each well of a 96-well plate and incubated at 37oC for 
24 hours; titrations of the TNF standard and dilutions of the samples in duplicate in 
medium containing 1 µg/ml actinomycin D (to inhibit L929 cell line growth) were 
added to the cells and incubated at 37oC for 24 hour; the cells were then washed, 
stained with 0.1% crystal violet for 10 min and fixed with 5% formalin. The 
absorbance at 620 nm was determined using an ELISA reader. The assay sensitivity 
for TNF-@ was 0.3 U/ml and 1 U of TNF is equivalent to 38 pg. 
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Figure 4.11. A standard curve of the IL-2 bioassay using IL-2 dependent cell line 
(CTLL-16) in a colorimetric microassay. The plot represents the optical density 
(OD) read in an ELISA reader using dual wavelength, with the test wave length set 
at 570 nm and the reference wave length set at 690 nm (vertical axis) versus the 
standard of IL-2 at a range of dilutions from 0.11-243 U/ml (horizontal axis).  
 
4.6.3 MITOGEN-INDUCED SECRETION OF CYTOKINE  
The majority of cytokines are not produced by peripheral blood mononuclear 
cells in isolation but usually together with mitogens (antigens) in vitro (Lewis, 
1991). Phytoheamoagglutinine (PHA) was found to stimulate only T cells while 
Lipopolysaccharride (LPS) stimulates macrophages (Hudson and Hay, 1989). 
Induction of cytokine secretion from these two population mononuclear cells was 
investigated in RPMI 1640 culture medium supplemented with PHA or LPS. PHA 
was used for induction of IL-2 and IFN-? (Karen et al., 1984) while LPS was used 
for induction of IL-1@ and TNF-@ secretion (Fomsgaard et al., 1990). Peripheral 
blood mononuclear cells (PBMC) were isolated from heparinised venous blood by 
sedimentation on a Ficoll-hypaque gradient, washed three times in HBSS and 
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resuspended at a concentration of 1 x 106/ml in RPMI 1640 culture medium. Cell 
viability was >90% as assessed by trypan-blue exclusion. PBMC were then divided 
into three tubes. The first and second tubes were treated with PHA and LPS 
respectively at concentration of 1µg/ml while the third tube contained PBMC only, 
without mitogens, as for control. After 24 hours of culture in humidified 95% air/5% 
CO2 atmosphere, supernatants were collected, centrifuged, sterilized by filtration 
(0.22 µm pore size) and stored at -20oC until tested.     
Since there was no difference in the spontaneous secretion of cytokines and 
after mitogens-stimulation between healthy children and adults, and therefore, these 
were considered as one control group. 
 
4.6.4 IMMUNOHISTOCHEMICAL AND IMMUNOFLUORESENT 
STAINING OF CYTOKINE PRODUCING CELLS IN NOD MOUSE 
PANCREAS SECTIONS  
 To investigate cellular expression of cytokine in sections of pancreas, 
immuno-histochemical and fluorescence staining was performed on cryostat 
pancreas sections from NOD mice with diabetes. The immunohistochemical staining 
was performed using two step immunoperoxidase technique in which peroxidase-
conjugated anti-species immunoglobulin was used to label anti-cytokine monoclonal 
and polyclonal antibodies (Foulis et al., 1991). Indirect immunofluorescence was 
performed using fluorescein isothiocyanate (FITC)-conjugated rabbit anti-species 
immunoglobulin to visualise anti-cytokine polyclonal antibodies (Hudson and Hay, 
1989).  
Pancreas. Sections had been taken from pancreata removed from sacrificed NOD 
mice with various stages of disease progression. Pancreata were embedded in OCT 
(OCT compound) mounting medium immediately upon collection and stored in 
liquid nitrogen until use. 
Immunological reagents. Monoclonal rat anti-mouse IFN-? and polyclonal sheep 
anti-mouse TNF-@ antibodies were employed for the detection of IFN-? and TNF-@
producing cells respectively in the pancreas sections of NOD mice. Peroxidase-
conjugated rabbit anti-rat immunoglobulin and FITC labelled donkey anti-sheep 
antisera were the second reagents used to label monoclonal and polyclonal 
antibodies in the two-step immunoperoxidase and immunofluorescent techniques. 
Optimum concentration of immunological reagents used in these techniques were 
determined as described previously (vide section 4.6.2.1). Table 4.5 shows the titres 
at which antibodies gave optimum staining performance and which were adopted in 
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the present study for use on murine pancreas sections.  
Sectioning of pancreas. OCT embedded pancreata were removed from liquid 
nitrogen and quickly mounted on the chuck of a cryostat and allowed to reach -20oC. 
5 µm thick sections were placed onto slides, which had previously been cleaned with 
a concentrated solution of hydrochloric acid, rinsed in distilled water, coated with a 
0.01% solution of poly-L-lysine (PLL) and allowed to dry. The use of PLL afforded 
two advantages: firstly, it retained the tissue section on the slide, and secondly by 
exerting a high surface tension, it prevented aqueous solutions applied to the slide 
from spreading. Two sections, one for each of the monoclonal or polyclonal 
antibodies to be used, including the control, were cut from each pancreas. 
Fixation of pancreas sections. After cutting, pancreas sections were allowed to air-
dry for 4-6 hours at room temperature. This ensures complete extraction of water 
from the sections, rendering them permeable to the fixative subsequently applied 
(Judd and Britten, 1982). Fixation was performed by immersion sections in a 1/1 
mixture of acetone and chloroform for 10 minutes. This is a mild form of fixation, 
which achieves the best compromise between the need to preserve the tissue 
specimen and the need to avoid the chemical changes which alter its structure at the 
molecular level (Senaldi et al., 1991). After fixation, sections were washed in three 
changes of PBS of 5 min each. 
 
STAINING OF PANCREAS SECTIONS 
Detection of IFN-+ producing cells. Immunohistochemical staining of IFN-?, was 
preceded by two preparatory steps: blocking of the endogenous peroxidase and 
activity blocking of non-specific binding of immunological reagents. 
 To block endogenous peroxidase activity, sections were covered with 1% 
solution of H2O2 in methanol for 20 min in a humidified atmosphere. This enzyme is 
present in large amounts in organs which are metabolically active such as the 
pancreas and may lead to high background levels of staining through its interaction 
with the reaction substrate (Khan et al., 1990). Sections were then washed and in 
order to block non-specific binding were incubated for 10 min with PBS containing 
10% normal rabbit serum. The use of rabbit serum in this step prevents non-specific 
binding of the peroxidase-conjugated antiserum, which is raised in rabbit (Straus, 
1979). After discarding the rabbit serum, the sections were immediately incubated 
for 1 hour with a 1/10 dilution of rat anti-mouse IFN-? monoclonal antibodies. 
Sections were then washed again and incubated with a dilution of 1/40 peroxidase-
conjugated rabbit anti-rat immunoglobulin in PBS, containing 5% normal mouse 
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serum. After incubation, sections were washed, immersed for 8 min in a solution of 
0.6 mg/ml diaminobenzidine hydrochloride and 0.03% H2O2 in PBS, rinsed in tap 
water, counterstained with Mayer's haematoxylin, washed again extensively in tap 
water and finally mounted with a 9/1 mixture of glycerol and PBS.  
 The specificity of the staining was determined by prior incubation of anti-
mouse IFN-? antibodies with 100 µg/ml of recombinant mouse IFN-? which resulted 
in abolition of the peroxidase staining.  
Detection of anti-TNF-* producing cells. An Immunohistochemical technique was 
used to detect TNF-@ producing cells in pancreas sections using polyclonal anti-
TNF-@ antibodies under the same conditions used for the detection of IFN-?.
Although this technique is very sensitive, a number of difficulties emerged. The 
positive staining of TNF-@ producing cells was weak and there was some non-
specific background staining due to endogenous peroxidase activity. The weakness 
of positive TNF-@ staining in pancreas may be due either to the low expression of 
TNF-@ or to the destruction of the antigen during the technique used to block the 
endogenous peroxidase activity. Therefore, immunohistochemical staining was 
replaced by an indirect immunofluorescent technique which was then attempted for 
detection of TNF-@ producing cells in pancreas sections.  
 5µm air-dried, fixed cryostat sections of pancreas were incubated with 50 µl 
sheep anti-mouse TNF-@ diluted in 1/100 in PBS for 60 minutes at room 
temperature. Following two 10-minute washes in PBS, TNF-@ was revealed using 
FITC labelled anti-sheep immunoglobulin G diluted 1:30 in PBS. After washing, the 
sections were examined using an ultraviolet (UV) microscope. This technique 
proved to be successful.   
Microscopic analysis. Stained and unstained mononuclear cells in three islets of N-
cells were counted using light microscopy for IFN-? producing cells while a UV 
microscope was used to count TNF-@ positive cells. The number of positive cells 
was calculated and expressed semiquantitatively, with 0 equalling no positive cells, 
1 minimal (<10%), 2 moderate (10-30%) and 3 abundant (>30%) quantities of 
positive cells. 
 
4.6.5  IMMUNOHISTOCHEMICAL STAINING OF CYTOKINE 
PRODUCING CELLS IN LIVER BIOPSIES   
To investigate the cellular expression of cytokine in the liver biopsies, we 
immunohistochemically stained cryostat liver sections from children with 
autoimmune liver disease. The mononuclear cells (MNC) infiltrate was 
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characterised in liver sections from 36 such biopsies.  
Liver biopsies. Biopsies were taken percutaneously with a 1.4 mm diameter 
Menghini needle and consisted of 3-5 mm long liver tissue cylinders. Only biopsy 
material in excess of the amount required for diagnostic examination was employed 
in this study. Biopsies were embedded in OCT medium immediately upon collection 
and stored in liquid nitrogen until use. 
Immunological reagents. Two murine MAb were employed for the detection of 
TNF-@ and IFN-? producing cells. They are anti-human TNF-@ (clone 357-27) and 
anti-human IFN-? (clone M23B5) monoclonal antibodies. Peroxidase-conjugated 
rabbit anti-mouse immunoglobulin antiserum was the revealing reagent.   
Staining of liver sections. Positive staining of TNF-@ and IFN-? producing cells 
was detected in liver sections using the two step indirect immunoperoxidase 
technique performed in a similar manner to that for IFN-? staining in pancreas 
sections of NOD mice (vide 4.6.4).  
 The specificity of the staining was determined by prior incubation of detector 
antibodies such as anti-TNF-@ and anti-IFN-? antibodies with 100 µg/ml of 
recombinant TNF-@ and IFN-? respectively which resulted in abolition of the 
peroxidase staining. 
Microscopic analysis. Stained and unstained mononuclear cells in one to three portal 
tracts were counted using light microscopy and scored as positive or negative in a 
blind study. The percentage of positive cells was calculated and expressed 
semiquantitatively, with 0 equalling no positive cells, 1 minimal (<5%), 2 moderate 
(5-10%) and 3 abundant (>10%) quantities of positive cells.   
 
4.6.6  METABOLIC STUDIES  
The metabolic disturbances associated with diabetes have been reported to 
influence immune function (Selam et al., 1979; Crosti et al., 1986). In order to be 
able to control for this, it is important to assess the degree of metabolic disturbance. 
Typically, this is achieved by measuring blood glucose and glycated haemoglobulin 
(HbA1) at the time of blood sampling. Blood glucose is an indicator of current 
metabolic control; HbA1 reflects metabolic control over the previous weeks 
(Kjaergaard and Ditzel, 1979).  
 Blood glucose levels were measured in the blood of patients with Type 1 
diabetes and discordant twins for diabetes using a glucose-oxidase method (Yellow 
Springs Analyser, Yellow Springs, OH, USA) and HbA1 by electroendosmosis 
(Corning Instruments, Corning, NY, USA). 
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4.6.7  C-PEPTIDE LEVELS  
Human C-peptide and insulin are formed from proinsulin, the precursor of 
endogenous insulin in the N-cells of the pancreas. Both proteins are released into the 
bloodstream simultaneously and in equimolar quantities. The measurement of 
human C-peptide provides an indicator of the residual synthetic capacity of N-cells. 
Serum levels of C-peptide were measured in patients with Type 1 and Type 2 
diabetes using a competitive radioimmunoassay (Heding, 1975). Assay sensitivity 
was 0.3 ng/ml, intra-and inter-assay coefficients of variation were 6.5% and 13% 
respectively.  
 
4.6.8 DETECTION OF ORGAN-SPECIFIC AND NON ORGAN-SPECIFIC 
AUTOANTIBODIES  
Cytoplasmic islet cell antibodies. Islet cell cytoplasmic antibodies (ICA) were 
detected in a two-step indirect immunofluorescence assay according to the technique 
of Bottazzo et al., (1979). Unfixed 5µm cryostat sections of blood group O human 
pancreas were used as substrate. 50 µl neat sera were incubated with the substrate for 
30 minutes at room temperature. Following two 10-minute washes in PBS, ICA 
were revealed using FITC anti-human immunoglobulin G F(ab')2 fragment diluted 
1:30 in PBS. Following two washes slides were viewed by UV microscopy. The 
results obtained are reported as positive (level >5 JDF [Juvenile Diabetes 
Foundation] units) or negative. The method of detection was similar to that 
performed in the stage III Immunology and Diabetes Workshop on ICA proficiency 
(Bonifacio et al., 1987), performing with 100% specificity, a detection limit of 5 
JDF units and with a correlation of observed with consensus JDF units of 0.74.  
Glutamic acid decarboxylase antibodies. Antibodies to glutamic acid 
decarboxylase (GAD) were measured by determining the enzyme activity 
immunoprecipitated by sera from a soluble extract of rat brain as previously 
described (Christie et al., 1992) and are reported here as positive (levels >2SD above 
normal values for our laboratory) or negative. In the first GAD antibody workshop 
our assay performed with a specificity of 100% and a sensitivity of 91.7%. 
 
Liver-kidney microsomal antibodies. Anti-liver-kidney microsomal (anti-LKM) 
antibodies were detected by two-step indirect immunofluorescence technique on 
unfixed 5 µm cryostat sections of rat liver, stomach and kidney as the substrate 
according to the technique of Smith et al., (1974). 50 µl of test sera diluted 1/10 in 
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PBS were incubated with the substrate and the pattern of positive staining of anti-
LKM antibodies is described in Table 4.10.
Non organ-specific autoantibodies detected by immunofluorescence. Non-organ 
specific autoantibodies (anti-nuclear (ANA), anti-smooth muscle (SMA), anti-
gastricparietal cell (GPC), anti-mitochondrial (AMA) and anti-reticulin (ARA) 
antibodies were detected in a serum by a technique similar to that mentioned in 
section 4.12.3 using rat liver, kidney and stomach as substrate (Johnson and 
Holborrow, 1986). The pattern of positive staining for these autoantibodies is 
described in Table 4.10.
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Table 4.10 Patterns of positive staining of non-organ specific autoantibodies by two step indirect immunofluorescence technique.
Auto-antibodies* Patterns
ANA Nucleic staining in all tissues
SMA Smooth muscle staining was seen in the sub-mucosal muscle layer of the stomach in conjunction with the staining of
smooth muscle fibres in the gastric mucosa. Blood vessels in both kidney and liver are also stained and in high titre
SMA the glomeruli are also stained.
AMA Liver cytoplasm stained with a speckled appearance Gastric cells also stained similarly, the parietal cells being
especially strong Kidney tubules stained to varying degrees depending on whether proximal or distal.
LKM Liver cytoplasm stained uniformly.
No staining in stomach Only the proximal tubules are stained the pattern being a slightly "feathery" appearance
compared to a AMA staining.
GPC Only the cytoplasm of the parietal cells of the stomach are stained with no involvement of other tissues.
ARA "Thread-like" linear staining in gastricmucosa
* Non-organ specific autoantibodies; ANA, anti-nuclear; SMA, anti-smooth muscle, AMA, anti-mitochondrial; LKM, anti-liver-kidney-microsomal;
GPC, anti-gastricparietal cell; ARA, anti-reticulin (ARA)
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Partical agglutination technique for thyroid autoantibodies. Autoantibodies 
reacting with thyroid microsomal antigens and with thyroglobulin were detected by 
particle agglutination using commercially available kits. In these, sensitised gelatin 
particles are incubated with serial dilutions of serum in the wells of round-bottomed 
microtitre plates. After 3 hours, positive results appear as a carpet of particles in the 
wells, negative as a tight button. 
 
4.6.9 HLA TYPING  
Class II HLA typing by Restriction Fragment Length  Polymorphism Analysis.
Class II HLA typing, performed using restriction fragment length polymorphisms 
(RFLP) (Doherty and Donaldson, 1991) on cryopreserved PBMN, was kindly 
carried out by Dr P. Donaldson, Institute of Liver Studies, King's College School of 
Medicine and Dentistry. HLA-DR B gene polymorphism were identified using a 517 
bp PstI fragment of the exon-specific HLA-DR B cDNA clone pRTv1 (Bidwell and 
Jarrold, 1986). HLA-DR B allogenotypes were identified from the hybridization 
patterns visualised by autoradiography (Bidwell and Jarrold, 1986; Bidwell, 1988). 
 
4.6.10 STATISTICAL ANALYSIS  
The distribution of the concentrations of cytokines and sIL-2 receptor did not 
satisfy the hypothesis of normality where this was assessed using the Kolmogorov-
Smirnov goodness of fittest and these were therefore compared using the non-
parametric Mann-Whitney U test. Correlation between variables were analysed by 
calculating Pearson's correlation coefficient or performing Spearman's rank 
correlation tests as appropriate. The frequency distribution of abnormal levels of 
cytokines in prediabetic and non-diabetic twins at least one and two occasions was 
compared using c2. Positively-stained cytokine-producing cells occurring in 
different patient group was also compared using c2.
Analyses giving p values of <0.05 were considered statistically significant.  
Statistical computation were performed using the Statistical Package for the Social 
Sciences on the University of London Computer Centre's Amdah l5980/300. 
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CHAPTER 5
STUDIES OF CIRCULATING LEVELS OF CYTOKINES IN PATIENTS  
 WITH TYPE 1 DIABETES 
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5.1 SUBJECTS 
 Thirty one recently diagnosed patients with Type 1 diabetes (17 males; 
median age 23 years, range 9-58) were studied. Seventeen of them were tested at 
diagnosis and before insulin-treatment, of the remainder 3 were tested within 2 
months of diagnosis and the remaining 11 between 4 and 6 months after diagnosis. 
Type 1 diabetes was diagnosed according to the National Diabetes Data Group 
(NATIONAL DIABETES DATA GROUP, 1979). A group of 32 patients with 
long-standing Type 1 diabetes (10 males; 39 years, 24-75), who had been diagnosed 
for more than 15 years was also studied.   
 As disease controls, two groups of patients were studied: (1) to allow for the 
effect of hyperglycaemia we tested 27 patients with Type 2 diabetes seen 
consecutively at the diabetic clinic at King's College Hospital (14 males; median age 
64 years, range 38-77; (2) to allow for the effects of a chronic autoimmune disease, 
21 patients with Graves' disease were studied but without diabetes, seen 
consecutively at King's College Hospital during the same period as the collection 
from diabetic patients (9 males; median age 40 years, range 18-67).  As normal 
control subjects, 41 healthy individuals (20 males; mean age 24 years, range 10-63) 
were studied. They were recruited from the local community and selected to achieve 
a similar distribution for age and sex to the twins and patients with diabetes. 
Twenty-four were adults recruited from the staff of King's College Hospital and 17 
were healthy children recruited by the Medway and Gillingham Branch (Kent) of the 
Children's Liver Disease Foundation (CLDF). All gave blood after informed consent 
from themselves or their parents, as appropriate. None of the control subjects had a 
family history of Type 1 diabetes or other diseases.  
 At the time of sampling, neither control subjects nor the patients with Type 1 
or Type 2 diabetes had clinical signs or symptoms of intercurrent illness.  
 
5.2 RESULTS 
Serum levels of IL-1@, IL-1N, IL-6 and TNF-@ (macrophage-derived 
cytokines), IL-2 and IFN-? (TH1-derived cytokines), IL-4 and IL-10 (TH2 derived-
cytokines) and sIL-2R were measured in patients with Type 1 diabetes of different 
disease duration.   
 
5.2.1 MACROPHAGE-DERIVED CYTOKINES  
TNF-*. Levels of TNF-@ were significantly higher in patients with recently 
diagnosed Type 1 diabetes (median, 29 pg/ml, range 0-434; p<0.001), long-standing 
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Type 1 diabetes (17 pg/ml, 0-110; p<0.005) and Type 2 diabetes (7 pg/ml, 0-75; 
p<0.01) when compared with normal control subjects (0 pg/ml, 0-9). Levels of TNF-
@ were significantly higher in patients with recently diagnosed Type 1 diabetes as 
compared with patients with either long-standing Type 1 (p<0.04), Type 2 diabetes 
(p<0.005) or Graves' disease (p<0.0002). Of patients with recently diagnosed Type 1 
diabetes, levels of TNF-@ were higher in those tested before insulin treatment (59 
pg/ml, 0-434) than in those tested a median of 4 months later (19 pg/ml, 0-54; 
p<0.01). Levels of TNF-@ were higher in patients with long-standing Type 1 
diabetes than in those with Graves' disease (p<0.001) and in those with Type 2 
diabetes although in the latter case the increase did not reach conventional levels of 
statistical significance (p<0.07). Levels of TNF-@ exceeding the highest normal 
value (>9 pg/ml) were found in 23/31 (74%) recently diagnosed patients and 18/32 
(56%) long-standing patients with Type 1 diabetes; 6/27 (22%) patients with Type 2 
diabetes, and 6/21 (28%) patients with Graves' disease (Figure 5.1).  
 Patients who had levels of TNF-@ exceeding the highest normal value and 
whose serum was available were also tested for TNF-@ bioactivity. Bioactive TNF-@
was detected in: 14/17 (88%) patients with recently diagnosed Type 1 diabetes 
(median 5 U/ml, range 0-18), 11 of whom had levels of TNF-@ >1 U/ml; 6/17 (35%) 
long-standing patients with Type 1 diabetes (median 0 U/ml, 0-18), 3 of whom had 
levels of TNF-@ >1 U/ml; and 2/11 (18%) patients with Type 2 diabetes (median 0 
U/ml, 0-18), both having levels more than 1 U/ml. Levels of bioactive TNF-@
correlated significantly with levels of TNF-@ obtained by immunoassay (r=0.65, 
p<0.003) in patients with recently diagnosed Type 1 diabetes while this correlation 
was not observed in patients with long-standing Type 1 diabetes and Type 2 
diabetes. 
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Figure 5.1. TNF-( values in the serum of patients with Type 1 diabetes of different 
duration, Type 2 diabetes, Graves' disease (GD) and normal subjects. The dashed 
line represents the upper limit of normal subjects. Levels of TNF-( are significantly 
higher in recently diagnosed (RD) (p<0.001) and long-standing (LS) patients with 
Type 1 diabetes (p<0.005) and Type 2 diabetes (p<0.01) than normal subjects. 
Horizontal bars represent medians. 
 
IL-1*. Levels of IL-1@ were significantly elevated in patients with recently 
diagnosed Type 1 diabetes (median 260 pg/ml, range 59-1421 pg/ml) compared with 
patients with either long-standing Type 1 (129 pg/ml, 30-303; p<0.001) or Type 2 
diabetes (105 pg/ml, 29-402; p<0.005), Graves' disease (84 pg/ml, 12-480; p<0.001) 
or normal control subjects (100 pg/ml, 23-233; p<0.001) (Figure 5.2). Of patients 
with recently diagnosed Type 1 diabetes, those tested before insulin treatment (260 
pg/ml, 61-521) had similar levels to those tested later (248 pg/ml, 59-1421). Levels 
of IL-1@ exceeding the highest normal value (>233 pg/ml) were found in 18/31 
(58%) recently diagnosed, 4/32 (13%) patients with long-standing Type 1 diabetes, 
5/27 (19%) patients with Type 2 diabetes and 7/21 (33%) patients with Graves' 
disease. Levels of IL-1@ did not differ significantly between patients with long-
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standing Type 1 and those with Type 2 diabetes and Graves' disease, or between 
either of these groups and control subjects.  
 
IL-1K and IL-6. Levels of IL-1N and IL-6 were not detectable in the serum of either 
patients or normal control subjects.  
 
Figure 5.2. IL-1( values in the serum of patients with Type 1 diabetes of different 
duration, Type 2 diabetes, Graves' disease (GD) and normal subjects. The dashed 
line represents the upper limit of normal subjects. Levels of IL-1( are significantly 
higher in recently diagnosed (RD) patients with Type 1 diabetes than in patients 
with long-standing (LS) Type 1 diabetes (p<0.01), Type 2 diabetes (p<0.005), 
Graves' disease (p<0.001) and normal subjects (p<0.001). Horizontal bars 
represent medians.   
 
5.2.2 TH1 PROFILE 
IL-2. Levels of IL-2 were significantly elevated in patients with recently diagnosed 
Type 1 diabetes (median 12 percent; range 3.7-56.0; p<0.0001), long-standing Type 
1 diabetes (8 percent;  3.2-30.5; p<0.001), Type 2 diabetes (6.4 percent, 1-21.0; 
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p<0.001) and Graves' disease (6.3 percent, 2.2-15; p<0.01) when compared with 
normal control subjects (3.6 percent, 1-8) (Figure 5.3).  
 
Figure 5.3. IL-2 values in the serum of patients with Type 1 diabetes of different 
duration, Type 2 diabetes, Graves' disease (GD) and normal subjects. The dashed 
line represents the upper limit of normal subjects. IL-2 levels were measured in a 
bioassay using an IL-2 dependent cell line, cytotoxic T-cell lymphocytes (CTLL), by 
a colorimetric method. The results are expressed as the percentage of maximal 
stimulation of CTLL in test samples. Horizontal bars represent medians. Levels of 
IL-2 are significantly higher in patients with recently diagnosed (RD) (p<0.0001) 
and long-standing (LS) Type 1 diabetes (p<0.001), Type 2 diabetes (p<0.001) and 
Graves' disease (p<0.01) when compared with normal subjects.  
 
Levels of IL-2 were significantly higher in patients with recently diagnosed 
Type 1 diabetes when compared with patients with either Type 2 diabetes (p<0.01) 
or Graves' disease (p<0.003). Levels of IL-2 were not significantly different in those 
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tested before insulin treatment (7.6 percent, 3.5-56) and those tested later (12 
percent, 4.3-49). Levels of IL-2 did not differ significantly between patients with 
long-standing Type 1 diabetes, Type 2 diabetes and Graves' disease. Levels of IL-2 
exceeding the highest normal value (>8 percent) were found in 20/31 (64%) recently 
diagnosed patients and 15/32 (47%) long-standing patients with Type 1 diabetes; 
11/27 (41%) patients with Type 2 diabetes, and 7/21 (33%) patients with Graves' 
disease.  
 
IFN-+. Levels of IFN-? were significantly higher in patients with recently diagnosed 
Type 1 diabetes (median 225 pg/ml, range 0-1500) compared with patients with 
long-standing Type 1 diabetes (0 pg/ml, 0-435; p<0.001), Type 2 diabetes (0 pg/ml, 
0-365; p<0.001), Graves' disease (0 pg/ml, 0-304; p<0.005) and normal control 
subjects (0 pg/ml, 0-130; p<0.0001) (Figure 5.4). 
 In patients with recently diagnosed Type 1 diabetes, levels of IFN-? were not 
significantly different in those tested before insulin treatment (405 pg/ml, 0-1310) 
and those tested later (95 pg/ml, 0-1500). Levels did not differ significantly between 
patients with long-standing Type 1, Type 2 diabetes and Graves' disease, or between 
either of these groups and control subjects. Levels of IFN-? exceeding the highest 
normal value (>130 pg/ml) were found in 18/31 (58%) recently diagnosed patients 
and 4/32 (13%) long-standing patients with Type 1 diabetes, 3/27 (11%) with Type 
2 diabetes and 2/21 (9%) with Graves' disease.  
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Figure 5.4. IFN-4 values in the serum of patients with Type 1 diabetes of different 
duration, type 2 diabetes, Graves' disease (GD) and normal subjects. The dashed 
line represents the upper limit of normal subjects. Levels of IFN-4 were significantly 
higher in recently diagnosed (RD) patients with Type 1 diabetes than patients with 
long-standing (LS) Type 1 diabetes (p<0.001), Type 2 diabetes (p<0.001), Graves' 
disease (p<0.005) and normal subjects (p<0.0001). Horizontal bars represent 
medians. 
 
5.2.3 TH2 PROFILE   
IL-4 and IL-10. Median levels of IL-4 and IL-10 were not significantly different in 
patients with recently diagnosed and long-standing Type 1 diabetes, patients with 
Type 2 diabetes and normal subjects (Figures 5.5A and B). Significantly elevated 
levels of IL-4 and IL-10 were present in patients with Graves' disease when 
compared with recently diagnosed and long-standing patients with Type 1 diabetes, 
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patients with Type 2 diabetes and normal subjects (p<0.001 for all). Levels of IL-4 
and IL-10 exceeding the highest normal value (42 pg/ml for both IL-4 and IL-10) 
were found in 3/31 (9%) and 1/31 (3%) recently diagnosed patients with Type 1 
diabetes, 4/32 (10%) and 0/32 (0%) long-standing patients with Type 1 diabetes; 
1/27 (3%) and 0 /27 (0%) patients with Type 2 diabetes, and 6/21 (28%) and 15/21 
(70%) patients with Graves' disease respectively. Levels of IL-6 were not detectable 
in the serum of either patients or normal control subjects.  
Figure 5.5. IL-4 (A) and IL-10 (B) values in the serum of patients with Type 1 
diabetes of different duration, type 2 diabetes, Graves' disease (GD) and normal 
subjects. The dashed line represents the upper limit of normal subjects. Levels of IL-
4 and IL-10 were not significantly different in patients with recently diagnosed (RD) 
and long-standing (LS) Type 1 diabetes, patients with Type 2 diabetes and normal 
subjects. Significantly elevated levels of IL-4 and IL-10 were present in patients with 
Graves' disease when compared with recently diagnosed and long-standing patients 
with Type 1 diabetes, patients with Type 2 diabetes and normal subjects (p<0.001 
for all). Horizontal bars represent medians. 
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5.2.4  LEVELS OF sIL-2R IN TYPE 1 DIABETES  
Levels of sIL-2R were significantly higher in patients with recently 
diagnosed Type 1 diabetes (median 384 U/ml, range 150-954) when compared with 
long-standing Type 1 diabetes (290 U/ml, 153-520; p<0.02), Type 2 diabetes (249 
U/ml, 96-753; p<0.03), Grave's disease  (252 U/ml, 100-760; p<0.03) and normal 
subjects (246 U/ml, 93-375; p<0.001) (Figure 5.6). Levels did not differ 
significantly between patients with long-standing Type 1, Type 2 diabetes, Graves' 
disease and normal controls. Levels of sIL-2R exceeding the highest normal value 
(375 U/ml) were found in 16/31 (51%) recently diagnosed patients and 9/31 (28%) 
long-standing patients with Type 1 diabetes, 4/23 (17%) patients with Type 2 
diabetes and 5/20 (25%) patients with Graves' disease.  
 
Figure 5.6. sIL-2R values in the serum of patients with Type 1 diabetes of different 
duration, Type 2 diabetes, Graves' disease (GD) and normal subjects. The dashed 
line represents the upper limit of normal subjects. Horizontal bars represent 
medians. Levels of sIL-2R are significantly higher in recently diagnosed (RD) 
patients with Type 1 diabetes than patients with long-standing Type 1 diabetes 
(p<0.02), Type 2 diabetes (p<0.03), Graves' disease (p<0.03) and normal subjects 
(p<0.001). 
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5.2.5  ASSOCIATION BETWEEN CYTOKINE LEVELS, sIL-2R, BLOOD 
GLUCOSE VALUES AND ISLET CELL AND GAD ANTIBODIES IN 
SUBJECTS STUDIED. 
Levels of IFN-? and TNF-@ were significantly correlated in patients with 
recently diagnosed Type 1 diabetes (r=0.51, p<0.05), while levels of IL-1@ and TNF-
@ were significantly correlated in patients with long-standing Type 1 diabetes 
(r=0.41, p<0.05). None of the other cytokines or sIL-2R were correlated with each 
other in any group studied. 
 Mean (± SD) blood glucose levels of patients with Type 1 and Type 2 
diabetes at sampling were 13.2 ± 4.3 mmol/l and 11.2 ± 2.9 mmol/l respectively. No 
correlation was found between TNF-@, IL-1@, IL-2, IL-4, IL-10, IFN-? or sIL-2R 
levels and blood glucose values of patients with Type 1 or Type 2 diabetes.   
 ICA and GAD antibodies were detected in 24/31 (78%) and 12/31 (39%) 
recently diagnosed patients respectively and in 6/32 (19%) and 3/32 (13%) long-
standing patients with Type 1 diabetes respectively. All patients with Type 2 
diabetes were negative for ICA and 4 of 27 (11%) were positive for GAD 
antibodies. In patients with Type 1 diabetes, there was no correlation between those 
whose levels of cytokines or sIL-2R exceeded the upper limit of normal and the 
presence of either ICA or GAD antibodies.   
5.2.6  ASSOCIATION BETWEEN LEVELS OF CYTOKINES, sIL-2R AND 
C-PEPTIDE LEVELS.  
As expected, median C-peptide levels were reduced in patients with recent 
onset and long-standing Type 1 diabetes (median 1.1, range 0.5-3.4 ng/ml and 0.77, 
0.39-1.75 ng/ml respectively) compared with patients with Type 2 diabetes and 
normal controls (2.68, 1.0-6.4 ng/ml and 1.9, 1.6-5.4 ng/ml respectively). There was 
a significant correlation between C-peptide and TNF-@ levels in patients with Type 1 
diabetes of recent onset (r=0.42, p<0.05) as well as in those with long-standing Type 
1 diabetes (r=0.51, p<0.05). There was no relationship between C-peptide levels and 
levels of IL-1@, IL-2, IL-4, IL-10, IFN-? and sIL-2R. 
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5.3  COMMENT 
Increased levels of TNF-@, IL-1@, IL-2 and IFN-? - were found in recently 
diagnosed patients with Type 1 diabetes when compared with both disease and 
metabolic control subjects and with normal controls. The presence of this profile of 
cytokines implies activation of the TH1 subset of helper cells near to diagnosis of 
Type 1 diabetes. Interferon-?, released by this subset of T lymphocytes, is a potent 
stimulator of macrophage function, and the elevated levels of macrophage-derived 
cytokines TNF-@ and IL-1@ at diagnosis could be secondary to the TH1 response. In 
contrast, no difference in the levels of IL-4 and IL-10 was observed between diabetic 
and normal control subjects, indicating a lack of recruitment of TH2 subset at 
diagnosis of Type 1 diabetes.  
 It has been proposed that the balance of TH1 and TH2 cells is critical in the 
development of Type 1 diabetes (Harrison et al., 1993). This suggestion is made on 
the basis that at-risk first degree relatives who have poor delayed-type 
hypersensitivity response to specific islet antigens (eg. GAD) may be less likely to 
develop diabetes (Harrison et al., 1993). In addition, there is evidence from the non-
obese diabetic (NOD) mouse model of spontaneous diabetes that GAD-responsive, 
IFN-? producing T lymphocytes are an early feature of the disease process (Rapoport 
et al., 1993). The present study lends support to this hypothesis, in that the 
predominant circulating cytokine profile at diagnosis of Type 1 diabetes is TH1, with 
little evidence of TH2 cytokines.      
 High levels of cytokines in recently diagnosed Type 1 diabetes could be due 
to either the disease process, a non-specific effect of ongoing autoimmune disease, 
metabolic disturbances or non-specific clinical illness. Clinical illness may be 
associated with raised levels of cytokines in patients at diagnosis of diabetes but 
cannot explain the elevated levels in long-standing patients who were without 
clinical signs or symptoms of illness at the time of sampling. Alternatively, high 
levels of cytokines could be due to metabolic disturbances or a chronic autoimmune 
process. However, levels of cytokines did not correlate with patients' blood glucose 
levels and there was no relationship in patients with Type 1 diabetes between 
cytokine levels and the presence of antibodies to ICA or GAD. It is unlikely that the 
high levels of cytokines are genetically determined since we detected normal levels 
in long-standing Type 1 diabetic patients. It is likely therefore that the high levels of 
cytokines we detected are related to an immune process associated with Type 1 
diabetes. This immune process is probably associated with the development of Type 
1 diabetes since we demonstrated persistently elevated levels of activated T cells in 
105
prediabetic twins but not in twins who did not develop Type 1 diabetes (Tun et al., 
1994).   
 The results in this section confirm the finding of Cavallo et al. (1991) that 
levels of TNF-@ are elevated in a proportion of newly-diagnosed patients with Type 
1 diabetes, while levels of IL-4 and IL-6 are undetectable (Cavallo et al., 1991). In 
contrast, they found normal levels of IL-1@ and IFN-? in patients with Type 1 
diabetes. This difference may be explained by differences in assay conditions or 
storage since cytokines are labile molecules with short half-lives; our serum samples 
were stored at -70°C and not -20°C as in that study. Elevated levels of TNF-@, but 
not IL-1@ or IL-1ß, were found in a group of long-standing patients with 
hyperglycaemia by Mooradian et al, but the nature of the diabetes (Type 1 or Type 2) 
in these patients was not given (Mooradian et al., 1991). We were unable to detect 
IL-1N in serum, possibly due to the presence of cytokine inhibitors. Some of these 
receptors ''binding protein'', such as type II receptors, are naturally-occurring 
inhibitors for IL-1N but do not bind IL-1@ (Scott et al., 1991).  
 High levels of TNF-@ and IL-1 (macrophage-derived cytokine) in recently 
diagnosed patients with Type 1 diabetes indicate that cytokines may be involved in 
mediating N-cell damage. Previous studies have demonstrated that ß-cells are 
selectively and exquisitely sensitive to cytotoxic effects of IL-1@ and IL-1ß (Palmer 
et al., 1989; Zawalich et al., 1989), whilst TNF-@ and IFN-? have a synergistic 
cytotoxic effect on islets (Pujol-Borrell et al., 1987). Thus, the macrophage could be 
an important effector of islet damage, since it is the main producer of these 
cytokines. Evidence from animal models of Type 1 diabetes supports such a role for 
macrophages (Hanenberg et al., 1989). In the BB rat, the appearance of macrophages 
in islets of Langerhans is the first event heralding the onset of insulitis (Walker et al., 
1988). Manoeuvres designed to inhibit macrophage function, such as administration 
of silica, inhibit the development of diabetes in the BB rat (Oschilewski et al., 1985). 
In man, at diagnosis of diabetes, the islets of Langerhans  show mononuclear cell 
infiltration, mainly by activated T cells and macrophages, and 40% of lymphocytes 
in this insulitis stain with antibody to IFN-? (Foulis et al., 1991), a potent stimulator 
of macrophage activation (Pujol-Borrell et al., 1987). Thus, release of IFN-? by 
activated T lymphocytes could lead to ß cell damage through inducing IL-1 and TNF 
release from macrophages (Hänninen et al., 1992).     
 Persistently high levels of cytokines in patients with established diabetes 
suggest that there is an unremitting, long-term immune process. C-peptide, an index 
of endogenous insulin secretion, and hence of intact N cells, did correlate with TNF-
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@ levels. By implication, therefore, the immune process which induces the 
production of increased TNF-@ is still active as long as islet N cells remain. The 
mechanism by which autoimmune reactions are initiated against the N-cells and the 
stimulus for cytokine production in Type 1 diabetes are not known. Viral infection 
could initiate the immune process; viruses are capable of inducing IFN-? (Trinchieri 
and Perussia, 1985) and have been shown to induce secretion of other cytokines 
such as TNF, IL-1N and IL-6 from human monocytes (Henke et al., 1992).  
 Levels of TNF-@, IL-2 and sIL-2 receptor were also raised in some patients 
with both long-standing Type 1 diabetes and Type 2 diabetes. These individuals are 
at risk of diabetic complications. Previous work in our laboratory has demonstrated 
high levels of circulating activated T lymphocytes in patients with symptoms and 
signs of diabetic neuropathy (Gilbey et al., 1988) and diabetic nephropathy (Bending 
et al., 1988). It is possible that complications of diabetes are associated with 
increased secretion of cytokines but further studies are required to address 
specifically this question.   
 In summary, this section shows that high levels of circulating IL-1@, TNF-@,
IL-2, IFN-? and sIL-2R are associated with the diagnosis of Type 1 diabetes. This 
supports the recent proposal that a balance in favour of TH1 lymphocytes is a key 
element in the development of Type 1 diabetes. Whichever the stimulus leading to 
cytokine production in Type 1 diabetes, this immune system imbalance may precede 
the clinical onset of the disease. A more detailed analysis of the immune changes 
present in the prediabetic period will be presented in chapter 6.
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CHAPTER 6
PROSPECTIVE STUDY OF CYTOKINE LEVELS IN IDENTICAL TWINS  
 OF PATIENTS WITH TYPE 1 DIABETES  
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6.1 SUBJECTS 
A consecutive series of non-diabetic identical co-twins of patients with Type 
1 diabetes referred within 4 years of the diagnosis of the index twin and seen 
between June 1982 and January 1992 were recruited for this study. Monozygosity 
was established in all the twin pairs as previously described (Barnett et al., 1981) 
using a minimum of 22 blood group antigens. All the twins had oral glucose 
tolerance tests (75g or 1.75g/kg, whichever was the less) both initially and at 
intervals thereafter to confirm that they were not diabetic. On every occasion, each 
twin was shown to have a fasting whole blood glucose level less than 6.7 mmol/l 
(i.e. within the normal range). Twins were followed either because they had 
developed Type 1 diabetes, or remained non-diabetic for a minimum of 6 years after 
which period their risk of developing Type 1 diabetes is less than 2% (see section 
4.1.4). Twenty-eight identical co-twins fulfilled the criteria of entry into the study. 
The twins were ascertained within one year (n=22), 2 years (n=2), 3 years (n=1) and 
4 years (n=3) of diagnosis of their index twin. Eight twins developed diabetes 
(prediabetic twins) (4 males; median age 13 years, range 10-20); they were tested on 
a median of 2 (range 2-8) occasions up to 5 years before diagnosis. Twenty twins 
(12 males; median age 19 years, range 7-53) remain non-diabetic (non-diabetic 
twins) (median follow up 11 years, range 6-19 years after diagnosis of their index 
twin). In the twins remaining non-diabetic for many years, multiple samples have 
been collected during follow-up. To facilitate the determination of changes in 
cytokine levels with time, samples from the non-diabetic twins were taken and 
measured on just two occasions, the first within 4 years of diagnosis of diabetes in 
the index twin, the second at least 5 years from diagnosis of the index twin.   
 As normal control subjects, 41 healthy individuals were studied and 
described in section 5.1.
At the time of sampling, all twins and controls subjects were healthy and had 
no clinical signs or symptoms of intercurrent illness. 
6.2 RESULTS  
In this cohort of non-diabetic identical twins of patients with Type 1 
diabetes, serum levels of IL-1@ and TNF-@, IL-2 and IFN-? and IL-4 and IL-10 were 
measured. Insufficient serum was available to measure levels of-IL-1N and IL-6.  
 The question being investigated in this section is whether abnormally 
elevated levels of cytokines (higher than the highest value in normal controls) is 
similar in prediabetic and non-diabetic twins. In order to avoid potential biases 
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caused by different numbers of measurements and different periods of follow-up for 
each twin, median levels of cytokines for each subject will be determined. If this is 
abnormally high, the subject is classified as having an abnormal levels of cytokines. 
The proportion of subjects with abnormal levels of cytokines in each group will be 
compared using the c2 test.  
6.2.1 MACROPHAGE-DERIVED CYTOKINES  
TNF-*. The number of twins who had abnormal median levels of TNF-@ was higher 
in prediabetic than the non-diabetic twins group (c2=6, p<0.01) (Figure and Table 
6.1).  
 Prediabetic and non-diabetic twins who had levels of TNF-@ exceeding the 
highest normal value and whose serum was available were also tested for TNF-@
bioactivity. Bioactive TNF-@ was detected on 11/16 occasions (67%) in prediabetic 
twins (median 0.9 U/ml, range 0-17), 8 of whom had levels of TNF-@ >1 u/ml and 
on 2/6 occasions (33%) in non-diabetic twins (median 0 U/ml, 0-2.3), only one of 
whom had TNF-@ levels >1 U/ml.  
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Figure 6.1. TNF-( levels in 8 prediabetic (A) and 20-non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of TNF-( over time was higher in prediabetic than in 
non-diabetic twin group (I2=6, p<0.01)  
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IL-1*. The number of twins who had abnormal median levels of IL-1@ was higher 
in prediabetic than the non-diabetic twins group (c2=13, p<0.0002) (Figure. 6.2)
(Table 6.1). 
Figure 6.2. IL-1( levels in 8 prediabetic (A) and 20-non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of IL-1( over time was higher in prediabetic than in 
non-diabetic twin group (I2=13, p<0.0002). 
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6.2.2 TH1 PROFILE   
IL-2. The number of twins who had abnormal median levels of IL-2 was not 
significantly different in prediabetic when compared with non-diabetic twins 
(c2=1.3, p<0.2) (Figure. 6.3) (Table 6.1).   
Figure 6.3. IL-2 levels in 8 prediabetic (A) and 20-non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of IL-2 over time was not significantly different in 
prediabetic when compared with-non-diabetic twin group (I2=1.3, p<0.2).  
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IFN-+. The number of twins who had abnormal median levels of IFN-? was not 
significantly different in prediabetic when compared with non-diabetic twins 
(c2=3.5, p<0.06) (Figure 6.4) (Table 6.1).   
Figure 6.4. IFN-? levels in 8 prediabetic (A) and 20-non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of IFN-? over time was not significantly different in 
prediabetic when compared with-non-diabetic twin group (c2=3.5, p<0.06). 
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6.2.3 TH2 PROFILE 
IL-4 and IL-10. The number of twins who had abnormal median levels of IL-4 and 
IL-10 was not significantly different in prediabetic when compared with non-
diabetic twins (c2=0.03, p<0.9 for IL-4 and c2=0.43, p<0.5 for-IL-10) (Figure 6.5 
and Figure 6.6) (Table 6.1).  
Figure 6.5. Levels of IL-4 in 8 prediabetic (A) and 20 non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of IL-4 over time was not significantly different in 
prediabetic when compared with non-diabetic twin group (I2=0.03, p<0.9).  
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Figure 6.6. Levels of IL-10 in 8 prediabetic (A) and 20 non-diabetic (B) twins. The 
dashed line represents the upper limit of normal subjects. The number of twins who 
had abnormal median levels of IL-10 over time was not significantly different in 
prediabetic when compared with non-diabetic twin group (I2=0.43, p<0.5).  
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6.2.4 PREVALENCE OF TH1 AND TH2 CYTOKINE PROFILES IN 
IDENTICAL TWINS OF PATIENTS WITH TYPE 1 DIABETES 
To examine whether a pattern of TH1 or TH2 dominance existed in 
prediabetic or non-diabetic twins, cytokine profiles were classified as TH1 (elevated 
levels of IL-2 or IFN-?) or TH2 (elevated levels of IL-4 or IL-10). In prediabetic 
twins, 3/8 (37%) had a predominantly TH1 and 2/8 (25%) TH2. In the remainder, 
neither T helper subset was dominant. In twins remaining non-diabetic, 1/20 (5%) 
had a predominantly TH1 profile and 8/20 (40%) TH2, whilst in the remainder 
neither subset was dominant.  
 
6.2.5 COMPARISON OF PREVALENCE OF TH1 AND TH2 CYTOKINE 
PROFILES IN IDENTICAL TWINS AND PATIENTS WITH TYPE 1 
DIABETES 
The number of individuals who had abnormal median levels of TH1 (IL-2 
and IFN-?) and TH2 (IL-4 and IL-10) cytokines were compared between recently 
diagnosed patients with Type 1 diabetes and groups of prediabetic and non-diabetic 
twins using c2 test.  
 
TH1 cytokines. The number of individuals who had abnormal median levels of TH1
cytokines was significantly higher in patients with recently diagnosed Type 1 
diabetes than in non-diabetic twins (p<0.01 for IL-2 and p<0.03 for IFN-?) (Table 
6.1). No difference in levels of TH1 cytokines between recently diagnosed patients 
with Type 1 diabetes and prediabetic twins was observed.  
 
TH2 cytokine. The number of individuals who had abnormal median levels of TH2
cytokines was significantly higher in both prediabetic and non-diabetic twins than in 
patients with recently diagnosed Type 1 diabetes (p<0.0001 and p<0.001 for IL-4 
and p<0.03 and p<0.0005 for IL-10 respectively) (Table 6.1). 
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Table 6.1 Comparison of prevalence of elevated levels of macrophage-derived cytokines and TH1 (IL-2 and IFN-4) and TH2 (IL-4 and IL-10)
cytokine profiles in identical twins and patients with Type 1 diabetes.
p values*
Cytokines Prediabetic twins Non-diabetic
twins
Recently
diagnosed
Type 1
diabetics
Prediabetic
twins v. recently
diagnosed Type 1
diabetics
Non-diabetic
twins v. recently
diagnosed Type 1
diabetics
Prediabetic v.
non-diabetic twins
TNF-* (Mø) 7/8
(88%)
6/20
(30%)
23/31
(74%)
NS 0.005 0.01
IL-1* (Mø) 6/8
(75%)
0/20
(0%)
18/31
(58%)
NS 0.0001 0.0002
IL-2 (TH1) 5/8
(63%)
6/20
(30%)
20/31
(64%)
NS 0.01 NS
IFN-+ (TH1) 5/8
(63%)
5/20
(25%)
18/31
(58%)
NS 0.03 NS
IL-4 (TH2) 5/8
(63%)
10/20 (50%) 3/31
(9%)
0.0001 0.001 NS
IL-10 (TH2) 3/8
(38%)
11/20 (55%) 1/31
(3%)
0.03 0.0005 NS
*Comparisons were made between recently diagnosed patients with Type 1 diabetes and groups of prediabetic and non-diabetic twins using the c2
test.
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6.2.6 ASSOCIATION BETWEEN LEVELS OF CYTOKINES, BLOOD 
GLUCOSE LEVELS AND AUTOANTIBODIES IN IDENTICAL TWINS 
 The mean (± SD) glucose level of all the blood samples obtained from 
prediabetic (n=22) and non-diabetic twins (n=35) were 4.3 ± 0.7 mmol/l (range 3-
5.3 mmol/l) and 4.7± 2 mmol/l (range 2.8-5.1 mmol/l) respectively. No correlation 
was found between levels of cytokines and blood glucose levels in either prediabetic 
or non-diabetic twins.  
 Islet cell antibodies (ICA) and GAD antibodies were detected in all but one 
of the 8 prediabetic twins in the first blood sample available for cytokine studies. All 
but two of the 20 twins who remain non-diabetic were negative for ICA and all but 
one were negative for GAD antibodies in the first blood sample available for 
cytokine studies. No correlation was found between levels of cytokines and the 
presence of ICA or anti-GAD antibodies in either prediabetic and non-diabetic 
twins.  
 In non-diabetic twins, levels of IL-4 were correlated with IL-10 (r=0.47, 
p<0.002) while levels of IL-2 were correlated with IFN-? in both prediabetic and  
non-diabetic twins (r=0.75 and r=0.65, p<0.002 and 0.0001 respectively).  
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6.3 COMMENT 
 Levels of macrophage-derived cytokines (IL-1@ and TNF-@) were elevated 
more frequently in prediabetic twins who developed diabetes than in non-diabetic 
twins who did not. In contrast, cytokine profiles classified as TH1 (elevated levels of 
IL-2 or IFN-?) or TH2 (elevated levels of IL-4 and IL-10) existed in both prediabetic 
or non-diabetic twins without dominance of either TH1 or TH2.   
 Elevated levels of TNF-@ and IL-1@ in identical twins at risk of developing 
Type 1 diabetes indicate that the predominant cytokines during the prediabetic 
period are macrophage-derived (TNF-@ and IL-1@). These results are consistent with 
the observation of a macrophage infiltration as the first event heralding the onset of 
insulitis in the NOD mouse and BB rat models of diabetes as discussed previously 
(vide 5.3). Thus, elevated levels of circulating IL-1@ and TNF-@ in prediabetic twins 
suggest that the macrophage could be an important effector, and macrophage-
derived cytokines an important marker of islet damage. 
 The presence of elevated levels of IL-1@ and TNF-@ in prediabetic twins 
long before there is hyperglycaemia indicates that an elevated levels of these 
cytokines is unlikely to be an epiphenomenon secondary to metabolic disturbance or 
clinical illness. In addition, there was no relationship between cytokine levels and 
the presence of antibodies to ICA or GAD. It is unlikely that the high levels of 
cytokines in prediabetic twins are genetically determined since normal levels were 
detected in the-non-diabetic twins of diabetic patients. It is likely therefore that the 
high levels of cytokines detected are related to an immune process associated with 
the development of Type 1 diabetes since persistently elevated levels of both TNF-@
and IL-1@ in prediabetic twins but not in twins who did not develop Type 1 diabetes 
were demonstrated in the present study.  
 As in recently diagnosed patients with Type 1 diabetes, the mechanism by 
which autoimmune reactions are initiated against the N-cells and the stimulus for 
cytokine production in prediabetic twins are not known but may involve viral 
infection (vide 5.3).  
 Although some prediabetic twins had primarily a TH1 profile of circulating 
cytokines, there was no clear pattern of TH1 or TH2 profile in twins destined to 
become diabetic, or in those remaining non-diabetic and unlikely to develop the 
disease. However, levels of cytokines typical of a TH2 profile were higher in non-
diabetic twins than in patients with recently diagnosed Type 1 diabetes. This finding 
supports a possible role for TH2 cytokines (IL-4 and IL-10) in preventing the disease 
processes by down-regulating autoimmune responsiveness. Recent evidence 
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supports the latter concept and it has been shown that IL-4 (Rapoport et al., 1993; 
Fowell and Mason, 1993) and IL-10 (Pennline, et al., 1994) prevent the onset of 
diabetes in NOD mice suggesting the role of TH2 cytokines in down-regulating the 
IFN-?-producing TH1 subset, an important mediator of islet N-cell destruction 
(Rabinovitch, 1994). This is supported by evidence that the two functional subsets 
are mutually antagonistic. For example, IL-10 suppresses synthesis of TH1 helper 
cytokines such as IL-2 and IFN-? (Moore et al., 1990; Vieira et al., 1991). It has also 
been shown that IL-4 suppresses LPS-induced stimulation of IL-1, TNF-@ and-IL-6 
synthesis by human monocytes (Cheung et al., 1990). These observations are in 
keeping with the finding in the present study that high levels of IL-4 and IL-10 in-
non-diabetic twins are associated with low levels of TNF-@ and IL-1@ and that levels 
of TH1 cytokines are lower than TH2 cytokines.      
 In conclusion, these data show that macrophage-derived cytokines (IL-1@
and TNF-@) are consistently raised throughout the prediabetic period. This supports 
the hypothesis that macrophages could be important effectors of islet damage. 
Analysis of TH1 or TH2 profiles of twin groups did not reveal a clear difference in 
the pattern obtained in the prediabetic twins compared with that in the twins 
remaining non-diabetic. The increased levels of TH2 cytokines in the non-diabetic 
twins but not in patients with diabetes may give support to the role of TH2 cells in 
preventing the disease.   
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CHAPTER 7
STUDIES ON CYTOKINE LEVELS AND THEIR RELATIONSHIP TO 
AUTOANTIBODIES AND HLA ALLELES IN DIABETIC CHILDREN  
 AND THEIR FIRST DEGREE RELATIVES 
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7.1 SUBJECTS 
Twenty-nine families, all with an index case of Type 1 diabetes attending the 
District Diabetes Centre, Farnborough Hospital, Kent, were studied. All families 
with children attending the Diabetes Centre were approached and all those willing to 
participate were recruited. As far as possible, blood samples were obtained from all 
siblings and both parents. The composition of the families studied is shown in Table 
7.1.
There were a total of 29 children with Type 1 diabetes (14 males, median age 
13 years, range 2-15) with a mean duration of diabetes of 3.1 ± 1.5 years. Duration 
of diabetes ranged from 3 months to 5 years, and 3 diabetic children were studied 
within 1 year of diagnosis. Type 1 diabetes was defined in accordance with the 
guidelines of the National Diabetes Data Group. At the time of sampling, the mean 
random blood glucose level amongst the diabetic children was 11.9 ± 5.5 mmol/l 
and the mean level of haemoglobulin A1C was 10.1 ± 1.8%. In addition, we studied 
51 parents, (25 males, median age 42 years, 30-46) and 34 siblings (15 males, 
median age 11 years, 3-20), none of whom had diabetes (mean ± SD level of 
haemoglobulin A1C 6.8% ± 0.7 in the siblings and 6.7% ± 0.7 in the parents).  
 As normal control subjects, we studied 41 healthy  individuals as described 
in section 5.1. 
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Table 7.1 Composition of families studied 
 
Number of 
Families 
Mother Father Diabetic Sib 1 Sib 2 Sib 3 
8 _ _ _ _ _
12 _ _ _ _
2 _ _ _
1 _ _ _ _ _
1 _ _ _ _
1 _ _ _
3 _ _
1 _ _
7.2 RESULTS 
Serum levels of TNF-@, IL-1@, IFN-? and sIL-2R in 29 children with Type 1 
diabetes and their first degree relatives (parents and siblings) and their relationship 
to HLA type and autoantibodies, are described in this section. 
 
7.2.1 CYTOKINE AND sIL-2R LEVELS. 
TNF-*. Levels of TNF-@ were significantly increased not only in children with Type 
1 diabetes but also in their non-diabetic siblings and parents when compared with 
the appropriate control group (p<0.02, for all) (Figure 7.1). Levels of TNF-@
exceeding the highest normal value (>9 pg/ml) were found in 13/29 (45%) diabetic 
children, 6/28 (21%) of their siblings and 6/33 (18%) of their parents. 
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Figure 7.1.  TNF-( values in the serum of children with Type 1 diabetes, in their 
parents and siblings and controls. The dashed line represents the upper limit of 
normal controls. Levels of TNF-( were significantly higher in children with Type 1 
diabetes, in their siblings and parents (p<0.02 for all) when compared with normal 
controls. Horizontal bars represent median values. 
 
IL-1*. A similar pattern was seen for IL-1@. However, although the levels were 
increased in the diabetic children, their siblings and parents, these elevations did not 
reach statistical significance (Figure 7.2). Levels of IL-1@ exceeding the highest 
normal value (>192 pg/ml) were found in 7/29 (24%) diabetic children, 8/33 (24%) 
of their siblings and 9/32 (28%) of their parents. 
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Figure 7.2.  IL-1( values in the serum of children with Type 1 diabetes, in their 
parents and siblings and controls. The dashed line represents the upper limit of 
normal controls. Levels of IL-1 were not significantly higher in children with Type 1 
diabetes, in their siblings and parents when compared with normal controls. 
Horizontal bars represent median vales.
IFN-+. A similar pattern was also seen for IFN-?. There was no significant 
difference in the levels of IFN-? between diabetic children, their siblings and parents 
and normal controls (Figure 7.3). Levels of IFN-? exceeding the highest normal 
value (>250 pg/ml) were found in 8/27 (30%) diabetic children, 8/26 (31%) of their 
siblings and 7/26 (27%) of their parents. 
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Figure 7.3.  IFN-4 values in the serum of children with Type 1 diabetes, in their 
parents and siblings and controls. The dashed line represents the upper limit of 
normal controls. Levels of IFN-4 were not significantly higher in children with Type 
1 diabetes, in their siblings and parents when compared with normal controls. 
Horizontal bars represent median values. 
 
sIL-2R. Levels of sIL-2R were significantly increased not only in diabetic children 
but also in their siblings and parents when compared with appropriate normal 
controls (p<0.001, for all) (Figure 7.4). Levels of sIL-2R exceeding the highest 
normal value (>410 U/ml) were found in 9/22 (40%) diabetic children, 11/20 (55%) 
of their siblings and 20/50 (40%) of their parents.  
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Figure 7.4.  sIL-2R values in the serum of children with Type 1 diabetes, in their 
parents and siblings and controls. The dashed line represents the upper limit of 
normal controls. Levels of sIL-2R were significantly higher in children with Type 1 
diabetes, in their siblings and parents (p<0.001 for all) when compared with normal 
controls. Horizontal bars represent median values. 
 
7.2.2 ASSOCIATION  BETWEEN LEVELS OF CYTOKINES AND ISLET 
CELL ANTIBODIES OR OTHER AUTOANTIBODIES. 
Islet cell antibodies (ICA) were detected in 18 diabetic children (62%), 4 
siblings (12%) and 2 parents (4%). Diabetic children with ICA had higher levels of 
IFN-? compared with their ICA-negative counterparts (median 100 pg/ml, range 0-
2310 versus 0 pg/ml, 0-615; p<0.05). In addition, in patients with ICA, levels of 
IFN-? were higher at times near to diagnosis than more distant from diagnosis. 
Levels of TNF-@, IL-1@ and sIL-2R were similar in siblings, parents or diabetic 
children irrespective of the presence or absence of ICA.  
 Autoantibodies other than ICA (such as GPC, TMA, TGA, ANA, SMA, 
ARA, AMA) were detected in 6 diabetic children (19%), 8 siblings (24%) and 15 
parents (29%) (Table 7.2). In 1 diabetic child, 4 siblings and 6 parents more than 
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one autoantibody was present, usually as a combination of GPC and TMA which 
accounted for 6 of the cases of multiple autoantibodies. There were no differences in 
levels of cytokines studied when diabetic children or their siblings and parents were 
divided according to the presence or absence of 1 or more of the non-ICA 
autoantibodies.  
 No correlation was found between TNF-@, IL-1@ and IFN-? levels in diabetic 
children, their siblings or their parents. 
129
Table 7.2 Prevalence (%) of organ-specific (excluding islet cell antibody) and non organ-specific autoantibodies in children with Type 1
diabetes, their siblings and parents and controls.
Subjects GPC
n (%)
TMA
n (%)
TGA n
(%)
ANA n
(%)
SMA n
(%)
ARA n
(%)
AMA n
(%)
1 of all
types
n (%)
Patients with Type 1
diabetes
6 (19) 3 (10) 1 (3) neg neg neg neg 6 (19)
Non-diabetic siblings 3 (9) 5 (15) Neg 1 (3) 1 (3) 1 (3) 2 (6) 8 (24)
Non-diabetic parents 8 (15) 11 (20) 2 (4) 1 (2) 1 (2) 2 (4) neg 15 (29)
Healthy children neg neg Neg neg neg neg neg 0 (0)
Healthy adults 1 (4) neg Neg neg neg neg neg 1 (4)
Abbreviations: GPC (gastric parietal cell antibody); TMA (thyroid microsomal antibody); TGA (thyroglobulin antibody); ANA (anti-
nuclear antibody); SMA (smooth muscle antibody); ARA (anti-reticulin antibody); AMA (anti-mitochondrial antibody).
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7.2.3 ASSOCIATION BETWEEN LEVELS OF CYTOKINES AND HLA 
CLASS II ALLELES.  
In previous studies it has been shown that approximately 90% of children 
with Type 1 diabetes possess at least one DR3 or DR4 allele, and it is likely that an 
influence of class II loci on immune function in this disease could operate through 
these two genes. For this reason, and because of the small numbers in each study 
group, individuals were assigned to the following 4 groups: These groups are :(1) 
possession of homozygous DR3/3 or heterozygous DR3/X; (2) heterozygous DR3/4; 
(3) homozygous DR4/4 or heterozygous DR4/X; and (4) DRX/X (where X is not 
DR3 or DR4). Amongst the diabetic children, 7 (23%) were DR3/3 or DR3/X, 13 
(42%) were DR3/4, 9 (29%) were DR4/4 or DR4/X and 2 (6%) were DRX/X so that 
94% of the diabetic children possessed at least one of the DR3 or DR4 alleles. 
Amongst the siblings, 12 (35%) were DR3/3 or DR3/X, 6 (18%) were DR3/4, 6 
(18%) were DR4/4 or DR4/x and 10 (29%) were DRX/X. The frequency of certain 
haplotypes was different in the diabetic children compared with the siblings. A 
significantly higher proportion of the diabetic children were DR3/4 heterozygous 
(Fisher's exact probability p=0.029), whilst significantly more of the siblings 
possessed alleles other than DR3 or DR4 (DRX/X; Fisher's exact probability 
p=0.018). Three of the parents were not HLA typed. Of the remainder, 18 (35%) 
were DR3/3 homozygous or DR3/X, 12 (23%) were DR3/4 heterozygous, 12 (23%) 
were DR4/4 or DR4/X and 10 (18%) were DRX/X.  
 No differences were seen in levels of cytokines between any of these groups 
in diabetic children, siblings or parents. 
 
7.2.4 ASSOCIATION BETWEEN LEVELS OF CYTOKINES, METABOLIC 
CONTROL AND DURATION OF DIABETES.  
Amongst the diabetic children, there was no relationship between the 
increased levels of cytokines and random blood glucose, haemoglobulin A1C, or 
duration of diabetes. To further examine the influence of metabolic control on 
cytokine release by lymphocytes, patients with Type 1 diabetes were divided into 
those with haemoglobulin A1C levels <10.0 and those >10.0. Again, none of the 
cytokine and sIL-2R levels were different in the two groups of diabetic children 
compared with controls and with each other.  
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7.3 COMMENT 
The study reported in this section shows that circulating levels of TNF-@ and 
sIL-2R are present in non-diabetic first degree relatives (i.e. siblings and parents) of 
children with Type 1 diabetes, as well as in the diabetic children themselves.   
 The observation of elevated levels of TNF-@ and sIL-2R in this different 
study population confirms the observation detailed in section 5.2 and indicates the 
activity of macrophages and T cells to be closely linked to Type 1 diabetes.  
 The finding that elevated levels of TNF-@ and sIL-2R are also present in 
siblings and parents of patients with Type 1 diabetes, though at lower levels is 
intriguing. Siblings of children with Type 1 diabetes, despite often sharing 
environmental and genetic risk of diabetes with diabetic members of their family, 
have a relatively low risk of developing the disease themselves (Allen et al., 1991). 
Thus, the elevated cytokine levels observed in siblings are unlikely to signify 
impending diabetes at least in the majority of the individuals studied. One possible 
explanation for the increased levels of TNF-@ and sIL-2R in the first degree relatives 
of diabetic children is  that the immune system is hyperactive in these individuals. 
Such an overactive immune system has been incriminated as a possible predisposing 
factor to autoimmune diseases in individuals with the haplotype A1 B8 DR3, who 
have also been reported to have impaired Fc receptor function (Lawley et al., 1981) 
and defective suppressor-cell function (Jaworski et al., 1983). The concept that 
genetic factors are responsible for an overactive immune system - exemplified by 
elevated levels of cytokines - does not appear to be sustained by the present data. 
Thus, no association was noted between elevated levels of cytokines and sIL-2R and 
any specific HLA class II allele (HLA-DR3/4), neither in diabetic children nor their 
relatives, suggesting that the DR3/4 alleles do not exercise a univocal influence on 
determining high cytokine levels. It is possible that hypersecretion of cytokines and 
sIL-2R is associated with other alleles not investigated in the present work. In 
relation to the present study it is of interest that the genes encoding the cytokines 
TNF-@ and TNF-N are located on the short arm of chromosome 6, between the HLA 
B and HLA DR loci (Campbell and Trowsdale, 1993). Furthermore an allelic 
polymorphism within the TNF-@ promotor region which is strongly associated with 
the HLA A1, B8 and DR3 alleles has been reported (Wilson et al., 1993) and it has 
been suggested that such polymorphisms may be important in understanding Type 1 
diabetes (Mølvig et al., 1990) and other autoimmune diseases (Fugger et al., 1989).  
 Increased levels of TNF-@ and sIL-2R in diabetic children could be due to 
either the disease process, a non-specific effect of ongoing autoimmune disease, 
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metabolic disturbances or non-specific clinical illness. Clinical illness could be 
responsible for raised levels of TNF-@ and sIL-2R in children with diabetes but 
cannot explain this elevation in their siblings and parents who were without clinical 
signs or symptoms of illness at the time of sampling. High levels of cytokines could 
also be due to metabolic disturbances or a chronic autoimmune process. However 
levels of cytokines did not correlate with blood glucose levels, haemoglobulin A1C
or presence of ICA or other autoantibodies. 
 Levels of other cytokines such as IL-1@ and IFN-? tended to be higher in 
diabetic children than in normal controls but the difference did not reach statistical 
significance. At first sight, these findings are in contrast with previous results in this 
thesis showing that levels of IL-1@ and IFN-? are elevated in patients with Type 1 
diabetes at diagnosis (vide 5.2). The apparent difference could be explained by the 
fact that the mean duration of diabetes in the present study was more than 3 years. It 
has been suggested that immune abnormalities begin to disappear 6 months after 
diagnosis, and are usually normal in patients with long-term disease (Drell and 
Notkins, 1987; Gilbey et al., 1988; Bending et al., 1988). The results observed are in 
agreement with previous findings by Mooradian et al., (1991) who showed that 
levels of IL-1@ and IL-1ß in a group of long-standing patients with hyperglycaemia 
were not different when compared with normal subjects, although the nature of the 
diabetes (Type 1 or Type 2) in those patients was not given. In contrast with the 
results presented here, Tova et al. (1984) found increased levels of IFN-? in newly 
diagnosed children with Type 1 diabetes. This difference could be explained by the 
duration of the disease in the patients studied. Interestingly, in the present study, in 
patients with ICA, levels of IFN-? were higher at times near to diagnosis than more 
distant from diagnosis, suggesting that levels of IFN-? are associated with the 
presence of ICA, levels of which decline with time.  
 In summary, increased circulating levels of TNF-@ and sIL-2R are present in 
diabetic children and give support to the hypothesis that activation of macrophages 
and T cells is linked to Type 1 diabetes. Elevated levels of cytokines and sIL-2R 
were also present in first degree relatives of children with Type 1 diabetes. Some of 
these abnormalities may be influenced by genes of the HLA system, and could 
represent one component of the susceptibility conferred by inheritance of particular 
alleles.    
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CHAPTER 8
STUDIES OF CYTOKINE SECRETION BY PERIPHERAL BLOOD  
 MONONUCLEAR CELLS IN DIABETIC CHILDREN AND  
 THEIR FIRST DEGREE RELATIVES 
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8.1 SUBJECTS  
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised 
blood obtained from family members of patients with Type 1 diabetes and tested for 
cytokine production in vitro. The study groups comprised 19 children with Type 1 
diabetes (12 males, median age 10, range 2-13 years), 23 parents (11 males, median 
age 35, 30-46 years) and 14 siblings (10 males, median age 10, 3-15 years). In 
addition, 39 healthy individuals comprising 19 adults (12 males, mean age 25 ± 9.1 
years) and 20 children (11 males, mean age 12.1 ± 5.1 years) were studied. The 
individuals studied in this section were chosen from the subjects described in section 
7.1. Selection being based on the availability of adequate amount of fresh, 
heparinised blood. 
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8.2 RESULTS  
Cytokine secretion induced from PBMC from first degree relatives (parents 
and siblings from 19 families) of patients with Type 1 diabetes was measured. 
Lipopolysaccharride (LPS) was used to induce IL-1@ and TNF-@ from macrophages 
while phytohaemagglutinin (PHA) was used to induce IL-2 and IFN-? from T cells.  
 
8.2.1 TNF-* AND IL-1* SECRETION  
TNF-* secretion: Levels of spontaneous TNF-@ secretion were not different in 
diabetic children, their siblings and parents when compared with normal controls. 
LPS-stimulated TNF-@ secretion was elevated in diabetic children (p< 0.02), their 
siblings and parents (p< 0.0001 and 0.001 respectively) when compared with normal 
controls (Table 8.1).   
 
Table 8.1. Levels of spontaneous and LPS-stimulated secretion of TNF-( by PBMC in 
diabetic children, their siblings and parents. 
 
Groups no.   (spontaneous) 
 TNF-* (pg/ml) 
Median   Range  
 (with LPS)     
 TNF-* (pg/ml) 
Median   Range 
Normal 
Controls 
39 47       (0-52) 372      (138-701) 
Diabetic  
Children 
19 22       (0-544)† 2279     (54-3761)*
Siblings 14 57       (0-734)† 1385     (165-2134)*
Parents 23 80       (9-642)† 2205     (605-3483)*
†no significant difference compared with normal controls using Wilcoxon's rank sum test. 
*p<0.01 compared with normal controls. 
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IL-1* secretion: Levels of spontaneous IL-1@ secretion by mononuclear cells were 
increased in diabetic children, their siblings and parents when compared with normal 
controls (p<0.03, 0.001 and 0.01 respectively). A similar pattern of increase was also 
observed after LPS-stimulation in  all groups studied when compared with normal 
controls (p<0.003, 0.003, 0.02 respectively) (Table 8.2).   
 
Table 8.2 Levels of spontaneous and LPS-stimulated secretion of IL-1( by PBMC 
and after LPS stimulation in diabetic children, their siblings and parents. 
 
Groups no.  (spontaneous) 
 IL-1* (pg/ml) 
Median   Range  
 (with LPS) 
 IL-1* (pg/ml) 
Median   Range 
Normal 
controls 
39 0        (0-12) 82       (23-509) 
Diabetic  
Children 
19 0 (0-282)* 195      (24-741)*
Siblings 14 23       (0-283)* 341      (110-915)*
Parents 23 0 (0-190)* 295      (0-626)*
*p<0.01 compared with normal controls using Wilcoxon's rank sum test. 
 
8.2.2 IL-2 AND IFN-+ SECRETION  
IL-2 secretion: Levels of PHA-induced secretion of IL-2 (calculated as the 
percentage of maximal cytotoxic T-lymphocyte line (CTLL) stimulation) by PBMC 
were not different between diabetic children (median 35%, range 20-59), their 
siblings (33%, 9-38) and parents (27%, 7-45) and normal controls (32%, 11-64) 
(Table 8.3).    
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Table 8.3 Levels of spontaneous and PHA-stimulated secretion of IL-2 by PBMC in 
diabetic children, their siblings and parents. 
 
Groups no.  (spontaneous) 
 IL-2 (% of CTLL 
stimulation) 
Median     Range  
 (with PHA) 
 IL-2 (% of CTLL 
stimulation) 
Median     Range 
Normal 
controls 
39 0          (0-0) 32         (11-64) 
Diabetic  
Children 
19 0          (0-0) 35         (20-59) 
Siblings 14 0          (0-0) 34         (9-38) 
Parents 23 0          (0-0) 28         (9-45) 
IFN-+ secretion: A similar pattern was obtained for IFN-?. Levels of PHA-induced 
IFN-? secretion by PBMC were not different between diabetic children (median 74 
pg/ml, range 0-1200), their siblings (median 73 pg/ml, 0-1500) and parents (median 
0 pg/ml, 0-650) when compared with normal controls (median 0 pg/ml, 0-360) 
(Table 8.4).  Spontaneous secretion of both IL-2 and IFN-? by PBMC was not 
detected in any group studied. 
 
Table 8.4 Levels of spontaneous and PHA stimulated secretion of IFN-4 by PBMC in 
diabetic children, their siblings and parents. 
 
Groups no.   (spontaneous) 
 IFN-+ (pg/ml) 
Median     Range  
 (with PHA)      
 IFN-+ (pg/ml) 
Median     Range 
Normal 
Controls 
39 0          (0-0) 0          (0-246) 
Diabetic 
Children 
19 0          (0-0) 51         (0-1200) 
Siblings 14 0          (0-0) 71         (0-950) 
Parents 23 0          (0-0) 0          (0-650) 
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8.2.3 ASSOCIATION BETWEEN LEVELS OF CYTOKINE SECRETION 
AND ICA OR OTHER AUTOANTIBODIES.  
 There were no differences in the levels of cytokine secretion when diabetic 
children or their siblings and parents were divided according to the presence or 
absence of ICA, or of 1 or more of the non-pancreatic autoantibodies.  
 
8.2.4 ASSOCIATION BETWEEN LEVELS OF CYTOKINE SECRETION, 
METABOLIC CONTROL, DURATION OF DIABETES AND HLA CLASS 
II  ALLELES. 
No correlation was found between levels of IL-1@, TNF-@, IL-2 and IFN-?
secretion and random blood glucose, HbA1C, or duration of diabetes. In addition, no 
association between cytokine secretion profiles and HLA class II alleles was 
observed. 
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8.3 COMMENT  
 The results in this section demonstrate that LPS-stimulated IL-1@ and TNF-@
secretion by PBMC in vitro is significantly increased in diabetic children and their 
siblings and parents when compared with normal controls. The spontaneous 
secretion of IL-1@ was also increased in diabetic children and their siblings and 
parents compared to normal controls. In contrast, levels of T-cell cytokines, IL-2 and 
IFN-?, released after PHA stimulation were similar in diabetic children, their 
siblings and parents, and in normal controls.  
 The hypersecretion of TNF-@ is in agreement with the studies in an animal 
model of diabetes of Rothe et al. who found that following activation by LPS, 
peritoneal macrophages from diabetes-prone BB rats secreted strikingly higher 
amounts of TNF-@ than those found in diabetes-resistant or normal Wistar rats 
(Rothe et al., 1990). This contrasts with an earlier study in the NOD mouse by Satoh 
et al. who found that the induction of TNF-@ in vitro after LPS stimulation was 
lower compared with normal animals (Satoh et al., 1989). Subsequent studies of 
TNF-@ production by monocytes in patients with Type 1 diabetes have been reported 
but none have examined IL-1@. Mølviq et al. (1990), Mooradian et al. (1991) and 
Ohno et al. (1993) reported no alteration in TNF-@ secretion.   
 Hypersecretion of TNF-@ and IL-1@ by PBMC of patients with Type 1 
diabetes in the present study again indicates that the macrophage could be an 
important effector of islet damage since it is the main producer of TNF-@ and IL-1@.
TNF-@, in conjunction with IL-1 and IFN-?, shows direct toxic effects on islet cells 
in vitro (Pukel et al., 1988). In addition, TNF-@ and IL-1@ are proinflammatory 
cytokines, the overproduction of which may favour chronic local inflammation such 
as pancreatic insulitis and thereby promote islet autoimmunity (Rothe et al., 1990). 
 The hypersecretion of IL-1@ and TNF-@ in siblings and parents is unlikely to 
represent imminent diabetes but it may represent hyperactivity of the immune 
system which is reported to be linked to particular HLA class II alleles (HLA-
DR3/4) as discussed (vide 7.3). Absence of an association between hypersecretion of 
cytokines and HLA-DR3 or DR4 in both diabetic children and their relatives may 
indicate that other alleles not investigated in the present work could be linked to 
cytokine secretion as discussed in previous chapter (vide 8.3).      
 It is unlikely that the hypersecretion of TNF-@ and IL-1@ in patients with 
Type 1 diabetes observed in this study is due to clinical illness or metabolic 
disturbances. It certainly cannot explain the elevated levels in siblings and parents 
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who were without clinical signs or symptoms of illness at the time of sampling. In 
addition levels of cytokine production did not correlate with patients' blood glucose 
levels.   
 Cytokine production such as IL-2 and IFN-? by T cells, after PHA 
stimulation was not different between family members with Type 1 diabetes, 
diabetic children and normal controls. These findings are in agreement with those of 
Toms et al. (1991), who found normal production of IFN-? in patients with Type 1 
diabetes after concanavalin A stimulation (a mitogen), in contrast with earlier 
studies by Kaye et al. (1986) and Giordano et al. (1989) who found a decreased 
synthesis of IL-2 by mitogen-stimulated lymphocytes from patients with Type 1 
diabetes. The discrepancy between the present results and others could be explained 
by different experimental conditions employed, or duration of diabetes in the 
subjects. Other studies used either a high concentration of PHA (25 µg/ml) 
(Giordano et al., 1989) as compared to 1 µg/ml of PHA in present study or used 
patients with Type 1 diabetes of <1 year duration from diagnosis (Kaye et al., 1986) 
compared to the majority of patients in the present study who were >1 year from 
diagnosis.    
 In summary, hypersecretion of TNF-@ and IL-1@ by PBMC was present in 
diabetic children and is consistent with the role of macrophages in N cell damage. 
Hypersecretion of these cytokines was also found in family members of children 
with Type 1 diabetes and some of this abnormality may be linked to genes coding 
the HLA system some of which increase risk of Type 1 diabetes. Normal secretion 
of IL-2 and IFN-? by PBMC of family members of patients with Type 1 diabetes and 
diabetic children indicates that T cell function is not impaired. 
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CHAPTER 9
CIRCULATING LEVELS OF CYTOKINES  
 IN  
 NON-OBESE DIABETIC (NOD) MICE   
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9.1 MICE 
A colony of NOD mice has been established in the Comparative Biology 
Unit (CBU) at King's. These studies have been ratified by the CBU and are covered 
under the animal (Scientific Procedures) Act 1986, Project Licence number PPL 
70/01555. These animals were obtained from Dr. Hattori, Joslin Diabetes Centre, 
Boston, U.S.A. The colony is tested weekly for urinary glucose until 30 weeks of 
age, by which time the incidence of diabetes is 74% in females and 47% in males.  
Forty seven NOD mice with Type 1 diabetes (26 females, median age 16 
weeks, range 8-28) and 37 NOD mice without diabetes (17 females), all aged 30 
weeks old and in whom diabetes would now be unlikely to develop were studied. As 
controls, we studied 23 NODxB10 F1 generation mice (12 females, median age 15 
weeks, 13-20) and 20 SJL mice (10 females) aged 15 weeks. SJL and B10 mice 
were chosen because they have a similar genetic background to the parent strain of 
NOD mice (Wicker et al., 1987). When B10 mice are crossed with NOD mice, the 
F1 generation mice has insulitis but does not develop diabetes.    
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9.2 RESULTS  
Serum levels of TNF-@ (macrophage derived cytokine), IL-2 (to denote the 
TH1 cytokine profile) and IL-4 (to denote the TH2 cytokine profile) were measured in 
diabetic and non-diabetic NOD mice, NODxB10 F1 mice and normal SJL mice. 
9.2.1 CIRCULATING LEVELS OF CYTOKINES IN NOD MICE  
TNF-*. Levels of TNF-@ were significantly increased in diabetic NOD mice 
(median 4 pg/ml, range 0-68) when compared with non-diabetic NOD mice (0 
pg/ml, 0-29, p<0.004), NODxB10 F1 mice (0 pg/ml, 0-8, p<0.001) and normal SJL 
mice in whom TNF-@ was not detected (0 pg/ml, 0-0, p<0.001) (Figure 9.1). No 
significant differences exist between non-diabetic NOD mice, NODxB10 F1 mice 
and normal SJL mice with respect to serum levels of TNF-@. Levels of TNF-@
exceeding the highest normal value (8 pg/ml) were found in 25/47 (53%) diabetic 
NOD mice, 7/37 (18%) non-diabetic NOD mice and 1/23 (4%) NODxB10 F1 mice. 
 
Figure 9.1.  TNF-( values in the serum of diabetic and non-diabetic NOD mice, 
NODxB10 F1 mice and normal SJL mice. The dashed line represents the upper limit 
of SJL mice. Levels of TNF-( were significantly higher in diabetic NOD mice when 
compared with non-diabetic NOD mice (p<0.004), NODxB10 F1 mice (p<0.001) 
and normal SJL mice (p<0.001). Horizontal bars represent medians. 
 
IL-2. Levels of IL-2 were significantly increased in diabetic NOD (median 170 
pg/ml,range 0-1142) when compared with non-diabetic NOD mice (0 pg/ml, 0-525, 
p<0.01), NODxB10 F1 mice (0 pg/ml, 0-40, p<0.001) and normal SJL mice in 
whom IL-2 was not detectable (0 pg/ml, 0-0, p<0.0001) (Figure 9.2). There were no 
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significant differences between non-diabetic NOD mice, NODxB10 F1 mice and 
normal SJL with regard to serum levels of IL-2. Levels of IL-2 exceeding the highest 
normal value (0 pg/ml) were found in  32/47 (68%) diabetic, 7/37 (19%) non-
diabetic NOD mice and 2/23 (8%) NODxB10 F1 mice.   
 
Figure 9.2.  IL-2 values in the serum of diabetic and non-diabetic NOD mice, 
NODxB10 F1 mice and normal SJL mice. The dashed line represents the upper limit 
of SJL mice. Levels of IL-2 were significantly higher in diabetic NOD mice when 
compared with non-diabetic NOD mice (p<0.01), NODxB10 F1 mice (p<0.001) and 
normal SJL mice (p<0.0001). Horizontal bars represent medians. 
 
IL-4. IL-4 was not detected in the serum of either test or control mice.   
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9.3 COMMENT 
This study demonstrates that levels of TNF-@ (macrophage-derived cytokine) 
and IL-2 (TH1 cytokine) are elevated in diabetic NOD mice when compared with 
non-diabetic NOD mice, NODxB10 F1 mice and normal SJL mice. The presence of 
this profile of cytokines implies activation of the TH1 subset of helper cells at 
diagnosis of Type 1 diabetes. In contrast, elevated levels of IL-4 (TH2 cytokine) were 
not detectable in the serum of either test or controls mice, indicating a lack of 
recruitment of TH2 cells at diagnosis of diabetes. 
 The finding of high levels of IL-2 but not IL-4 in our study indicates that a 
cellular immune response involving TH1 cells characterises the onset of diabetes in 
this animal model as discussed in section 5.3.   
 Increased levels of TNF-@ in diabetic NOD mice give support to a critical 
role for macrophages in the pathogenesis of diabetes in this model as discussed (vide 
5.7). It has been suggested that the release of TNF-@ by cells infiltrating the 
pancreatic islets is a major effector mechanism of tissue destruction in Type 1 
diabetes (Bendtzen, 1989).  
 Increased levels of cytokines in this animal model of Type 1 diabetes could 
be due to either environmental factors or be genetically determined. It is unlikely 
that high levels of cytokines in the present study are solely determined by genetic 
factors since levels of IL-2 and TNF-@ in non-diabetic NOD mice or NODxB10 F1 
mice were within the normal range. It is likely therefore that high levels of cytokines 
are related to immune processes triggered by environmental factors such as a viral 
infection, as discussed before (vide 5.3).  
 In conclusion, the results in this section demonstrate that cytokines produced 
by macrophages (TNF-@) and TH1 cells (IL-2) are elevated in association with the 
development of diabetes in this animal model of Type 1 diabetes and argue for a 
TH1-directed process of N cell damage, with the involvement of activated 
macrophages.  
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CHAPTER 10
STUDIES OF CELLULAR EXPRESSION OF TNF-* AND IFN-+
IN  
 PANCREATIC SECTIONS FROM NON-OBESE DIABETIC (NOD) MICE   
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10.1  MICE   
 A total of 39 mice were studied. Nineteen NOD mice of various ages were 
examined comprising 10 diabetics (6 females, median age 16 weeks, range 8-23) 
and 9 NOD mice at a pre-diabetic stage (7 females, median age 10 weeks, 4-15) 
(colony incidence >70%). As controls, 10 NODxB10 F1 mice (5 females, median 
age of 15 weeks, 13-20) and 10 SJL control mice (5 females) at age of 15 weeks 
were also studied.  
 Mice were sacrificed and pancreata were removed from all animals. Serial 
sections of the blocks were cut and consecutive sections were examined for cytokine 
producing cells. At least three islets were counted for the positive staining of 
cytokine producing cells. The mononuclear cell (MNC) infiltrate was characterised 
in pancreas sections using three grades of severity: no infiltration; a small number of 
infiltrating mononuclear cells at the islet periphery but covering <20% of the 
perimeter (moderate); islet perimeter completely surrounded by a mantle of 
mononuclear cells (severe). All diabetic pancreas sections had severe islet 
lymphocytic infiltrate.  
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10.2 RESULTS  
Cellular expression of cytokines such as TNF-@ and IFN-? was examined in 
islets of Langerhans of NOD mice with diabetes and those at a pre-diabetic stage, 
NODxB10 F1 mice and normal SJL mice using indirect immunohistochemical or 
immunofluorescence techniques. 
 
10.2.1 EXPRESSION OF IFN-+ AND TNF-* IN ISLETS OF LANGERHANS  
Using an indirect immunoperoxidase technique, IFN-? producing cells were 
detected within the inflammatory cell infiltrate in pancreas sections of diabetic mice 
(Figure 10.1). No staining was detected for TNF-@ producing cells within the 
inflammatory cell infiltrate. However, positive staining for TNF-@ was detected 
within islet cells (Figure 10.2) and the latter pattern was confirmed using an 
immunofluorescence technique (Figure 10.3).  
 
Figure 10.1. Pancreatic section from diabetic NOD mice showing mononuclear 
cells with a diffuse cytoplasmic staining of IFN-4 (stained dark brown). Positively 
stained cells are mainly surrounding islet A cells. (immunoperoxidase staining, 
original magnification 25x) 
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Figure 10.2.  Pancreatic section from diabetic NOD mice showing islet cells 
staining with TNF-( (stained weak brown or yellow) (immunoperoxidase staining, 
original magnification 40x) 
 
Figure 10.3. Pancreatic section from diabetic NOD mice showing islet cells staining 
of TNF-( (bright fluorescing) and surrounding negative staining of mononuclear 
cell infiltration (black cells). (Immunofluorescence staining, original magnification 
40x) 
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9 of 10 diabetic NOD mice were positive for IFN-? and 8 for TNF-@. Both 
cytokines were detected simultaneously in eight and the score of the expression of 
TNF-@ correlated with the score of the expression of IFN-? (r=0.76, p<0.01) (Table 
10.1). Expression of TNF-@ and IFN-? was also detected in NOD mice at the pre-
diabetic stage (Figure 10.4).  7 of 9 pre-diabetic NOD mice were positive for IFN-?
and five for TNF-@. None of the sections from control mice, whether normal or with 
insulitis, was positive for either cytokine. The frequency of expression of TNF-@ and 
IFN-? was significantly higher in diabetic NOD mice than control mice with insulitis 
(c2= 5.7, p<0.04 for both cytokines).  
 
Figure 10.4. Pancreatic section from a NOD mouse at the pre-diabetic stage (10 
weeks old) showing mononuclear cells with a diffuse cytoplasmic staining of IFN-4
(stained dark brown). Positively stained cells are mainly surrounding islet cells. 
(immunoperoxidase staining, original magnification 25x)  
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Table 10.1 Age, sex, immunological and histological details of NOD mice.  
 
NOD mice Sex Age (wks) Islet cell 
infiltrate 
TNF-* IFN-+
Diabetic 
1 F 20 Severe 1 3 
2 F 8 Severe 2 3 
3 F 16 Severe 2 2 
4 F 20 Severe 3 3 
5 F 12 Severe 0 1 
6 M 20 Severe 0 0 
7 M 16 Severe 1 2 
8 M 12 Severe 2 3 
9 M 23 Severe 1 2 
10 M 16 Severe 2 2 
"Pre-diabetic" 
1 F 4 Negative 0 0 
2 F 8 Moderate 0 1 
3 F 10 Severe 2 2 
4 F 15 Severe 0 2 
5 F 15 Severe 2 2 
6 M 4 Moderate 0 0 
7 M 8 Moderate 2 2 
8 M 10 Severe 1 2 
9 M 15 Severe 1 2 
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10.3 COMMENT  
 The results in this section demonstrate that both IFN-? and TNF-@ producing 
cells are present in the islet of Langerhans of diabetic NOD mice. Cells with positive 
staining for IFN-? are detected within the inflammatory cell infiltrate, while TNF-@
staining is found within islet cells. None of the sections from SJL mice or 
NODxB10 F1 mice were positive for either cytokine suggesting that these mediators 
may play a role in N cell damage in diabetics as already discussed (vide 5.3).  
 There has been much interest in the possible roles of IL-1 and TNF-@, both 
macrophage products, in the pathogenesis of Type 1 diabetes (Mandrup-Poulsen et 
al. 1987b; Pujol-Borrell et al., 1987). TNF-@ producing cells associate the 
inflammatory cell infiltrate were not detectable but the possibility that macrophages 
have a critical role in the disease process in this animal model of diabetes can not be 
excluded. The finding of positive staining for TNF-@ apparently within the islet cells 
in present study gives support to the hypothesis that N cells are able to produce 
cytokines. Evidence to support this concept comes from in vitro experiments shows 
that pancreatic N cells produce TNF-@ after exposure to IL-1 and IFN-? (Yamada et 
al., 1993) and IL-6 (Campbell et al., 1989) and that this production is up-regulated 
when cytokines are given in combination.  
 The fact that the presence of TNF-@ producing-cells strongly correlates with 
that of IFN-? producing-cells suggests that these cytokines may act pathogenically in 
concert by enhancing/inducing MHC class II molecules, a critical step in the process 
of antigen recognition, and by recruiting inflammatory cells to the site of the lesion 
(Foulis et al., 1991). Although mice with insulitis have an inflammatory cell 
infiltrate of a severity similar to that in diabetic mice, they did not have positive 
staining for TNF-@ or IFN-?, suggesting that these cytokines may be closely related 
to the autoimmune attack.        
 The view that cytokine producing cells are involved in the pathogenic 
process of autoimmune Type 1 diabetes is supported by observations that in other 
autoimmune diseases, such as the autoimmune form of hepatitis (vide section 12) 
and rheumatoid arthritis, TNF-@ and IFN-? producing-cells are prominent in the 
characteristic inflammatory lesions in the liver and synovium respectively (Hussain 
et al., in press; Chu et al., 1991).  
 In conclusion, the presence of IFN-? and TNF-@ producing cells in the 
inflamed islet in diabetic NOD mice and not in animals without the disease implies 
that cytokines may be involved in the autoimmune process of Type 1 diabetes. The 
expression of TNF-@ within islet cells supports the hypothesis that N cell destruction 
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and MHC class II antigen expression in autoimmune diabetes may be attributable to 
endogenous cytokine production by N-cells.  
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CHAPTER 11
STUDIES OF CYTOKINE LEVELS IN AUTOIMMUNE HEPATITIS,  
 AN ORGAN-SPECIFIC AUTOIMMUNE DISEASE  
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11.1 PATIENTS 
 A total of 67 patients (39 females, median age 11 years, range 1-17) were 
studied. Twenty-three patients had autoimmune hepatitis (AIH) (19 females, median 
age 12 years, range 2-17) and were diagnosed according to internationally agreed 
criteria (Scheuer, 1991) (Table 11.1). Five of these were positive for anti-nuclear 
antibody (ANA) and smooth muscle antibody (SMA), one for ANA and liver kidney 
microsomal antibody (LKM), 4 for ANA alone, 8 for SMA alone and 1 for LKM.  
Eight patients were tested before immunosuppressive therapy and had high values of 
aspartate aminotransferase (AST), immunoglobulin G (IgG) and non-organ specific 
autoantibodies. Fifteen were tested while on immunosuppressive treatment 
(Prednisolone 0.5-2 mg/kg/day; azathioprine 1-1.5 mg/kg/day). Four of them had 
signs of active disease (defined by having severe portal and peri-portal tract 
infiltrate) with elevated values of AST, IgG and autoantibodies. The remainder had 
no biochemical, immunological or histological evidence of active disease. Seven of 
them had associated cirrhosis.  
 Eleven children had autoimmune sclerosing cholangitis (ASC) (6 females, 
median age 11 years, range 5-15) (Table 11.2). All had characteristic endoscopic 
retrograde cholangio-pancreatographic changes (El-Shabrawi et al., 1987). Six were 
positive for SMA and ANA, 2 for SMA only and one for ANA only. Seven were 
tested at diagnosis before therapy and all had active disease. Four were tested while 
on treatment with salazopyrine 30 mg/kg/day and prednisolone 0.5 mg/kg/day. 
Three patients had signs of active disease with high values of AST and IgG and 
associated cirrhosis.  
 As pathological controls, 35 children with other liver disorders due to 
metabolic causes, including Wilson's disease (WD, progressive liver disorder 
associated with abnormality of copper metabolism) and alpha-1-antitrypsin 
deficiency (A1ATD, progressive liver disorder associated with abnormal alpha 1 
phenotype causing deficiency of A1AT) were studied. 11 had Wilson's disease (2 
females, median age 16 years, range 8-19) (Table 11.3). All patients were tested 
while on treatment with penicillamine 20 mg/kg/day and only one had histological 
evidence of active disease. Twenty-four patients had A1ATD (12 females, median 7 
years, 1-14) (Table 11.4). Twenty-one patients were receiving no treatment; 10 had 
signs of active disease and eight had cirrhosis. The remainder were tested while 
receiving treatment with colchicine 25 µg/kg/day and/or penicillamine 20 
mg/kg/day. These children were selected because their liver biopsy samples showed 
degrees of portal tract infiltration and piecemeal necrosis similar to those observed 
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in chronic autoimmune hepatitis.  
 We also studied 25 healthy children as controls (18 females, median age 8 
years, range 2-17) who were recruited by the Medway and Gillingham Branch 
(Kent) of the Children's Liver Disease Foundation (CLDF), and gave blood after 
informed consent from themselves or their parents, as appropriate. 
Table 11.1 Clinical, biochemical, immunological and histological details of the patients with autoimmune hepatitis 
at the time of testing. 
 
Patien-ts  
 no. 
Sex Age 
(yrs) 
Disease 
statusA
Immunosup-
pressive 
treatment*
Cirrho-sis AST** 
(IU/l) 
IgG*** 
g/l 
Autoantibodies# SMA   
ANA   LKM 
1 M 12 Active none Present 490 32.7 320   20    Neg 
2 F 13 Active none Absent 840 50.3 Neg   640   Neg 
3 F 5 Active none Absent 1480 18.2 20    160   Neg 
4 F 5 Active none Absent 185 20.6 Neg   160   640 
5 F 8 Active none Present 222 18 40    Neg   Neg 
6 F 11 Inactive Pred Present 34 ND ND    ND    ND 
7 F 14 Active Pred Present 465 35.5 160   Neg   Neg 
8 F 11 Inactive Pred/Aza Present 66 24.5 Neg   Neg   160 
9 F 9 Active none Present 930 39 640   Neg   Neg 
10 M 15 Inactive Pred Present 55 12.5 160   Neg   Neg 
11 F 5 Active none Present 293 37.4 Neg   40    Neg 
12 F 13 Active none Present 100 ND 640   Neg   Neg 
13 M 12 Inactive Pred Present 46 16.4 10    20    Neg 
14 F 2 Active Pred Present 114 20.8 Neg   10    Neg 
15 F 12 Active Pred/Aza Present 139 9.7 10    Neg   Neg 
16 F 12 Inactive Pred Absent 21 ND ND    ND    ND 
17 F 12 Inactive Pred Present 35 36.4 ND    ND    ND 
18 F 17 Inactive Pred Present 55 22.7 160   Neg   Neg 
19 F 9 Inactive Pred Present 15 12.7 20    10    Neg 
20 M 7 Active Pred Absent 89 10.5 40    Neg   640 
21 F 13 Inactive Pred/Aza Absent 63 13.5 160   Neg   Neg 
22 F 17 Inactive Pred/Aza Absent 59 10.9 10    20    Neg 
23 F 6 Inactive Pred Absent 32 10.5 Neg   40    Neg 
Overa-ll 
group 
19F:4
M
12  
(2-17) 
12A:11In 15Tr:8Untr 15P:8A 89 (15-
1480) 
19 (9.7-
50) 
14/19 9/19 2/19 
ADisease status; patients with active disease were chosen  on the basis that they had histological and/or biochemical 
evidence of disease activity at time of study. * Treatment; Pred=prednisolone, Aza=azathioprine; ** Normal value < 
45 IU/l; *** Normal values for children aged between 2 and 5 years are >5 and < 17 g/l; 5 and 16 years are >7 and 
<18 g/l. # Autoantibodies were detected on rat tissue by indirect immunofluorescence. SMA =anti-smooth muscle 
antibody; ANA =anti-nuclear factor antibody; LKM =anti-liver kidney microsomal antibody. 
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Table 11.2 Clinical, biochemical, immunological and histological details of patients with autoimmune sclerosing cholangitis at the time of testing.
Patients no. Sex Age
(yrs)
Disease
statusA
Immunosuppressive
treatment*
Cirrhosis AST**
(IU/l)
IgG*** g/l Autoantibodies#
SMA ANA LKM
1 M 11 Active None Present 125 17.2 Neg Neg Neg
2 F 13 Active Pred/SLZ Present 178 11.6 640 640 Neg
3 F 7 Active None Present 93 8.8 40 640 Neg
4 M 5 Active None Absent 120 16.4 160 Neg Neg
5 M 14 Active None Present 389 29.4 640 640 Neg
6 F 8 Active None Absent 177 16.2 160 40 Neg
7 F 12 Active None Absent 504 42.3 640 40 Neg
8 F 7 Inactive Pred/SLZ Absent 49 16.2 10 Neg Neg
9 M 8 Active None Present 174 70.8 40 640 Neg
10 M 14 Inactive Pred/SLZ Absent 18 20.9 Neg 40 Neg
11 F 15 Active Pen Present 103 13.9 40 Neg Neg
Overall group 6F:5
M
11 (5-15) 9A:2In 4Tr:7Untr 6P:5A 120 (18-
504)
16.4 (8.8-
70.8)
9/11 7/11 0/0
ADisease status; patients with active disease were chosen on the basis that they had histological and/or biochemical evidence of disease activity at
time of study. * Treatment: Pred=prednisolone; SLZ=salazopyrine; Pen=penicillamine. ** Normal values < 45 IU/l. *** Normal value for children
aged between 2 and 5 years are >5 and <17 g/l, and 5 and 16 years are >7 and <18 g/l. # Autoantibodies as detected on rat tissue by indirect
immunofluorescence. SMA =anti-smooth muscle antibody; ANA =anti-nuclear factor antibody; LKM =anti-liver kidney microsomal antibody.
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Table 11.3 Clinical, biochemical, immunological and histological details of the patients with Wilson's disease at the time of testing.
Patients no. Sex Age (yrs) Disease statusA Treatment* Cirrhosis AST** (IU/l)
1 M 10 Active Penc Present 290
2 F 8 Inactive Penc Present 51
3 M 11 Inactive Penc Absent 32
4 M 19 Inactive Penc Absent 38
5 M 14 Inactive Penc Present 36
6 M 16 Inactive Penc Present 33
7 M 12 Inactive Penc Absent 22
8 M 16 Inactive Penc Present 34
9 M 23 Inactive Penc Absent 32
10 F 21 Inactive Penc Absent 62
11 M 19 Inactive Penc Absent 33
Overall group 2F:9M 16 (8-23) 1A:10In 11Tr:0Untr 5P:6A 34 (22-290)
ADisease status; patients with active disease were chosen on the basis that they had histological and/or biochemical evidence of disease activity at
time of study. * Treatment; Pen= penicillamine. ** Normal value <45 IU/l
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Table 11.4 Clinical, biochemical, immunological and histological details of the patients with @-
1-anti-trypsin deficiency (A1ATD) at the time of testing. 
 
Patients no. Sex Age 
(yrs) 
Disease 
statusA
Treatment* Cirrhosis AST** 
IU/l 
1 F 2 Inactive None Absent 42 
2 M 3 Inactive None Absent 47 
3 M 2 Active None Present 770 
4 F 1 Active None Present 232 
5 M 7 Inactive None Absent 53 
6 F 10 Inactive Col Present 50 
7 M 14 Inactive None Absent 52 
8 F 14 Active  Penc Present 102 
9 M 8 Inactive Col Present 38 
10 M 2 Active None Present  98 
11 F 3 Active None Absent 60 
12 M 3 Inactive None Present 58 
13 F 3 Active None Absent 87 
14 M 11 Active None Present 133 
15 F 12 Inactive None Absent 33 
16 F 4 Active None Present 302 
17 F 4 Active None Present 121 
18 M 6 Active None Present 261 
19 F 6 Inactive None Absent 45 
20 F 7 Active None Present 162 
21 M 9 Inactive None  Absent 48 
22 F 7 Inactive None Absent 37 
23 M 8 Inactive None Absent 45 
24 M 9 Inactive None Absent 48 
Overall  
group 
12F: 
12M 
7 (1-14) 11A:13In 3Tr:21Un-tr 12P:12A 59 (37-
770 
ADisease status; patients with active disease were chosen  on the basis that they had histological 
and/or biochemical evidence of disease activity at time of study. * Treatment: Col= colchicine; 
Pen= penicillamine ** Normal value < 45 IU/l 
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11.2  RESULTS 
Serum levels of TNF-@, IL-1@, IL-6 (macrophage-derived cytokine), IFN-? (TH1-
derived cytokine), IL-4 (TH2-derived cytokines) and sIL-2R were measured in 
children with autoimmune liver disease (AIH and ASC) and those with liver 
disorders due to metabolic causes, namely Wilson's disease and alpha 1 antitrypsin 
deficiency at various disease stages, as well as control subjects. 
 
11.2.1 MACROPHAGE-DERIVED CYTOKINES 
TNF-*. Levels of TNF-@ were significantly higher in children with AIH (median 7 
pg/ml, range 0-132, p<0.003) and A1ATD (median 8 pg/ml, range 0-51, p<0.007) 
when compared with normal controls (median 0 pg/ml, range 0-10) (Figure 11.1). In 
children with AIH, ASC and A1ATD, levels of TNF-@ were significantly higher in 
patients with active than inactive disease (p<0.01). Levels of TNF-@ exceeding the 
highest normal value (>10 pg/ml) were found in 9/21 (43%) children with AIH, 5/11 
(46%) with ASC, 1/8 (13%) with WD and 7/21 (33%) with A1ATD.   
IL-1*. Levels of IL-1@ were significantly elevated in children with AIH (median 170 
pg/ml, range 38-1980, p<0.002), ASC (median 393 pg/ml, range 30-1980, p<0.002), 
WD (median 60 pg/ml, range 20-1900, p<0.03) and A1ATD (median 275 pg/ml, 
range 60-994, p< 0.003) when compared to normal controls (median 50 pg/ml, range 
30-192) (Figure 11.2). In children with  AIH and ASC, levels of IL-1@ were 
significantly higher in patients with active than inactive disease (p<0.01). Levels of 
IL-1@ exceeding the highest normal value (>192 pg/ml) were found in 7/23 (30%) 
children with AIH, 7/11 (64%) with ASC, 4/11 (35%) with WD and 12/21 (57%) 
with A1ATD. 
 
162
Figure 11.1. TNF-( levels in the serum of children with different chronic liver 
diseases. The dashed line represents the upper limit of normal children. Levels of 
TNF-( were significantly higher in children with autoimmune hepatitis (AIH) 
(p<0.003) and alpha-1-antitrypsin deficiency (A1ATD) (p<0.007) when compared 
with normal children (NC). In children with AIH, autoimmune sclerosing 
cholangitis (ASC) and A1ATD, levels of TNF-( were significantly higher in patients 
with active () than inactive disease () (p<0.01). Horizontal bars represent 
medians.  
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Figure 11.2.  IL-1( levels in the serum of children with different chronic liver 
disease. The dashed line represents the upper limit of normal children. Levels of IL-
1( were significantly higher in children with autoimmune hepatitis (AIH) (p<0.002), 
autoimmune sclerosing cholangitis (ASC) (p<0.002), Wilson's disease (WD) 
(p<0.03), and alpha-1-antitrypsin deficiency (A1ATD) (p<0.003) when compared 
with normal children (NC). In children with  AIH and ASC, levels of IL-1( were 
significantly higher in patients with active () than inactive disease () (p<0.01). 
Horizontal bars represent medians.  
 
IL-6. Levels of IL-6 were significantly increased in children with AIH (median 28 
pg/ml, range 0-55, p<0.001), ASC (median 23 pg/ml, range 0-65, p< 0.02) and WD 
(median 0 pg/ml, range 0-34, p<0.03) when compared with normal controls (median 
0 pg/ml, range 0-10) (Figure 11.3). In children with  A1ATD, levels of IL-6 were 
significantly higher in patients with active than inactive disease (p<0.01).   Levels of 
IL-6 exceeding the highest normal value (>10 pg/ml) were found in 14/21 (67%) 
children with AIH, 6/11 (55%) with ASC, 5/11 (46%) with WD and 8/21 (38%) 
with A1ATD.   
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Figure 11.3.  IL-6 levels in the serum of children with different chronic liver 
diseases. The dashed line represents the upper limit of normal children. Levels of 
IL-6 were significantly higher in children with autoimmune hepatitis (AIH) 
(p<0.001), autoimmune sclerosing cholangitis (ASC) (p<0.02), Wilson's disease 
(WD) (p<0.03) when compared with normal children (NC). In children with  alpha-
1-antitrypsin deficiency (A1ATD), levels of IL-6 were significantly higher in patients 
with active () than inactive disease () (p<0.01). Horizontal bars represent 
medians.  
 
11.2.2 TH1 PROFILE 
IFN-+. Cytokines produced by T cells such as IFN-? were also measured. Levels of 
IFN-? were significantly increased only in children with AIH (median 310 pg/ml, 
range 0-3500, p<0.04) when compared with normal controls (median 0, range 0-
250) (Figure 11.4). Levels of IFN-? were not different between ASC, WD, A1ATD 
and NC. In children with A1ATD, levels of IFN-? were significantly increased in 
patients with active disease compared to those with inactive (p<0.01). Levels of 
IFN-? exceeding the highest normal value (>250 pg/ml) were found in 11/21 (52%) 
AIH, 4/11 (36%) ASC, 3/11 (27%) WD and 9/21 (43%) A1ATD.     
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Figure 11.4.  IFN-4 levels in the serum of children with different groups of chronic 
liver disease. The dashed line represents the upper limit of normal children. Levels 
of IFN-4 were significantly higher in children with autoimmune hepatitis (AIH) 
when compared with normal children (NC) (p<0.04). In children with  alpha-1-
antitrypsine deficiency (A1ATD), levels of IFN-4 were significantly increased in 
patients with active () than inactive disease () (p<0.01). Autoimmune sclerosing 
cholangitis=ASC and Wilson's disease=WD. Horizontal bars represent medians. 
 
11.2.3 TH2 PROFILE 
IL-4. The median levels of IL-4 were not different in children with AIH, ASC, WD 
and A1ATD when compared with normal controls. Levels of IL-4 exceeding the 
highest normal value (30 pg/ml) were found in 3/21 (14%) children with AIH, 1/11 
(8%) with ASC, 0/11 (0%) with WD, and 0/21 (0%) with A1ATD.  
 
11.2.4  LEVELS OF sIL-2R IN CHILDREN WITH AUTOIMMUNE 
CHRONIC LIVER DISEASE 
sIL-2R. Significantly increased levels of sIL-2R were observed only in patients with 
autoimmune liver diseases; AIH (median 615 U/ml, range 50-2970, p<0.003) and 
ASC (median 585 U/ml, range 210-3500, p<0.002) when compared with normal 
controls (median 220 U/ml, range 115-455) (Figure 11.5). Levels exceeding the 
highest normal value (>455 U/ml) were found in 12/21 (57%) children with AIH, 
9/11 (81%) with ASC, 3/11 (27%) with WD and 4/21 (19%) with A1ATD.   
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Figure 11.5. sIL-2R levels in the serum of children with different chronic liver 
diseases. The dashed line represents the upper limit of normal children. Levels of 
sIL-2R were significantly higher in children with autoimmune hepatitis (AIH) 
(p<0.003) and autoimmune sclerosing cholangitis (ASC) (p<0.002) when compared 
with normal children (NC). Levels of sIL-2R were not different between patients 
with active () and inactive disease () in each group of patients studied. 
Horizontal bars represent medians. 
 
11.2.5 ASSOCIATION BETWEEN LEVELS OF CYTOKINES, sIL-2R AND 
DISEASE STAGE  
 Levels of TNF-@, IL-1@, IL-6 and sIL-2R were significantly higher in 
patients with cirrhosis (n=37)  than non-cirrhotic patients (n=34) (p<0.02 for TNF-@,
p<0.007 for IL-1@, p<0.005 for IL-6,  and p<0.01 for sIL-2R) (Table 11.5). There 
was no significant difference in the levels of IL-4 and IFN-? between patients with 
and without cirrhosis.  
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Table 11.5 Levels of cytokines and sIL-2R in patients with chronic liver disease (all 
groups) according to presence or absence of cirrhosis.  
 
Cytokines  with cirrhosis median    
range 
 Without      median  
range 
 P values 
TNF-*
(pg/ml) 
10       (0-132) 0       (0-77) 0.02 
IL-1* (pg/ml) 330      (0-1980) 147     (0-1487) 0.007 
IL-6 (pg/ml) 27       (0-78) 0       (0-53) 0.005 
IFN-+ (pg/ml) 470      (0-3500) 0       (0-3500) NS*
sIL-2R (U/ml) 485      (65-3135) 251     (33-3500) 0.01 
*NS=not significant 
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11.2.6 ASSOCIATION BETWEEN LEVELS OF CYTOKINES AND sIL-2R 
AND DISEASE ACTIVITY   
 Levels of TNF-@, IL-1@, IL-6, IFN-? and sIL-2R were significantly higher in 
patients with active disease (n=32) than patients with inactive disease (n=37) 
(p<0.003 for TNF-@, p<0.02 for IL-1, p<0.005 for IL-6, p<0.03 for IFN-? and 
p<0.01 for sIL-2R) (Table 11.6). 
 
Table 11.6. Levels of cytokines and sIL-2R in patients with chronic liver disease (all 
groups) according to the disease activity (active or inactive).  
 
Cytokines  Active disease median  
range 
 Inactive disease median   
range 
 P values 
TNF-*
(pg/ml) 
14      (0-87) 0        (0-132) 0.003 
IL-1* (pg/ml) 340     (38-1980) 163      (20-1800) 0.02 
IL-6 (pg/ml) 32      (0-79) 0        (0-53) 0.005 
IFN-+ (pg/ml) 440     (0-3500) 0        (0-3470) 0.03 
sIL-2R (U/ml) 695     (100-3500) 227      (33-1500) 0.01 
11.2.7 ASSOCIATION BETWEEN CYTOKINES AND IgG LEVELS IN 
SUBJECTS STUDIED 
 Levels of cytokines or sIL-2R were not correlated with each other in any 
group studied. No correlation was found between levels of cytokines or sIL-2R and 
IgG values in any group studied. 
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11.3 COMMENT  
The results in this section show that serum levels of the cytokines IL-1@, IL-
6 and TNF-@ are significantly elevated in patients with various forms of chronic 
liver disease, including those with autoimmune hepatitis, when compared with 
normal controls. Levels of IFN-? and sIL-2R were significantly increased in patients 
with autoimmune hepatitis when compared with other forms of liver disease and 
normal controls. In contrast, levels of IL-4 were not different between patients with 
various forms of chronic liver disease and normal controls. Levels of IL-1@, IL-6, 
TNF-@ and sIL-2R were significantly higher in patients with cirrhosis than in 
patients without. A similar picture was found for disease activity and showed that 
levels of IL-1@, IL-6, TNF-@ and sIL-2R are significantly higher in patients with 
active disease than those with inactive disease.  
 The results observed confirm the finding of Tilg et al. (1992) that levels of 
IL-1, IL-6, TNF-@ and IFN-? are elevated in patients with various forms of chronic 
liver disease, including autoimmune liver disease and metabolic liver disease. That 
study also demonstrated higher levels of cytokines in patients with cirrhosis than in 
those without. Increased levels of cytokines were also reported in various liver 
diseases in earlier studies by Deviêre et al. (1990) who found increased levels of 
TNF-@, IL-1@ and IL-6 in 50% of patients with stable alcoholic liver cirrhosis and by 
Khoruts et al. (1991) who found increased plasma concentrations and in vitro 
production of TNF-@ in patients with chronic hepatitis B virus infection. 
 Increased levels of cytokines in chronic liver diseases of various aetiologies 
could be the consequence of different mechanisms. Firstly, following injury the liver 
shows an immense ability for regeneration. Regeneration of the liver is controlled by 
cytokines (Andus et al., 1991). Stimulatory and inhibitory effects on hepatocyte 
growth have been described for TNF-@, IL-1 and IL-6. However, since the data are 
contradictory (Feingold et al., 1988; Nakamura et al., Arakaki and Ichihara, 1988; 
Kuma et al., 1990; Cornell et al., 1990), the role of cytokines in vivo remains to be 
determined.  Secondly, the liver appears to represent a major site of cytokine 
clearance (Andus et al., 1991). Cytokines are cleared from the plasma by the liver 
within a few minutes, as has been shown for IL-1N (Klapproth et al., 1989), IL-3 
(Metcalf and Nicola, 1988), IL-6 (Castell et al., 1988; Sonne et al., 1990), TNF-@
(Ferraiolo et al., 1988) and IFN-? (Diez et al., 1987). Thus, elevated levels of 
endogenous cytokines in the present study could be a consequence of chronic liver 
failure resulting in an impairment of cytokine clearance.     
 Cytokine release is a sign of activation of the cellular immune system, and 
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the finding of high levels of IFN-? and sIL-2R in children with autoimmune hepatitis 
is consistent with the previous finding that as increased number of circulating 
activated T lymphocytes expressing the IL-2 receptor is associated with this disorder 
and with disease activity (Lobo-Yeo et al., 1990B). The finding of high levels of 
IFN-? (TH1 derived) but not IL-4 (TH2 derived) in children with autoimmune 
hepatitis in our study indicates that the disease could be mediated by TH1 and not 
TH2 cells. It has been proposed that the balance of TH1 and TH2 cells is critical in the 
development of autoimmune disease, as discussed for Type 1 diabetes (vide 5.7). 
Results obtained here again lend support to this hypothesis, in that the predominant 
circulating cytokine profile in patients with autoimmune hepatitis is TH1, with little 
evidence of release of TH2 cytokines.  
 The mechanism by which an autoimmune reaction is initiated against 
hepatocytes is not known. However, viral infections could initiate the immune 
process and are capable of inducing secretion of cytokines such as IFN-?, TNF-@,
IL-1N and IL-6 as discussed previously (vide 5.7).  
 The finding of higher levels of cytokines in patients with cirrhosis, than in 
patients without cirrhosis in the present study is consistent with the hypothesis that 
cytokines are the major regulator of the development of fibrosis development 
(Castilla et al., 1991). The involvement of both IL-1N and TNF-@ in fibroblast 
proliferation has been shown in vitro and has been reported in a variety of fibrotic 
disorders (Chojkier and Brenner, 1988; Kovacs, 1991). Increased levels of cytokines 
in a considerable number of patients with fibrosis in the present study, independent 
of the causative factors, indicates that cytokines may have a role in the fibrotic and 
cirrhotic transformation of the liver. 
 The observation that levels of cytokines are higher in patients with active 
disease, who have severe hepatic inflammatory infiltration and high levels of 
transaminases (an index of membrane disruption) suggests a possible role of 
cytokines in causing liver damage directly. The hypothesis that these cytokines are 
involved directly in damaging the hepatocyte has been proposed. The ability of 
cytokines to harm a variety of cell targets is documented (Brennan and Feldmann, 
1992; Gilles et al., 1992; Shinagawa et al., 1991; Pujol-Borrell et al., 1987). 
Hepatocytes have been shown not only to be selectively vulnerable to the action of 
cytokines in an HBsAg-positive transgenic mouse model (Gilles et al., 1992) but 
also normal hepatocytes in culture undergo cytolysis in the presence of TNF-@ and 
IFN-? (Shinagawa et al., 1991). Alternatively, cytokines could cause the death of 
hepatocytes indirectly. IFN-? for example, induces the expression of class II MHC 
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products on hepatocytes in vitro (Franco et al., 1988). It has been proposed that 
aberrant expression of class II MHC molecules might promote presentation of self 
antigens by the hepatocytes to T-lymphocytes, resulting in the initiation of an 
autoimmune attack and subsequent hepatocyte death (Rosa and Fellous, 1984; Lobo 
Yeo et al., 1990A; Senaldi et al., 1991).  
 In summary, high levels IFN-? and sIL-2R are found in children with 
autoimmune hepatitis indicating a predominant TH1 cytokine profile. The finding of 
high levels of cytokines in other chronic liver disease could be a consequence of 
chronic liver failure and impaired cytokine clearance. Elevated levels of cytokines in 
patients with active disease suggests a pathogenic role in chronic liver disease and 
cytokines may have a role in fibrotic and cirrhotic transformation of the liver in 
these patients.  
 
172
CHAPTER 12
CELLULAR EXPRESSION OF TUMOUR NECROSIS FACTOR-*
AND INTERFERON-+ IN LIVER BIOPSIES OF  
 CHILDREN WITH CHRONIC LIVER DISEASE    
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12.1 SUBJECTS 
A total of 36 patients were studied. Twenty-one patients had autoimmune 
liver disease: eleven had autoimmune hepatitis (Table 12.1) and were diagnosed 
according to internationally agreed criteria (Scheuer, 1991). Ten were females 
(median age 12, range 2-14 years). Four were positive for ANA and SMA, one for 
ANA alone and one for SMA alone, while 5 were positive for LKM-1. Six patients 
were tested before immunosuppressive therapy was started and had high values of 
AST, IgG, non-organ specific autoantibodies and severe piecemeal necrosis in the 
liver biopsy. Four were tested while on immunosuppressive treatment (azathioprine 
1-1.5 mg/kg/day and/or prednisolone 0.5-2 mg/kg/day). Two of these had severe a 
portal tract infiltrate in the liver biopsy, one moderate and one mild. Ten children 
had autoimmune sclerosing cholangitis (Table 12.1).  Five were females (median 
age 13, range 4-18 years), all had characteristic changes on endoscopic retrograde 
cholangio-pancreatography (El-Shabrawi et al., 1987). Seven were positive for SMA 
and ANA, two for SMA only and one for ANA only. Five were tested at diagnosis 
before therapy; two of them had mild and three a severe portal tract inflammatory 
cell infiltrate. Five patients were tested while on treatment with azathioprine (1.5 
mg/kg/day) and/or prednisolone (0.5-1.5 mg/kg/day). One of them was also 
receiving colchicine 25 µg/kg/day. Of these patients, three had mild, one moderate 
and one a severe portal tract inflammatory cell infiltrate.  
 As a pathological control, fifteen children with liver biopsies showing a 
mononuclear cell infiltrate in the portal tract were studied (Table 12.2): eight had 
Wilson's disease (6 male, median age 14, range 3-20 years), one with severe, two 
with moderate and five with a mild portal tract inflammatory changes. Five were 
untreated, two were receiving penicillamine 20 mg/kg/day, one trientine 300 
mg/daily and zinc sulphate 250 mg/daily. The other seven had alpha-1-antitrypsin 
deficiency (4 female, median age 5, range 3-14 years), 6 were receiving no treatment 
while one was receiving colchicine (25 µg/kg/day) (Table 12.2). Six of them had 
mild and one moderate portal tract lymphocytic infiltrate. All patients with Wilson's 
disease and alpha 1 antitrypsin deficiency were negative for ANA, SMA and LKM 
autoantibodies. 
 Four normal liver biopsies obtained from transplant donors were studied as 
controls (3 male and one female, ages 19, 20, 45 and 26 years). 
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12.2 RESULTS 
 Both TNF-@ and IFN-? producing cells were detected within the 
inflammatory cell infiltrate in the liver biopsies of patients with autoimmune liver 
disease and showed a diffuse cytoplasmic staining (Figure 12.1 and Figure 12.2). 
Ten of 11 children with autoimmune hepatitis were positive for TNF-@ and 9 for 
IFN-?. Both cytokines were detected simultaneously in nine children (Figure 12.3A 
and 3B). Positive staining for both TNF-@ and IFN-? was also present in 7 of 10 
patients with autoimmune sclerosing cholangitis. The score of the expression of 
TNF-@ correlated significantly with the score of the expression of IFN-? (r=0.62, 
p<0.02) (Table 12.1).  
 TNF-@ staining was positive in only 1 out of 8 patients with WD while IFN-
? was detected in none of them. None of the sections from patients with A1ATD or 
from the livers of organ donors were positive for either cytokine (Table 12.2). The 
frequency of expression of TNF-@ and IFN-? was significantly higher in patients 
with autoimmune diseases than in patients with metabolic diseases (c2= 11, p<0.001 
for both cytokines).  
 The association between the degree of inflammatory cell infiltrate and 
positive staining for cytokines was also studied. In children with autoimmune liver 
disease, there was a significant correlation between score of cytokine expression and 
severity of inflammatory cell infiltrate (for TNF-@, r=0.50, p<0.03 and for IFN-?,
r=0.43, p<0.05). The only patient amongst those with metabolic diseases in whom a 
minimal number of TNF-@ stained cells was detected, a child with Wilson's disease, 
had severe portal tract inflammatory changes. In children with autoimmune liver 
disease, there was a significant correlation between the score of both cytokine 
expression and levels of AST (r=0.56, p<0.008 for TNF-@ and r=0.47, p<0.03 for 
IFN-?) (Figure 12.4). No correlation was observed between the levels of IgG and 
the score of cytokine expression. The score of expression of TNF-@ and IFN-? was 
not different between treated and untreated patients. In autoimmune liver disease, 
when there were <10% of cells positive for either cytokine, there were typically 
within portal tract. In contrast, when >10% of cells were positive, they were 
typically seen within both portal and peri-portal areas (Figure 12.2). 
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Figure 12.1 Liver section from a patient with autoimmune hepatitis showing large 
cells with a diffuse cytoplasmic staining for TNF-( within the portal inflammatory 
cell infiltrate. (Immunoperoxidase staining, original magnification 40x)    
 
Figure 12.2 Liver section from a patient with autoimmune sclerosing cholangitis 
showing large cells with a diffuse cytoplasmic staining of IFN-4 within the 
inflammatory cell infiltrate. Positively stained cells are mainly within the portal 
tract, with a few occurring some distance into the parenchyma. (Immunoperoxidase 
staining, original magnification 25x)    
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(A) 
 
(B) 
 
Figure 12.3. Liver sections from a patient with autoimmune hepatitis. Simultaneous 
presence of cells positively stained for TNF-( (3A) and IFN-4 (3B) within the portal 
inflammatory cell infiltrate. (Immunoperoxidase staining, original magnification 
25x). 
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Figure 12.4. Correlation between levels of aspartate aminotransferase (AST) and 
the score of the expression of TNF-( in children with autoimmune liver disease 
(=patients with autoimmune hepatitis, =patients with autoimmune sclerosing 
cholangitis). 
 
12.3 COMMENT  
The results in this section show that cells producing TNF-@ and IFN-? are 
present in the liver inflammatory infiltrate of children with autoimmune chronic 
liver diseases but are rarely seen in metabolic diseases such as Wilson's disease and 
alpha 1 antitrypsin deficiency. This suggests that cytokines may play a role in 
autoimmune liver damage. The observation that the number of cytokine-producing 
cells correlates with both levels of transaminases and the magnitude of the 
inflammatory infiltrate suggests potential mechanisms whereby autoimmune liver 
damage arises.  
 A direct cytolytic mechanism is suggested by the relationship between the 
number of cytokine-producing cells and increased circulating levels of the 
transaminase AST. In this scenario, the well-known ability of TNF-@ and IFN-?,
both independently and synergistically, to damage a variety of cell targets inducing 
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hepatocytes may account for autoimmune liver damage, as discussed previously 
(vide 11.3).  
 Cytokine-mediated recruitment of inflammatory cells to the inflamed area is 
another possible mode of liver cell injury in autoimmune liver disease. This 
mechanism is suggested by the correlation between the number of cytokine-
producing cells and the overall severity of the mononuclear cell infiltrate. Both 
TNF-@ and IFN-? have chemotactic properties and are thought to increase the 
cellular traffic into sites of inflammation and to enhance the immune response by 
increasing the co-stimulatory signals required for T cell activation (Munro et al., 
1989; Thornhill et al., 1991). Although some of the children with metabolic diseases 
studied had inflammatory cell infiltrates of a severity similar to those with 
autoimmune disease, they did not have cells positively staining for TNF-@ and IFN-
?, suggesting that these two cytokines are closely linked to the autoimmune nature of 
the target organ damage. 
 The fact that the presence of TNF-@ producing-cells strongly correlates with 
that of IFN-? producing-cells suggests that these two cell types have interacting 
functions. Since IFN-? producing-cells typically belong to the TH1 subset, it is 
possible to suggest the following pathogenic scenario. Recirculating TH1 cells 
encounter their specific antigenic peptide in the liver, presented by HLA class II on 
professional antigen presenting cells such as the Kupffer cells. Recognition of the 
antigen leads TH1 cells to release the powerful macrophage activator, IFN-?. This in 
turn leads cells of the macrophage lineage to release the pro-inflammatory cytokine 
TNF-@. The two cytokines can thus deliver their pathogenic potential by i) 
enhancing/inducing HLA class II molecules, a critical step in the process of antigen 
recognition, ii) recruiting inflammatory cells to the site of the lesion, iii) exerting a 
direct cytotoxic effect on the hepatocyte. In any of these cases, the nature of the 
initial stimulus, the antigenic peptide, remains to be elucidated.  
 The view that cytokine producing cells are involved in the pathogenic 
process of autoimmune liver disease is supported by observations that in other 
autoimmune diseases such as Type 1 diabetes and rheumatoid arthritis, TNF-@ and 
IFN-? producing-cells are prominent in the characteristic lesions, namely the 
insulitis and the inflamed synovium respectively (Foulis et al., 1991; Chu et al., 
1991).  
 In conclusion, the relationship between numbers of cytokine producing cells, 
the severity of the inflammatory infiltrate and the levels of transaminases suggests a 
pathogenic role for cytokines in autoimmune liver disease. If this hypothesis is 
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correct, anti-cytokine antibody treatment (Shinagawa et al., 1991) which has been 
effective in animal models of cytokine-induced liver damage, or the use of cytokine 
antagonists (Dinarello et al., 1991) would be worth considering in the treatment of 
autoimmune liver disease.  
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CHAPTER 13
GENERAL DISCUSSION 
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GENERAL DISCUSSION 
13.1 ONSET OF TYPE 1 DIABETES IS ASSOCIATED WITH 
PRODUCTION OF TH1 CYTOKINES 
The main objective of this thesis was to assess the involvement of 
cytokines in the development of Type 1 diabetes using a predominantly in vivo 
approach. Cytokines have previously been implicated in the immunopathology of 
several autoimmune diseases including Type 1 diabetes (Dinarello and Mier, 
1987). There is evidence from in vitro studies that cytokines could have a direct 
role in promoting N-cell death (Mandrup-Poulsen et al., 1989). However, evidence 
from in vivo studies to support a role for cytokines in the pathogenesis of Type 1 
diabetes is scant. The results in this thesis indicate that serum levels of four of the 
eight cytokines measured - namely IL-2, IFN-?, TNF-@ and IL-1@ - are increased 
in recently diagnosed patients with Type 1 diabetes when compared to both 
disease and metabolic control subjects and also to normal controls. At diagnosis of 
Type 1 diabetes, 89% of patients had elevated levels of at least one of these four 
cytokines. This finding strongly suggests that TH1 cells are activated in these 
patients, leading in turn to enhanced production of macrophage-derived cytokines 
such as TNF-@ and IL-1@.
There are a number of possible alternative reasons why circulating 
cytokine levels may be elevated in recently diagnosed Type 1 diabetes. 
Concomitant illness such as infection may be associated with raised levels of 
cytokines in patients at diagnosis of diabetes but cannot explain the elevated levels 
in long-standing patients who were without clinical symptoms of illness at the 
time of sampling. Metabolic disturbance or chronic autoimmunity are unlikely to 
result in these findings since levels of cytokines did not correlate with patients' 
blood glucose levels or the presence of antibodies to ICA or GAD. It is likely 
therefore that the high levels of cytokines noted in this thesis are related to an 
immune process associated with Type 1 diabetes of recent onset. This immune 
process is probably relevant to the development of disease since elevated levels of 
activated T cells have been repeatedly demonstrated in recently diagnosed patients 
with Type 1 diabetes (Alviggi et al, 1984; Peakman et al, 1990) and also in 
prediabetic twins but not in twins who did not develop Type 1 diabetes (Tun et al.,
185
1994). 
It has previously been proposed that the balance between TH1 and TH2
cells is critical in the development of Type 1 diabetes (Harrison et al., 1993). This 
suggestion is made on the basis that at-risk first degree relatives who have poor 
delayed-type hypersensitivity response to specific islet antigens (eg. GAD) may be 
less likely to develop diabetes (Harrison et al., 1993). In addition, there is 
evidence from the non-obese diabetic (NOD) mouse model of spontaneous 
diabetes that GAD-responsive, IFN-? producing T lymphocytes are an early 
feature of the disease process (Kaufman et al., 1993). The findings in this thesis 
complement these other reports by providing evidence that TH1 cell activation is 
found in the majority of patients with Type 1 diabetes. By contrast, the finding of 
elevated levels of TH2 cytokines (IL-4 and IL-10) in patients with Graves' disease 
is of interest since it is consistent with an antibody-mediated pathogenesis for this 
disease.     
The mechanism by which autoimmune reactions are initiated against the N-
cells and the stimulus for cytokine production in Type 1 diabetes are not known. 
Viral infection could initiate the immune process since viruses are capable of 
inducing IFN-? (Trinchieri and Perussia, 1985) and have also been shown to 
induce secretion of other cytokines such as TNF-@, IL-1N and IL-6 from human 
monocytes (Henke et al., 1992).   
The results obtained are in agreement with Cavallo et al. (1991) who found 
that levels of TNF-@ are elevated in a proportion of recently diagnosed patients 
with Type 1 diabetes. Elevated levels of IFN-? in recently diagnosed patients with 
Type 1 diabetes in the present study is concordant with the observation of Tova et 
al. (1984) but is in contrast with the study of Cavallo et al. (1991) who found that 
levels of IL-1@ and IFN-? in patients with Type 1 diabetes were normal. 
Methodological differences such as differences in assay condition are likely to 
account for this discrepancy. Furthermore, since cytokines are labile molecules 
with short half-lives, serum samples used in this study were stored at -70oC and 
not at -20oC as in that study (Cavallo et al. 1991). Mooradian et al. (1991) found 
no detectable levels of IL-1@ and IL-1N in a group of long-standing patients with 
hyperglycaemia, although the nature of diabetes (Type 1 or Type 2) in these 
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patients was not stated. In the present study IL-1N was not detected in serum, 
possibly due to the inability of our assay to measure IL-1N in serum, the presence 
of cytokine inhibitors such as IL-1N type II receptors which are naturally occurring 
inhibitors for IL-1N, but do not bind IL-1@ (Scott et al., 1991). Elevated levels of 
IL-4, IL-6 and IL-10 were not detectable in the serum of any of the diabetic or 
normal control subjects in this thesis, in agreement with the finding of Cavallo et 
al. (1991) that levels of IL-4 and IL-6 are undetectable in patients with Type 1 
diabetes, indicating a lack of recruitment of the TH2 subset at diagnosis of Type 1 
diabetes.    
In summary, this study shows that high levels of circulating IL-2,-IFN-?,
IL-1@ and TNF-@ are associated with the diagnosis of Type 1 diabetes. This 
supports the recent proposal that preferential activation of TH1 lymphocytes is a 
key element in the development of Type 1 diabetes (Harrison et al., 1993). In 
order to determine whether TH1 activation precedes the clinical onset of Type 1 
diabetes, circulating cytokine profiles were characterised in a cohort of-non-
diabetic identical twins of patients with Type 1 diabetes, some of whom went on 
to develop the disease themselves.  
 
13.2 CYTOKINE PROFILE IN A COHORT OF NON-DIABETIC 
IDENTICAL TWINS OF PATIENTS WITH TYPE 1 DIABETES  
The investigation was then extended to twins to determine whether 
abnormally elevated levels of cytokines is similar in prediabetic and non-diabetic 
twins who have a relatively high risk of developing the disease themselves. Levels 
of macrophage-derived cytokines (TNF-@ and IL-1@) were elevated above the 
normal range with a higher prevalence in the twins who developed diabetes than 
in those who did not. These findings are consistent with evidence that the 
appearance of macrophages in islets of Langerhans is the first event heralding the 
onset of insulitis in the NOD mouse (Walker et al., 1988). In addition, 
manoeuvres designed to inhibit macrophage function, such as administration of 
silica, inhibit the development of diabetes in the BB rat (Oschilewski et al., 1985).  
The analysis of the TH1 and TH2 cytokine profiles did not reveal a clear 
difference in the pattern obtained in the prediabetic twins compared with the twins 
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remaining non-diabetic although some prediabetic twins had primarily a TH1
profile of circulating cytokines. However, levels of cytokines typical of a TH2
profile were higher in non-diabetic twins than in patients with recently diagnosed 
Type 1 diabetes. This raises the possibility that TH2 cytokines could protect 
against onset of Type 1 diabetes, perhaps reflecting an "appropriate" immune 
response to environmental trigger(s) which initiate the autoimmune process. This 
concept is supported by a number of lines of evidence. Firstly, administration of 
IL-4 (Rapoport et al., 1993; Fowell and Mason, 1993) or IL-10 (Pennline et al.,
1994) to NOD mice prevents the onset of diabetes in these animals. In addition, 
the adoptive transfer of IL-4-secreting TH2 splenocytes into neonatal NOD mice 
prevents the progression of diabetes while transfer of IFN-?-secreting TH1 cells 
promotes the onset of disease (Katz et al., 1995; Healy et al., 1995).  
The mechanism by which TH2 cells protect against the development of 
Type 1 diabetes is unknown; however, a possible role for TH2 cytokines (IL-4 and 
IL-10) in preventing the disease processes by down-regulating autoimmune 
responsiveness has been suggested. This is supported by evidence suggesting that 
TH1 and TH2 subsets are mutually antagonistic. For example, IL-10 suppresses 
synthesis of TH1 helper cytokines such as IL-2 and IFN-? (Moore et al., 1993). It 
has also been shown that IL-4 suppresses LPS-induced stimulation of IL-1, TNF-@
and IL-6 synthesis by human monocytes (Cheung et al., 1990). These observations 
are in keeping with the finding in the present study that high levels of IL-4 and IL-
10 in non-diabetic twins are associated with low levels of TNF-@ and IL-1@.
In summary, this study has shown that macrophage-derived cytokines are 
elevated to a greater extent in twins who progress to diabetes than in those who do 
not. While the ratio of TH1/TH2 cytokines was not correlated with the disease 
progression, non-diabetic twins exhibited higher levels of TH2 cytokines than 
newly diagnosed diabetes. In order to understand the factors which influence 
cytokines production in diabetic patients, the role of genetic traits in this process 
was examined. 
 
13.3.1 THE ROLE OF UNDERLYING GENETIC TRAITS IN 
INFLUENCING CYTOKINE LEVELS IN PATIENTS WITH TYPE 1 
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DIABETES AND THEIR SIBLINGS AND PARENTS 
To determine whether cytokines levels are genetically determined, 
measurements were made of circulating cytokine levels and mitogen-stimulated 
secretion of cytokines by PBMC in both diabetic children and their first degree 
relatives. These results indicated that circulating levels of TNF-@ and sIL-2R are 
elevated in non-diabetic first degree relatives (i.e. sibs and parents), as well as in 
children with Type 1 diabetes. In addition, hypersecretion of IL-1@ and TNF-@ by
mitogen-stimulated PBMC was found in this population. These abnormalities of 
cytokine production in first degree relatives are of interest since these individuals 
have a relatively low risk of progression to diabetes (Allen et al., 1991). Thus, 
overproduction of IL-1@ and TNF-@ is not sufficient in isolation to promote 
diabetes.  
One possible explanation for the increased circulating levels of cytokines 
and their hypersecretion by PBMC in the first degree relatives is that the immune 
system is hyperactive in these individuals. Overactivity of the immune system has 
been implicated as a possible predisposing factor to autoimmune diseases in 
individuals with particular HLA class II alleles-(HLA-DR3/DR4) (Jaworski et al.,
1983). However in the present study, no association between HLA DR3/4 and 
either circulating levels of cytokines nor their secretion by PBMC was found in 
both diabetic children or their relatives, suggesting that the DR3/4 alleles do not 
exercise a unequivocal influence on determining high cytokine levels. This finding 
is in agreement with the study by Mølvig et al. (1990) who did not find a 
significant association between production of IL-1N and TNF-@ by monocytes and 
HLA-DR phenotype.  
It is possible that other alleles could be linked to the abnormalities in 
cytokine secretion reported here. The genes encoding TNF-@ and TNF-N are both 
located on the short arm of chromosome 6 between HLA B and HLA DR loci 
(Campbell and Trowsdale, 1993). Wilson et al. (1993) have shown that a 
polymorphism in the TNF-@ gene is strongly associated with the HLA A1, B8, 
DR3 haplotype, which is prevalent in Type 1 diabetes and in other autoimmune 
diseases. Furthermore, RFLP analysis of TNF-N gene has shown that fragments of 
5.5 kb and 10.5 kb are associated with Type 1 diabetes susceptibility haplotypes 
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(DR3/4) (Pociot et al., 1991) and are commonly found in both diabetics and in 
their first degree relatives (Ilonen et al., 1992). Conseqently, it would be 
interesting to examine whether the elevated production of TNF-@ found in diabetic 
children and their relatives is associated with any of the TNF-gene polymorphisms 
described in these studies.  
The data presented in this thesis suggest that genetic factors may influence 
cytokine levels in the diabetic children and in first degree relatives. However, two 
pieces of evidence indicate that genetic background is not the sole influence on 
circulating TNF-@ levels in these subjects. Firstly, although elevated, TNF-@ levels 
were lower in first degree relatives than in either prediabetic twins or recently 
diagnosed patients with Type 1 diabetes. In addition, TNF-@ levels were similar in 
non-diabetic twins compared to normal controls. Thus, environmental factors, 
such as viral infection, must also contribute to enhanced TNF-@ production in 
diabetic patients.  
To investigate the activation of macrophages and T cells in diabetic 
children, cytokine secretion by mitogen stimulated PMBC was measured.   
13.3.2 MITOGEN-STIMULATED SECRETION OF CYTOKINES BY 
PBMC IN IN CHILDREN WITH TYPE 1 DIABETES    
In support of a central role for macrophages in the pathogenesis of Type 1 
diabetes, the results in the present study demonstrate that LPS-stimulated IL-1@
and TNF-@ secretion by PBMC in vitro is significantly increased in diabetic 
children. In support of this, hypersecretion of TNF-@ has previously been reported 
in an animal model of diabetes (Rothe et al., 1990). That study indicates that 
following activation by LPS, peritoneal macrophages from diabetes-prone BB rats 
secrete strikingly higher amounts of TNF-@ than those from diabetes-resistant or 
normal Wistar rats. However, these findings contrast with an earlier study in the 
NOD mouse by Satoh et al. who found that the induction of TNF-@ in vitro after 
LPS stimulation was lower than in control mice (Satoh et al., 1989) and with 
studies showing no alteration in TNF-@ secretion (Mølviq et al., 1990; Mooradian 
et al., 1991; Ohno et al., 1993) compared with normal animals. Discrepancy 
between the results presented here and by others could be explained by different 
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experimental conditions employed such as the number of cells and concentration 
of mitogen used in assays (Ohno et al., 1993; Mølviq et al., 1990). In addition, in 
one study the nature of the diabetes in those patients was not given (Mooradian et 
al., 1991). 
Production of cytokines such as IL-2 and IFN-? by mitogen (PHA) 
stimulated-T cells has been reported in patients with Type 1 diabetes. Toms et al. 
(1991) found normal production of IFN-?, concordant with the results in this 
thesis, suggesting that T cell function in Type 1 diabetes is not impaired although 
the present findings are in contrast with earlier studies by Kaye et al., (1986) and 
Giordano et al., (1989) who found a decreased synthesis of IL-2 by mitogen-
stimulated lymphocytes from patients with Type 1 diabetes. Again these 
differences may be explained by differences in assay conditions such as 
concentration and duration of exposure to mitogen.     
The finding of elevated levels of TNF-@ and sIL-2R in diabetic children is 
in agreement with the data presented here (section 5.2) indicating that these 
cytokines are also elevated in patients of with recently diagnosed Type 1 diabetes. 
These findings indicate that activation of macrophages and T cells is closely 
linked to Type 1 diabetes (Foulis et al., 1991; Lee et al., 1988). Levels IL-1@ and 
IFN-? in diabetic children are not significantly different when compared with 
normal controls. The results observed are in agreement with the previous studies 
by Mooradian et al. (1991) who found that levels of IL-1@ and IL-1ß in a group of 
long-standing patients with hyperglycaemia were not different when compared 
with normal subjects. By contrast, Tova et al. (1984) found elevated levels of IFN-
? in recently diagnosed Type 1 diabetes. This difference could be explained by the 
duration of the disease in the patients studied.  
In summary, elevated circulating levels of TNF-@ and sIL-2R and 
hypersecretion of macrophage-derived cytokines by PBMC was found in diabetic 
children. This supports the hypothesis that activation of macrophages and T cells 
is associated with Type 1 diabetes although is highly unlikely in isolation to 
explain the pathogenesis of this disease. Elevated levels of cytokines (circulating 
and secreted by PBMC) are also present in first degree relatives of children with 
Type 1 diabetes suggesting that the immune system in these individuals is 
191
hyperactive.  
While the data presented in this thesis show that abnormalities in cytokine 
levels are associated with Type 1 diabetes, they do not address the issue of local 
cytokine production within the pancreas. In order to examine this question, 
cytokines producing cells were examined in the closest animal model of human-
insulin-dependent diabetes, the NOD mouse.  
 
13.4 PRODUCTION OF CIRCULATING AND PANCREATIC 
CYTOKINES IN AN ANIMAL MODEL OF DIABETES - THE NOD 
MOUSE 
Cytokines were studied in the NOD mouse, an animal model bearing a 
striking resemblance to human Type 1 diabetes. In this setting, it was possible to 
investigate cytokines in the circulation and in the pancreas and to address the 
question, unanswerable in humans, as whether the events occurring in the islets 
are reflected in the circulation. 
Similar to patients with Type 1 diabetes (chapter 5.2), circulating levels of 
cytokines produced by macrophages (TNF-@) and TH1 cells (IL-2) were elevated 
in association with the development of diabetes in this animal model of Type 1 
diabetes. Furthermore, in agreement with the human data presented earlier 
(chapter 5.2), elevated levels of IL-4 (TH2 cytokine) were not detectable in the 
serum of either test or controls mice. The association between overproduction of 
TH1 cytokines and onset of diabetes in the NOD mouse is in agreement with a 
number of other studies. Katz et al., 1995 have demonstrated that diabetes is 
rapidly induced in neonatal NOD mice after transfer of TH1-like cells in almost all 
recipients while none of recipients of TH2-like cells developed diabetes. The 
generation of TH1 and TH2 subsets is influenced by the cytokines present during 
the initial phase of the immune response and a major role is played by IFN-? and 
IL-4 (Paul and Seder, 1994). IFN-? appears to be important in the development of 
insulin-dependent diabetes as demonstrated by the possibility to induce diabetes in 
transgenic mice expressing IFN-? under the control of the insulin promotor 
(Sarvetuick et al., 1988). Conversely, the TH2-derived cytokines IL-4 and IL-10 
appear to inhibit progression to diabetes in NOD mice (Rapoport et al., 1993;
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Pennline et al., 1994). These findings are likely to be of direct relevance to human 
insulitis in view of the data presented here which indicate the similarity between 
circulating cytokine levels in NOD mice and in humans with Type 1 diabetes of 
recent onset. It is unlikely that high levels of cytokines found in NOD mice in the 
present study are solely determined by genetic factors since levels of IL-2 and 
TNF-@ in non-diabetic NOD mice or NODxB10 F1 mice were within the normal 
range. Thus, high levels of cytokine production in NOD mice are likely to be 
related to an immune process triggered by environmental factors (Trinchieri and 
Perussia, 1985)  
The release of TNF-@ by cells infiltrating the pancreatic islets is believed 
to be a major effector mechanism of tissue destruction in Type 1 diabetes 
(Bendtzen, 1989). Immunohistochemical or immunofluorescence techniques in the 
present study succeeded in detecting both IFN-? (TH1 profile) and TNF-@
producing cells in the islet of Langerhans of diabetic NOD mice. The presence of 
IFN-? producing cells in the islet of Langerhans of diabetic NOD mice (Rothe et 
al., 1994) and in diabetic patients (Foulis et al., 1991) suggests that IFN-? may 
also be important in the pathogenesis of this disease. In support of this, it has been 
reported that IFN-? upregulates MHC class I and class II antigens on various cells 
including pancreatic N-cells (Wright et al., 1986; Campbell et al., 1986) and 
enhances TNF-induced cytotoxicity of human islet cells (Soldevila et al., 1991). In 
addition,  antibodies to IFN-? protect  against diabetes development in NOD mice 
and BB rats (Debraysachs  et al., 1991). In the present study, the finding of 
positive staining for TNF-@ apparently within the islet cells gives support to the 
hypothesis that N-cells themselves are also able to produce cytokines. This concept 
is supported by in vitro experiments showing that pancreatic N-cells produce TNF-
@ in culture. Furthermore, it has been reported that TNF-@ mRNA expression was 
induced in N-cells after exposure to IL-1 and IFN-? (Yamada et al., 1993) or IL-6 
(Campbell et al., 1989). These findings suggest that TNF-@ produced by islet N-
cells may act as a costimulator for autoreactive B and T lymphocytes in 
autoimmune diabetes. The presence of both TNF-@ and IFN-? producing-cells in 
pancreatic islets suggests that these two cell types may act in concert to induce 
MHC class II molecules upon N-cells, a critical step for autoimmune N-cell 
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destruction. Evidence to support this hypothesis comes from an 
immunohistochemical study of pancreas obtained from patients with recent onset 
of diabetes (Foulis et al., 1991). This analysis indicated that at diagnosis of 
diabetes, the islet of Langerhans are infiltrated by mononuclear cells (insulitis), 
consisting of mainly activated T cells and macrophages. In this study, 40% of the 
infiltrating lymphocytes stained with antibody to IFN-?, while the N-cells stained 
positively for MHC class II expression. Thus, release of IFN-? by activated T 
lymphocytes could lead to N-cell damage through induction of TNF release from 
macrophages (Fowell and Mason, 1993).       
In summary, these results demonstrate that, similar to human Type 1 
diabetes, circulating levels of cytokines produced by macrophages (TNF-@) and 
TH1 cells (IL-2) are elevated in association with the development of diabetes in 
this animal model and reflect events occurring in the islets. The presence of IFN-?
and TNF-@ producing cells in the inflamed islets in diabetic NOD mice but not in 
animals without the disease implies that these cytokines may be involved in the 
pathogenesis of Type 1 diabetes.  
The data presented here provide strong evidence supporting a role for 
locally produced cytokines in the development of Type 1 diabetes. In order to 
examine whether cytokine production contributes to the genesis of other organ-
specific autoimmune disease, this study was extended to an examination of 
cytokine production in auotimmune hepatitis. 
13.5 ROLE OF CYTOKINES IN THE PATHOGENESIS OF 
AUTOIMMUNE HEPATITIS  
The role of cytokines in the pathogenesis of other organ-specific 
autoimmune disease such as autoimmune hepatitis was also investigated, using as 
controls patients with liver disorders due to metabolic causes (Wilson's disease 
and alpha-1-antitrypsin deficiency) at various disease stages. Elevated levels of 
circulating cytokines such as IL-1@, IL-6 and TNF-@ were detected in patients with 
various forms of chronic liver disease, including those with autoimmune hepatitis, 
when compared with normal controls, consistent with earlier studies by Devière et 
al. (1990), Khoruts et al. (1991), Bird et al., (1990), and Tilg et al. (1992). Levels 
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of cytokines and-sIL-2R were significantly higher in patients with cirrhosis and 
active liver disease (severe hepatic inflammation and high levels of transaminases) 
in agreement with Devière et al. (1990) and Tilg et al. (1992). The finding of high 
levels of IFN-? and sIL-2R in children with autoimmune hepatitis is consistent 
with the previous finding that increased number of circulating activated T 
lymphocytes expressing the IL-2 receptor are found in this disorder, particularly in 
the presence of active disease (Lobo-Yeo et al., 1990B). The observation in the 
present study of high levels of IFN-? (TH1 cell-derived) but not IL-4 (TH2 cell-
derived) in children with autoimmune hepatitis suggests that TH1 cytokines are 
predominant in this disease.  
The fact that cytokine levels are higher in patients with active liver disease 
raised the possibility that cytokines may cause liver damage directly. In agreement 
with this, hepatocytes have been shown to be selectively vulnerable to the toxic 
action of cytokines in an HBsAg-positive transgenic mouse model (Gilles et al.,
1992). In addition, normal hepatocytes in culture undergo cytolysis in the presence 
of TNF-@ and IFN-? (Shinagawa et al., 1991). An indirect mechanism by which 
cytokines could cause hepatocyte death is also possible since IFN-? can induce the 
expression of class II HLA molecules on hepatocytes in vitro (Franco et al., 1988;
Senaldi et al., 1991). This would be expected to promote presentation of self 
antigens by the hepatocytes to autoreactive T-lymphocytes, resulting in the 
initiation of an autoimmune attack and subsequent hepatocyte death (Rosa and 
Fellous, 1984; Lobo Yeo et al., 1990A; Senaldi et al., 1991).  
Levels of cytokines were higher in patients with cirrhosis than in patients 
without cirrhosis in the present study, a finding consistent with studies which 
suggest that cytokines are the major regulator of fibrosis development (Kovacs, 
1991; Castilla et al., 1991). These groups have demonstrated that, in patients with 
chronic hepatitis, the level of TGFN1 expression was closely correlated the 
expression of procollagen and with fibrosis. Furthermore, IL-6 and IL-1 induce 
acute phase reactants including fibrinogen and also induce proliferation of 
fibroblasts. 
Increased levels of cytokines in chronic liver diseases could be the 
consequence of different mechanisms. Firstly, following injury the liver shows an 
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immense ability for regeneration which is cytokine-led (Andus et al., 1991). 
Secondly, it is possible that cytokine clearance is impaired as a result of chronic 
liver failure (Klapproth et al., 1989; Metcalf and Nicola, 1988; Castell et al.,
1988; Sonne et al., 1990). These studies demonstrated the accumulation of TNF, 
IL-6 and macrophage-colony stimulating factor (M-CSF) in the liver 5-18 minutes 
after intravenous administration of these cytokines. Thirdly, activation of the 
cellular immune system may lead to increased serum cytokine levels. This is 
consistent with the previous finding that an increased number of circulating 
activated T lymphocytes expressing the IL-2 receptor is associated with these 
disorders and with disease activity (Lobo-Yeo et al., 1990B).  
 The liver biopsies of patients with autoimmune liver diseases are 
characterised by a dense mononuclear cell infiltrate in portal tracts. To investigate 
whether these cells produce TNF-@ and IFN-?, immunohistochemical examination 
was performed, using anti-TNF-@ and IFN-? Mab. Both TNF-@ and IFN-?
producing cells were detected simultaneously within the inflammatory cell 
infiltrate in the liver biopsies of these patients. Although some of the children with 
metabolic diseases studied had inflammatory cell infiltrates of a severity similar to 
those with autoimmune disease, they did not have cells which stained positively 
for TNF-@ and IFN-?, suggesting that these two cytokines are closely linked to the 
autoimmune nature of the target organ damage. A direct cytolytic mechanism for 
these cytokines was suggested by the relationship between the number of 
cytokine-producing cells found and circulating levels of liver transaminases. This 
is supported by previous reports which suggest that cytokines can promote 
hepatocyte death through a direct mechanism (Gilles et al., 1992; Shinagawa et 
al., 1991). It is possible, however, that cytokines-induced toxicity may also be 
mediated through an indirect mechanism such as induction of expression of class 
II HLA molecules on hepatocytes. This could result in the initiation of an 
autoimmune attack leading to subsequent hepatocyte death (Rosa and Fellous, 
1984; Lobo-Yeo et al., 1990A; Senaldi et al., 1991).   
The concept that cytokine producing cells are involved in the pathogenic 
process of autoimmune liver disease is supported by the observation that in other 
autoimmune diseases such as Type 1 diabetes and rheumatoid arthritis, TNF-@ and 
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IFN-? producing cells are prominent in the characteristic lesions of these two 
disorders, the insulitic lesion and the inflamed synovium respectively (Foulis et al.,
1991; Chu et al., 1991). However, as is the case for a number of other organ-
specific autoimmune diseases, the nature of the initial stimulus and the target 
antigens involved in the disease process remain unknown.  
 
13.6 PRACTICAL APPROACHES TOWARD THERAPY 
The results in this thesis suggest that cytokines are important in the 
pathogenesis of human Type 1 diabetes and of autoimmune hepatitis. Consequently 
it would be anticipated that treatment with either anti-cytokine (in particular anti-
TH1 and macrophage-derived cytokines) antibody  or TH2 cytokines (such as IL-4 
and IL-10) would be beneficial for the treatments of these autoimmune disease. 
Recently, it has been suggested that the cellular effector mechanism by which 
cytokine-induced N-cell death occurs involves the enzyme nitric oxide (NO) 
synthase, which catalyses the formation of the free radical NO (Corbett et al.,
1992). This hypothesis proposes that cytokines promote expression of an inducible 
isoform of NO synthase in the N-cells of pancreatic islets and that causes islet 
damage (Corbett et al., 1991; Rothe et al., 1994). Anti-cytokine antibodies and 
inhibitors of the inducible NO synthase, such as aminoguanidine (Corbett et al.,
1992) also present a possible therapeutic approach to halt or prevent the 
diabetogenic process and this study is currently in progress in our laboratory, using 
the NOD mouse.  
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